Formulations of plasma kallikrein inhibitors
KVD900 in the form of oral dispersed tablets solves the problem of inconvenience in the treatment of existing injections, providing a bradykinin-mediated angioedema treatment program that is convenient for swallowing and efficient, suitable for a wide range of patient populations, especially young, elderly or Patients with dysphagia have achieved early intervention and efficient treatment effects.
Patent Information
- Application Number
- CN202380036493.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-04-27
- Filing Date
- 2023-04-27
- Publication Date
- 2024-12-06
AI Technical Summary
Existing treatments for angioedema, especially bradykinin-mediated angioedema, such as HAE and BK-AEnH, have problems with high burden and low compliance, especially injectable treatment for some patients. , such as young, elderly or dysphagia patients, and lack effective oral treatment options on demand.
A KVD900 in the form of oral dispersed tablets was developed as a plasma kallirein inhibitor, providing a convenient and efficient treatment regimen for patients with difficulty swallowing tablets through a rapid disintegration design in the oral cavity. The ODT form of KVD900 has been used to overcome the preparation of BCS Class IV drugs and achieve high dose concentration drug release.
This oral dispersed tablet allows early intervention, reduces therapeutic disorders of bradykinin-mediated angioedema onset, provides similar pharmacokinetic features as swallowable immediate release tablets, is suitable for large-scale manufacturing, and improves Patient compliance and treatment convenience.
Smart Images

Figure CN119095589A_ABST
Abstract
Description
[0001] The present invention relates to the treatment of bradykinin-mediated angioedema with a plasma kallikrein inhibitor. In particular, the present invention provides a pharmaceutical dosage form in the form of an orodispersible tablet comprising a plasma kallikrein inhibitor, a mixture for use in a manufacturing process for producing an orodispersible tablet of the present invention, and uses of such orodispersible tablets. The orodispersible tablets of the present invention are particularly suitable for patients who may have difficulty swallowing tablets. The present invention provides for the on-demand treatment of bradykinin-mediated angioedema by orally administering a plasma kallikrein inhibitor in the form of an orodispersible tablet to a patient in need thereof. Background Art
[0002] Inhibitors of plasma kallikrein have many therapeutic applications, particularly in the treatment of bradykinin-mediated angioedemas, such as hereditary angioedema and bradykinin-mediated non-hereditary angioedema (BK-AEnH).
[0003] Plasma kallikrein is a trypsin-like serine protease that can release kinin from kininogen (see, KD Boola et al., "Kallikrein-Kinin Cascade", Encyclopedia of Respiratory Medicine, pp. 483-493; JW Bryant et al., "Human plasma kallikrein-kinin system: physiological and biochemical parameters" Cardiovascular and haematological agents in medicinal chemistry, 7, pp. 234-250, 2009; KD Boola et al., Pharmacological Rev., 1992, 44, 1; and DJ Campbell, "Towards understanding the kallikrein-kinin system: insights from the measurement of kinin peptides", Brazilian Journal of Medical and Biological Research 2000, 33, 665-677). It is an essential member of the intrinsic coagulation cascade, although its role in the cascade does not involve the release or enzymatic cleavage of bradykinin. Plasma kallikrein is encoded by a single gene and can be synthesized in the liver as well as other tissues. It is secreted by hepatocytes as an inactive plasma kallikrein that circulates in the plasma as a heterodimeric complex bound to high molecular weight kininogen (HK), which is activated to produce active plasma kallikrein. This contact activation system (or contact system) can be activated by a negatively charged surface that activates factor XII (FXII) to factor XIIa (FXIIa), by certain proteases (e.g., plasmin) (Hofman et al., Clin Rev Allergy Immunol 2016), which may not require a negative surface, or by misfolded proteins (Maas et al., J Clinical Invest 2008). FXIIa mediates the conversion of plasma kallikrein to plasma kallikrein and the subsequent cleavage of high molecular weight kininogen (HK) to generate bradykinin, a potent inflammatory hormone.Kinins are potent inflammatory mediators acting through G protein-coupled receptors, and kinin antagonists (such as bradykinin receptor antagonists) have previously been studied as potential therapeutic agents for the treatment of many diseases (F. Marceau and D. Regoli, Nature Rev., Drug Discovery, 2004, 3, 845-852).
[0004] Plasma kallikrein is believed to play a role in many inflammatory diseases. The main inhibitor of plasma kallikrein is the serpin C1 esterase inhibitor. Patients with genetic defects in C1 esterase inhibitors suffer from hereditary angioedema (HAE), which causes intermittent swelling of the face, hands, throat, gastrointestinal tract and genitals. The blisters formed during the acute attack period contain high levels of plasma kallikrein, which cuts high molecular weight kininogen (HK) and releases bradykinin, resulting in increased vascular permeability. Treatment with large protein plasma kallikrein inhibitors has been shown to effectively treat HAE by preventing the release of bradykinin, which causes increased vascular permeability (A. Lehmann "Ecallantide (DX-88), aplasma kallikrein inhibitor for the treatment of hereditary angioedema and the prevention of blood loss in on-pump cardiothoracic surgery" Expert Opin. Biol. Ther. 8, pp. 1187-99). However, the risk of allergic reactions to Ecallantide has been reported.
[0005] Hereditary angioedema is a rare genetic disease characterized by recurrent acute attacks in which fluid accumulates outside of blood vessels, obstructing the normal flow of blood or lymph and causing rapid swelling of tissues (such as the hands, feet, limbs, face, intestines, or airways). Thus, "hereditary angioedema" can be defined as any disease characterized by recurrent attacks of bradykinin-mediated angioedema (e.g., severe swelling) caused by a genetic dysfunction / defect / mutation. There are currently three known types of HAE: (i) type 1 HAE, (ii) type 2 HAE, and (iii) normal C1 inhibitor HAE (normal C1-InhHAE). However, the field of HAE is rapidly evolving and additional types of HAE may be defined in the future.
[0006] Without wishing to be bound by theory, it is believed that type 1 HAE is caused by a mutation in the SERPING1 gene that results in reduced levels of C1 inhibitor in the blood. Without wishing to be bound by theory, it is believed that type 2 HAE is caused by a mutation in the SERPING1 gene that results in dysfunction of C1 inhibitor in the blood. Without wishing to be bound by theory, the cause of normal C1-Inh HAE is not clear, and the underlying gene dysfunction / defect / mutation may sometimes remain unknown. It is known that the cause of normal C1-Inh HAE is not related to reduced or dysfunctional levels of C1 inhibitor (in contrast to type 1 and type 2 HAE). Normal C1-Inh HAE can be diagnosed by reviewing family history and noting that angioedema is inherited from the previous generation (thus it is hereditary angioedema). Normal C1-Inh HAE can also be diagnosed by determining that there is dysfunction / defect / mutation in genes other than those genes associated with C1 inhibitor. For example, it has been reported that dysfunction / defect / mutation of plasminogen may lead to normal C1-Inh HAE (see, e.g., Veronez et al., Front Med (Lausanne). 2019 Feb 21;6:28. doi:10.3389 / fmed.2019.00028; or Recke et al., Clin Transl Allergy. 2019 Feb 14;9:9. doi:10.1186 / s13601-019-0247-x.). It has also been reported that dysfunction / defect / mutation of factor XII may lead to normal C1-Inh HAE (see, e.g., Mansi et al., The Association for the Publication of the Journal of Internal Medicine Journal of Internal Medicine, 2015, 277; 585-593; or Maat et al., J Thromb Haemost. 2019 Jan; 17(1): 183-194. doi: 10.1111 / jth.14325).
[0007] Acute HAE attacks usually go through three key different clinical stages: the initial prodromal stage (usually can last up to 12 hours), followed by the swelling stage, and then the absorption stage. Most HAE attacks announce themselves with prodromal symptoms. Two-thirds of the prodromal symptoms appear less than 6 hours before the onset of HAE, and no prodromal symptoms appear more than 24 hours before the onset of HAE (Magerl et al., Clinical and Experimental Dermatology 2014, 39, 298-303). For example, the following prodromal symptoms may begin to be observed: slight swelling (especially affecting the face and neck), typical abdominal pain, typical skin reddening (called "marginal erythema"). When the maximum degree of swelling has been reached and the maximum pain (e.g., abdominal attack), discomfort (e.g., peripheral attack) or threat to life (e.g., laryngeal attack) occurs, the attack is fully developed. Once the attack reaches its peak, the subsequent time to return to normal depends on the time it takes for the swelling to disappear and the fluid that has penetrated the tissue to be reabsorbed.
[0008] However, angioedema is not necessarily hereditary. In fact, another type of angioedema is bradykinin-mediated non-hereditary angioedema (BK-AEnH), which is not caused by hereditary gene dysfunction / defect / mutation. The potential cause of BK-AEnH is usually unknown and / or unclear. However, the signs and symptoms of BK-AEnH are similar to those of HAE, and are not bound by theory, which is believed to be due to the bradykinin-mediated pathway shared between HAE and BK-AEnH. Specifically, BK-AEnH is characterized by repeated acute attacks, in which fluid accumulates outside the blood vessels, hindering the normal flow of blood or lymph and causing rapid swelling of tissues (such as hands, feet, limbs, face, intestines, airways or genitals). BK-AEnH attacks are acute and usually go through three key different clinical stages: the initial prodromal stage (usually can last up to 12 hours), followed by a swelling stage, and then an absorption stage. Most attacks announce themselves with prodromal symptoms. Two-thirds of the prodromal symptoms occur less than 6 hours before the onset, and no prodromal symptoms appear more than 24 hours before the onset (Magerl et al., Clinical and Experimental Dermatology (2014) 39, pp. 298-303). For example, the following prodromal symptoms may begin to be observed: mild swelling (especially affecting the face and neck), typical abdominal pain, typical reddening of the skin (called "marginal erythema"). The attack is fully developed when the maximum swelling has been reached and the maximum pain (e.g., abdominal attack), discomfort (e.g., peripheral attack) or threat to life (e.g., laryngeal attack) occurs. Once the attack reaches its peak, the subsequent return to normal time depends on the time it takes for the swelling to disappear and the fluid that has penetrated the tissue to be reabsorbed.
[0009] Specific types of BK-AEnH include: non-hereditary angioedema with normal C1 inhibitor (AE-nC1Inh), which may be environmentally, hormonally, or drug-induced; acquired angioedema; angioedema associated with allergic reactions; angioedema induced by angiotensin-converting enzyme (ACE) inhibitors; angioedema induced by dipeptidyl peptidase 4 inhibitors; and tPA-induced angioedema (tissue plasminogen activator-induced angioedema). However, the reason why these factors and conditions cause angioedema in only a relatively small percentage of individuals is unclear.
[0010] Environmental factors that may induce AE-nC1 Inh include air pollution (Kedarisetty et al., Otolaryngol Head Neck Surg. 2019 Apr 30:194599819846446. doi:10.1177 / 0194599819846446) and silver nanoparticles, such as those used as antimicrobial components in healthcare, biomedical, and consumer products (Long et al., Nanotoxicology. 2016;10(4):501-11. doi:10.3109 / 17435390.2015.1088589).
[0011] Various publications suggest a connection between bradykinin and contact system pathways and BK-AEnH, and the potential efficacy of treatment, see, for example: Bas et al. (N Engl J Med 2015); Leibfried and Kovary. (J Pharm Pract 2017); van den Elzen et al. (Clinic Rev Allerg Immunol 2018); Han et al. (JCI 2002).
[0012] tPA-induced angioedema has been discussed in various publications as a potentially life-threatening complication following thrombolytic therapy in acute stroke victims (see, e.g. et al., Blood. 2017 Apr 20;129(16):2280-2290. doi:10.1182 / blood-2016-09-740670; et al., Stroke. 2019 Jun 11:STROKEAHA119025260. doi:10.1161 / STROKEAHA.119.025260; Rathbun, Oxf Med Case Reports. 2019 Jan 24;2019(1):omy112. doi:10.1093 / omcr / omy112; Lekoubou et al., Neurol Res. 2014 Jul;36(7):687-94. doi:10.1179 / 1743132813Y.0000000302; Hill et al., Neurology. 2003 May 13;60(9):1525-7).
[0013] Stone et al. (Immunol Allergy Clin North Am. 2017 Aug;37(3):483-495.) reported that certain drugs may cause angioedema.
[0014] Scott et al. (Curr Diabetes Rev. 2018;14(4):327-333. doi:10.2174 / 1573399813666170214113856) reported a case of dipeptidyl peptidase 4 inhibitor-induced angioedema.
[0015] Hermanrud et al. (BMJ Case Rep. 2017 Jan 10;2017.pii:bcr2016217802) reported recurrent angioedema associated with pharmacological inhibition of dipeptidyl peptidase IV and discussed acquired angioedema associated with angiotensin-converting enzyme inhibitors (ACEI-AAE). Kim et al. (Basic Clin Pharmacol Toxicol. 2019 Jan;124(1):115-122.doi:10.1111 / bcpt.13097) reported angioedema associated with angiotensin II receptor blockers (ARBs). Reichman et al., (Pharmacoepidemiol Drug Saf. 2017 Oct;26(10):1190-1196.doi:10.1002 / pds.4260) also reported the risk of angioedema in patients taking ACE inhibitors, ARB inhibitors, and beta blockers. Diestro et al. (J Stroke Cerebrovasc Dis. 2019 May;28(5):e44-e45.doi:10.1016 / j.jstrokecerebrovasdis.2019.01.030) also reported a possible association between some angioedema and ARBs.
[0016] Giard et al. (Dermatology. 2012; 225(1): 62-9. doi: 10.1159 / 000340029) reported that estrogen contraception may accelerate bradykinin-mediated angioedema.
[0017] Synthetic small molecule plasma kallikrein inhibitors have been described previously, for example, by Garrett et al. ("Peptidealdehyde ..." J. Peptide Res. 52, 62-71 (1998)), T. Griesbacher et al. ("Involvement of tissue kallikrein but not plasma kallikrein in the development of symptoms mediated by endogenous kinins in acute pancreatitis in rats" British Journal of Pharmacology 137, 692-700 (2002)), Evans ("Selective dipeptide inhibitors of kallikrein" WO03 / 076458), Szelke et al. ("Kininogenase inhibitors" WO92 / 04371), D. M. Evans et al. (Immunolpharmacology, 32, pp. 115-116 (1996) ... inhibitors" WO95 / 07921), Antonsson et al. ("New peptides derivatives" WO94 / 29335), J. Corte et al. ("Six membered heterocycles useful as serine protease inhibitors" WO2005 / 123680), J. Stürzbecher et al. (Brazilian J. Med. Biol. Res 27, pp. 1929-34 (1994)), Kettner et al. (US 5,187,157), N. Teno et al. (Chem. Pharm. Bull. 41, pp. 1079-1090 (1993)), WB Young et al. ("Small molecule inhibitors of plasma kallikrein" Bioorg. Med. Chem. Letts.16, pp. 2034-2036 (2006)), Okada et al. ("Development of potent and selective plasmin and plasma kallikrein inhibitors and studies on the structure-activity relationship" Chem. Pharm. Bull. 48, pp. 1964-72 (2000)), Steinmetzer et al. ("Trypsin-like serine protease inhibitors and their preparation and use" WO08 / 049595), Zhang et al. ("Discovery of highly potent small molecule kallikrein inhibitors" Medicinal Chemistry 2, pp. 545-553 (2006)), Sinha et al. ("Inhibitors of plasma kallikrein" WO08 / 016883), Shigenaga et al. ("Plasma Kallikrein Inhibitors" WO2011 / 118672) and Kolte et al. ("Biochemical characterization of anovel high-affinity and specific kallikrein inhibitor”, British Journal of Pharmacology (2011), 162(7), 1639-1649). In addition, Steinmetzer et al. (“Serine protease inhibitors” WO2012 / 004678) described cyclized peptide analogs that are inhibitors of human plasmin and plasma kallikrein.
[0018] As explained above, HAE can manifest in patients who have a defect or dysfunction in the C1 esterase inhibitor gene. Therefore, some current HAE treatments involve administering a C1 esterase inhibitor to normalize the defect or dysfunction of the C1 esterase inhibitor. Such treatments can be preventive (i.e., administered in the absence of symptoms of an acute HAE attack to prevent / reduce the likelihood of an acute HAE attack) and / or acute treatment (i.e., administered when symptoms of an acute HAE attack are noted in an attempt to prevent or reduce the severity of an acute HAE attack).
[0019] and Contains a C1 esterase inhibitor and is licensed for the prevention of acute HAE attacks (i.e., prophylactic treatment). Treatment requires preparing a solution from a powder and then injecting it every 3 or 4 days. Treatments require preparation of a solution from a powder and then injection twice a week. Patients are not always able to self-administer these treatments and, if this is the case, they are required to visit a clinic for treatment. Therefore, both preventive treatments face a high patient burden. In addition, The FDA package insert states that it “should not be used to treat acute HAE attacks,” so if an HAE attack occurs, patients may require additional treatment.
[0020] and contains a C1 esterase inhibitor and is licensed for the treatment of acute HAE attacks. Both of these treatments also involve the preparation of an injectable solution, which is then injected. This process can be burdensome for the patient, especially when the patient is suffering from an acute HAE attack. Self-administration of the dose is not always possible, and if it is not, the administration of the drug may be significantly delayed, thereby increasing the severity of the patient's acute HAE attack.
[0021] (active ingredient ecallantide) and (active substance lanadelumab) is a selective plasma kallikrein inhibitor approved for medical use in the treatment of HAE. Both treatments are formulated as solutions for injection. Ecallantide is a large protein plasma kallikrein inhibitor and carries a risk of allergic reactions. In fact, The EU marketing authorization application for The benefits of lanariumab do not outweigh its risks. Lanariumab is a recombinant fully human IgG1κ light chain monoclonal antibody. Adverse reactions reported with treatment with lanariumab include hypersensitivity, injection site pain, injection site erythema, and injection site bruising. The authorized EMA label for (the active substance lanariumab) states that it is “not intended for the treatment of acute HAE attacks” and that “in the case of breakthrough HAE attacks, individual treatment should be initiated with approved rescue medications.” Additionally, as injections, both treatments involve a high patient burden.
[0022] Berotralstat (BCX7353) has been approved in some countries for the preventive treatment of HAE (not as an on-demand treatment), such as under the brand name Hwang et al. (Immunotherapy (2019) 11(17), 1439-1444) noted that higher doses were associated with more gastrointestinal adverse effects, suggesting increased toxicity at higher levels.
[0023] In addition, many molecules in the known art are characterized by highly polar and ionizable guanidine or amidine functional groups. It is well known that such functional groups may be limited by intestinal permeability and therefore by oral availability. For example, Tamie J.Chilcote and Sukanto Sinha ("ASP-634: An Oral Drug Candidate for Diabetic Macular Edema", ARVO May 6, 2012 - May 9, 2012, Fort Lauderdale, Florida, Presentation 2240) have reported that ASP-440 is a benzamidine with the disadvantage of poor oral availability. It is further reported that absorption can be improved by creating prodrugs (such as ASP-634). However, it is well known that prodrugs may face several disadvantages, such as poor chemical stability and potential toxicity from inert carriers or unexpected metabolites. In another report, indoleamides were claimed to be compounds that could overcome the problems associated with drugs with poor or inadequate ADME-tox and physicochemical properties, although inhibition of plasma kallikrein was not proposed or claimed (Griffioen et al., “Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases”, WO2010142801).
[0024] Other plasma kallikrein inhibitors known in the art are generally small molecules, some of which contain highly polar and ionizable functional groups, such as guanidine or amidine. Recently, plasma kallikrein inhibitors that do not feature guanidine or amidine functional groups have been reported. For example, Brandl et al. (“N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides as inhibitors of plasma kallikrein” WO2012 / 017020), Evans et al. (“Benzylamine derivatives as inhibitors of plasma kallikrein” WO2013 / 005045), Allan et al. (“Benzylamine derivatives” WO2014 / 108679), Davie et al. (“Heterocyclicderivates” WO2014 / 188211), Davie et al. (“N-((het)arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors” WO2016 / 083820).
[0025] The applicant has developed a series of new plasma kallikrein inhibitor compounds, which are disclosed in WO2016 / 083820 (PCT / GB2015 / 053615). These compounds show good selectivity for plasma kallikrein. One such compound is N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide. Certain dosage forms containing this compound are disclosed in Collett et al. WO2019 / 106361. The name N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide represents the structure shown below, which is referred to as "KVD900". The INN of KVD900 is sebetralstat.
[0026]
[0027] As described, hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent episodes of severe swelling. The swelling is usually in the face, hands, throat, gastrointestinal tract and / or genitals. If not treated, swelling episodes can be very unpleasant and dangerous, sometimes leading to abdominal pain, diarrhea, vomiting, and even death. Existing HAE treatments are administered on demand or as preventives. On-demand treatment is administered in response to a specific attack to reduce its severity, for example, at the first sign of an attack symptom. Preventive treatment involves receiving treatment continuously and regularly to reduce the likelihood of an attack, i.e., not in response to a specific attack. Preventive treatments are usually not completely effective, and patients receiving preventive treatment often suffer from breakthrough attacks. Therefore, for HAE patients who take preventive treatment, on-demand treatment is usually used as a backup for such breakthrough attacks (this treatment is usually referred to as "rescue treatment"). Therefore, regardless of their current treatment regimen (or lack of treatment regimen), all HAE patients will benefit from effective on-demand treatment of HAE, which is the need addressed by the present invention.
[0028] Therefore, there is a need for a treatment of bradykinin-mediated angioedema (e.g., HAE or BK-AEnH) that is less burdensome to the patient to improve patient compliance. In particular, there is a need for a treatment of bradykinin-mediated angioedema (e.g., HAE or BK-AEnH) that can be administered orally. After early treatment, HAE attacks resolve faster and last shorter (Maurer M et al., PLoS ONE 2013; 8(2): e53773.doi: 10.1371 / journal.pone.0053773), so early intervention when an attack is expected or ongoing is essential for ideal management of the disease. Therefore, there is also a need for an on-demand oral treatment of acute bradykinin-mediated angioedema (e.g., HAE or BK-AEnH) attacks, such as after the symptoms of an acute bradykinin-mediated angioedema (e.g., HAE or BK-AEnH) attack are recognized, and does not require regular (or continuous) administration, such as a treatment that does not require injections twice a week. In particular, there is a need for an effective oral treatment for young patients (e.g., aged 2 to less than 18 years old). Existing injectable treatments may cause pain at the injection site, and the injection itself may cause stress in children. In addition, there is a need for specific oral dosage forms that are more suitable for patients who may have difficulty swallowing tablets (e.g., children, the elderly, patients with laryngeal attacks or patients with conditions such as dysphagia).
[0029] To date, there is a lack of approved oral treatments for bradykinin-mediated angioedema (e.g., HAE or BK-AEnH) (see, e.g., Craig et al., Int Arch Allergy Immunol. 2014; 165(2): 119-27. doi: 10.1159 / 000368404; Mager et al., Immunol Allergy Clin North Am. 2017 August; 37(3): 571-584). There is no approved on-demand oral treatment for bradykinin-mediated angioedema diseases (e.g., HAE or BK-AEnH). Instead, most of the available treatments are injections. Compared with oral treatments, injections face many disadvantages, largely related to patient compliance. For example, injections are more inconvenient than oral treatments, such as requiring preparation in a suitable environment and then injection, and also causing pain at the injection site. Reduced patient compliance may lead patients to delay treatment (which often results in worsening of attack symptoms) or even avoid treatment altogether. Indeed, many patients with HAE simply hope that any attack will dissipate on its own to avoid administering injections. Injectable treatments face the risk of late administration, as patients may need to prepare the dosage form or even go to the hospital for treatment. Thus, HAE treatment is often undermined by late administration due to high patient burden. In fact, Maurer M et al. (PLoS ONE 2013; 8(2): e53773. Doi: 10.1371 / journal.pone.0053773) explained that more than 60% of patients were administered HAE injections more than one hour after an attack occurred. HAE drugs are often used off-label to treat some types of BK-AEnH, so issues associated with HAE treatment similarly apply to BK-AEnH treatment.
[0030] Icatibant (trade name: ) is the main on-demand treatment for HAE, administered by subcutaneous injection. In a real-life study of HAE patients using icatibant (Maurer M et al., PLoS ONE 2013; 8(2): e53773.doi:10.1371 / journal.pone.0053773), less than 40% of treated attacks were administered within one hour of onset, and 30% were not treated until more than 5 hours after onset. In addition, 45% of attacks in this study were not treated at all. Therefore, there is an unmet need to provide patients with improved treatment options to treat HAE attacks on demand.
[0031] As mentioned above, there is a lack of any approved on-demand oral treatments for bradykinin-mediated angioedema diseases such as HAE and BK-AEnH. KVD900 is currently in a Phase 3 clinical trial (called the KONFIDENT study, https: / / konfidentstudy.com / ), all Phase 2 efficacy and safety endpoints have been met (see, clinical trial NCT04208412). In these clinical studies, KVD900 is administered as a swallowable tablet.
[0032] However, there remains a need to provide treatment options that can provide early intervention, which is known to shorten the duration of bradykinin-mediated attacks (e.g., HAE attacks) and lead to faster resolution of attacks. In addition, there remains a need to provide treatment options for people who may have difficulty swallowing, for example due to youth or old age, during laryngeal attacks, in situations where the patient does not have access to water, and / or in situations where the patient suffers from a condition such as dysphagia. In addition, during abdominal attacks, there is a risk of vomiting, which leads to uncertainty about how much of the dose is absorbed, and the act of drinking water itself (which is required to swallow a tablet) can often exacerbate the feeling of needing to vomit. Summary of the invention
[0033] The present invention aims to solve the above problems, and in particular, to provide a treatment for bradykinin-mediated angioedema diseases (such as HAE and BK-AEnH) that is particularly suitable for patients who need a dosage form that is easy to administer orally. Such patients include young patients (e.g., those aged 2 to less than 18 years, especially those aged 2 to less than 12 years), elderly patients (e.g., those aged 70 years or more), patients who often suffer from bradykinin-mediated attacks (laryngeal attacks), patients who may often not have easily available liquids (e.g., water) to help swallow oral dosage forms, or patients with conditions (such as dysphagia). Orodispersible tablets are also beneficial for other patients who prefer the convenience of easily swallowable dosage forms and for patients for whom treatment compliance may be difficult (e.g., for psychiatric disorders).
[0034] The present invention addresses these needs by providing the first orodispersible tablet (ODT) for on-demand treatment of bradykinin-mediated angioedema diseases such as HAE and BK-AEnH. The orodispersible tablet of the present invention allows for earlier intervention and has been developed to reduce barriers to treatment.
[0035] Orodispersible tablets (eg, orodispersible mini-tablets) are intended to be placed directly into the mouth where they rapidly disintegrate in the saliva before being swallowed. ODTs are not swallowable tablets, such as conventional swallowable tablets or capsules.
[0036] There are several challenges in the development of ODT formulations, such as the need for ODT to have sufficient mechanical strength while also providing a fast disintegration time. In particular, since ODT must have a feasible tablet size and drug loading, ODT is limited by the amount of drug that can be incorporated into each unit dose, so drugs with high dose concentrations (>200 mg) are not well suited for ODT. This presents a particularly challenging KVD900 development process, because the dose of KVD900 that was proven safe and effective in Phase 2 is 600 mg, and this dose needs to be provided in as few unit doses as possible to ensure patient compliance.
[0037] In addition, KVD900 is also particularly difficult to formulate into an ODT because it has been classified as a BCS class IV compound (in accordance with the ICH guideline: BIOPHARMACEUTICS CLASSIFICATION SYSTEM-BASED BIOWAIVERS M9, final version adopted on November 20, 2019). BCS class IV drugs are considered to be poorly soluble and poorly permeable, meaning that they may have poor oral bioavailability and / or oral absorption may be too low to allow them to be administered by the oral route. Due to their many unfavorable characteristics, BCS class IV drugs are particularly challenging to formulate into oral dosage forms, especially ODTs. In fact, ODTs for BCS class IV drugs are not generally known in the art.
[0038] The present applicants have sought to overcome these difficulties and have provided ODTs of KVD900 which are the ODTs described herein as part of the present invention. These ODTs have been manufactured and administered to humans in a Phase 1 study.
[0039] In order for an ODT to be useful for clinical purposes, it must be manufacturable on a large scale. To this end, the mixture of active ingredient and excipient must have sufficient processability and flowability while providing an ODT that meets the above requirements. These depend on the specific physicochemical properties of the drug candidate, including its compressibility, solubility and particle size, the desired pharmacokinetic and pharmacodynamic properties, and the flow properties of the drug and excipients. These properties are unique to the active ingredient and cannot be accurately predicted before formulation development is carried out. In addition, the ODT must have a pleasant taste, must not disintegrate into larger particles in the oral cavity, and should be formulated to leave minimal or no residue in the mouth after oral administration.
[0040] In developing the ODT of the present invention, the inventors encountered problems in trying to provide a suitable ODT. Initial attempts to make an ODT of KVD900 were unsuccessful, and the inventors encountered degradation problems of KVD900 as well as processability problems, such as insufficient flowability. The inventors have addressed these problems, for example, by using a mixture of KVD900 and excipients and the methods of making the ODT described herein.
[0041] As explained above, KVD900 has been shown to be safe and effective, meeting all Phase 2 safety and efficacy endpoints. For subsequent ODT formulations, it is advantageous to have pharmacokinetic and pharmacodynamic characteristics comparable to those of KVD900 formulations that have been tested in clinical trials (e.g., the immediate release (IR) formulations of KVD900 used in Phase 2 and Phase 3 studies described herein).
[0042] definition
[0043] As used herein, unless otherwise expressly stated, the term "compound" means "KVD900". KVD900 may exist as a pharmaceutically acceptable salt and / or solvate thereof. The structure of KVD900 is shown below, and its name is: N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide.
[0044]
[0045] The KVD900 used in the present invention may also be a preferred crystalline form (Form 1) which exhibits at least the following characteristic X-ray powder diffraction peaks (Cu Kα radiation, expressed in 2θ degrees) at approximately the following positions:
[0046] (1) 11.2, 12.5, 13.2, 14.5 and 16.3; or
[0047] (2) 11.2, 12.5, 13.2, 14.5, 16.3, 17.4 and 17.9; or
[0048] (3) 11.2, 12.5, 13.2, 14.5, 16.3, 17.4, 17.9, 21.2 and 22.0.
[0049] In this context, the term "about" means that there is an uncertainty in the measurement of degrees 2θ of ±0.3 (expressed in degrees 2θ), preferably ±0.2 (expressed in degrees 2θ).
[0050] Form 1 may also have an X-ray powder diffraction pattern comprising characteristic peaks (expressed in degrees 2-theta) at approximately 4.4, 11.2, 12.5, 13.2, 14.5, 16.3, 17.4, 17.9, 21.2, 22.0, and 22.6.
[0051] Form 1 can also have Figure 1 The diffraction pattern shown is essentially the same as the X-ray powder diffraction pattern.
[0052] It should be understood that "pharmaceutically acceptable salts and / or solvates thereof" means "pharmaceutically acceptable salts thereof", "pharmaceutically acceptable solvates thereof" and "solvates of pharmaceutically acceptable salts thereof". The preferred form of KVD900 is the free base form, particularly the anhydrous free base form (when it can keep the free base anhydrous).
[0053] The term "pharmaceutically acceptable salt" means a physiologically or toxicologically tolerable salt, which may be, for example, a pharmaceutically acceptable acid addition salt. For example, since KVD900 contains a basic group, such as a basic nitrogen, pharmaceutically acceptable acid addition salts that may be formed include hydrochloride, hydrobromide, sulfate, phosphate, acetate, citrate, lactate, tartrate, methanesulfonate, succinate, oxalate, phosphate, ethanesulfonate, toluenesulfonate, benzenesulfonate, naphthalene disulfonate, maleate, adipate, fumarate, hippurate, camphorate, xinafoate, paracetamol, dihydroxybenzoate, hydroxynaphthoate, succinate, ascorbate, oleate, bisulfate, etc. The pharmaceutically acceptable salt of the preferred compound is hydrochloride.
[0054] Hemi-salts of the acids may also be formed, for example hemi-sulfate salts.
[0055] For a review of suitable salts, see Stahl and Wermuth "Handbook of Pharmaceutical Salts: Properties, Selection and Use" (Wiley-VCH, Weinheim, Germany, 2002).
[0056] The term "solvate" is used herein to describe a molecular complex comprising a compound of the invention and one or more pharmaceutically acceptable solvent molecules (e.g., ethanol or water). The term "hydrate" is used when the solvent is water, and for the avoidance of any doubt, the term "hydrate" is encompassed by the term "solvate".
[0057] "KVD900" may include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, compounds in which hydrogen is replaced by deuterium or tritium, or compounds in which carbon is replaced by 13C or 14 C substituted compounds are within the scope of the present invention.
[0058] As used herein, the term "orodispersible tablets" (ODT) means tablets intended to be placed directly into the mouth where they rapidly disintegrate in the saliva before being swallowed. ODTs are not swallowable tablets, such as conventional swallowable tablets or capsules.
[0059] In the context of embodiments of the present invention, the term "mixture" as used herein refers to a mixture of KVD900 and excipients used in a manufacturing process to provide an ODT of the present invention. For example, a mixture of KVD900 and excipients may include a blend of KVD900 and its excipients produced before the blend is pressed into an ODT. A "mixture" may be a powder mixture.
[0060] The terms "acute attack of bradykinin-mediated angioedema," "acute attack of bradykinin-mediated angioedema," "attack of bradykinin-mediated angioedema," or "attack of bradykinin-mediated angioedema" are used interchangeably herein. "Bradykinin-mediated angioedema" can be HAE or BK-AEnH. Preferably, the bradykinin-mediated angioedema is HAE, and in this case, the "acute attack of bradykinin-mediated angioedema" would be an "acute attack of HAE," which can be used interchangeably with "acute attack of HAE," "attack of HAE," or "attack of HAE."
[0061] The term "hereditary angioedema" (abbreviated as HAE) means any bradykinin-mediated angioedema caused by inherited gene dysfunction, defect or mutation. As a result, the term "HAE" includes at least type 1 HAE, type 2 HAE and normal C1 inhibitor HAE (normal C1-Inh HAE).
[0062] The term "bradykinin-mediated non-hereditary angioedema" or "BK-AEnH" is bradykinin-mediated angioedema that is not caused by an inherited gene dysfunction / defect / mutation, i.e., it is not hereditary angioedema (HAE). The underlying cause of BK-AEnH may be unknown and / or undefined, but the signs and symptoms of BK-AEnH are similar to those of HAE, and without being bound by theory, this is believed to be due to the bradykinin-mediated pathway shared between HAE and BK-AEnH. Specific BK-AEnH that can be treated according to the present invention are selected from: non-hereditary angioedema with normal C1 inhibitor (AE-nC1Inh), which may be environmentally, hormonally or drug-induced; acquired angioedema; angioedema associated with allergic reactions; angioedema induced by angiotensin-converting enzyme (ACE or ACE) inhibitors; angioedema induced by dipeptidyl peptidase 4 inhibitors; and tPA-induced angioedema (tissue plasminogen activator-induced angioedema).
[0063] The skilled artisan will understand that in the context of bradykinin-mediated angioedema (BK-AEnH or preferably HAE), "on-demand" treatment means that KVD900 is administered in conjunction with a specific bradykinin-mediated angioedema episode (BK-AEnH episode or preferably HAE episode) when treatment is needed. As described herein, such a specific bradykinin-mediated angioedema episode (BK-AEnH episode or preferably HAE episode) can be ongoing (e.g., treatment is initiated after symptoms of a bradykinin-mediated angioedema episode are identified) or may occur (e.g., when a patient is expected to induce or trigger a bradykinin-mediated angioedema episode). Multiple doses of KVD900 can be administered as part of an on-demand treatment, but these multiple doses will be administered in conjunction with the same single bradykinin-mediated angioedema episode (BK-AEnH episode or preferably HAE episode). In other words, regardless of the situation of bradykinin-mediated angioedema attack (BK-AEnH attack or preferably HAE attack), "on demand" does not require continuous administration of KVD900 at regular time intervals (e.g., once a week, twice a week, etc.). In the treatment of the present invention, KVD900 is used when the patient needs a fast-acting therapeutic effect. Specific "on demand" treatments of the present invention include: (i) when KVD900 is administered after the symptoms of a bradykinin-mediated angioedema attack (BK-AEnH attack or preferably HAE attack) are identified, bradykinin-mediated angioedema attack (BK-AEnH attack or preferably HAE attack) is treated on demand, and (ii) preventively reduce the possibility of bradykinin-mediated angioedema attack (BK-AEnH attack or preferably HAE attack) on demand, such as when it is expected that a bradykinin-mediated angioedema attack (BK-AEnH attack or preferably HAE attack) may be induced (or triggered). These are discussed in more detail below.
[0064] In any treatment of the present invention described herein, the patient is preferably a human. Bradykinin-mediated angioedema (e.g., BK-AEnH or preferably HAE) can affect patients of all ages. Thus, a human patient can be a child (aged 0 to less than 18 years old) or an adult (18 years old or older). In any treatment described herein, the patient may have a tendency to angioedema. Specifically, the patient may be 12 years old and older. The patient may also be 2 years old and older.
[0065] The human patient may be 2 to less than 18 years old. The human patient may be 2 to less than 12 years old. The human patient may be 12 to less than 18 years old. The patient may be at least 70 years old.
[0066] As used herein, the term "bioequivalent" describes a dosage form that is therapeutically equivalent to the innovator's reference product (e.g., any approved dosage form containing KVD900) when given under the same conditions in a pharmacokinetic evaluation. For example, these can comply with the FDA Bioequivalence Testing Guide (https: / / www.fda.gov / files / drugs / published / Bioavaila bility-and-Bioequivalence-Studies-Submitted-in-NDAs-or-INDs-%E2%80%94-General-Considerations.pdf) or EMA Guide (https: / / www.ema.europa.eu / en / documents / scientific-guideline / guideline-investigation-bioequivalence-rev1_en.pdf). As used herein, a "bioequivalent" value means a pharmacokinetic value (such as Cmax or AUC of a formulation described herein) that exhibits substantially similar pharmacokinetic characteristics or therapeutic effects. Bioequivalence can be demonstrated by in vivo and in vitro methods. These methods may include, for example, pharmacokinetic, pharmacodynamic, clinical and in vitro studies. Bioequivalence may be demonstrated using any suitable pharmacokinetic measurement or combination of pharmacokinetic measurements known in the art, including loading dose, steady-state dose, initial or steady-state concentration of the drug, biological half-life, elimination rate, area under the curve (AUC), clearance rate, peak blood or plasma concentration (Cmax), time to peak concentration (Tmax), bioavailability and efficacy. When the geometric mean of AUC (0-t) (area under the plasma concentration curve from administration to the last observed concentration at time t), AUC (0-∞) (area under the plasma concentration curve extrapolated to infinite time), Cmax (maximum plasma concentration) is 80% to 125% (e.g., at a 90% confidence interval) of the reference pharmacokinetic value, the value may be bioequivalent to the reference pharmacokinetic value.
[0067] Thus, the present invention provides an orodispersible tablet that is bioequivalent to any orodispersible tablet described herein, wherein "bioequivalent" means that one or more of AUC(0-t), AUC(0-∞), Cmax is 80% to 125% (e.g., at a 90% confidence interval) of the orodispersible tablet described herein.
[0068] Thus, in any treatment of the invention disclosed herein, particularly after a dose of KVD900 of at least about 30 mg (more specifically, at least about 40 mg, at least about 50 mg, at least about 60 mg, at least about 70 mg or about 80 mg, such as about 80 mg to about 900 mg, about 100 mg to about 800 mg, about 200 mg to about 700 mg, about 300 mg to about 600 mg, or about 400 mg to about 600 mg, specifically 600 mg, or about 400 mg to about 500 mg, specifically 500 mg), in addition to inhibiting plasma kallikrein, the treatment may also reduce the cleavage of plasma prekallikrein to produce plasma kallikrein and / or reduce factor XIIa (FXIIa) production after administration. Thus, in some embodiments, treatment can block the cleavage of plasma kallikrein to form plasma kallikrein and / or block the cleavage of FXII to form FXIIa, particularly after a dose of KVD900 of at least about 30 mg (more specifically, at least about 40 mg, at least about 50 mg, at least about 60 mg, at least about 70 mg or about 80 mg, such as about 80 mg to about 900 mg, about 100 mg to about 800 mg, about 200 mg to about 700 mg, about 300 mg to about 600 mg, or about 400 mg to about 600 mg, specifically 600 mg, or about 400 mg to about 500 mg, specifically 500 mg).
[0069] Orodispersible tablet according to the invention
[0070] The orodispersible tablets of the present invention are advantageous because they allow for early intervention and have been developed to reduce the treatment barrier for bradykinin-mediated angioedema (e.g., HAE) attacks. In addition, the orodispersible tablets of the present invention can be manufactured on a large scale because the underlying mixture / blend used to make the ODT has excellent flowability and compressibility.
[0071] KVD900 in the orodispersible tablet of the present invention is administered at a safe and effective dose with a pharmacokinetic profile comparable to that of the swallowable immediate-release tablet used in the Phase 2 study.
[0072] The present invention provides an orodispersible tablet comprising KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof).
[0073] The orodispersible tablets of the present invention may contain from about 25 mg to about 1000 mg of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof). The orodispersible tablets of the present invention may contain from about 100 mg to about 1000 mg of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof). Unless expressly stated to the contrary, the amount of KVD900 in mg in the orodispersible tablets and mixtures of the present invention should be understood to mean the amount of KVD900 in its free base form (i.e., without taking into account the weight of any counterions, if present). The orodispersible tablets of the present invention may contain from about 150 mg to about 1000 mg of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof). The orodispersible tablets of the present invention may contain from about 100 mg to about 700 mg of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof). The orodispersible tablets of the present invention may contain about 200 mg to about 600 mg of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof). The orodispersible tablets of the present invention may contain about 200 mg to about 350 mg of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof). The orodispersible tablets of the present invention may contain about 250 mg to about 300 mg of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof). The orodispersible tablets of the present invention may contain about 250 mg of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof). Alternatively, the orodispersible tablets of the present invention may contain about 275 mg of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof). Alternatively, the orodispersible tablets of the present invention may contain about 300 mg of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof).
[0074] The orodispersible tablets of the present invention may contain about 25 mg to about 500 mg of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof). The orodispersible tablets of the present invention may contain about 25 mg to about 200 mg of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof). The orodispersible tablets of the present invention may contain about 25 mg to about 150 mg of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof). The orodispersible tablets of the present invention may contain about 150 mg of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof).
[0075] The orodispersible tablets of the present invention may contain about 25 mg to about 100 mg of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof). The orodispersible tablets of the present invention may contain about 25 mg to about 80 mg of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof). The orodispersible tablets of the present invention may contain about 25 mg to about 75 mg of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof). The orodispersible tablets of the present invention may contain about 75 mg of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof). Alternatively, the orodispersible tablets of the present invention may contain about 50 mg of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof). Alternatively, the orodispersible tablets of the present invention may contain about 25 mg of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof).
[0076] The orodispersible tablets of the present invention may contain about 10% to about 70% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof). The orodispersible tablets of the present invention may contain about 15% to about 60% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof). The orodispersible tablets of the present invention may contain about 15% to about 50% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof). The orodispersible tablets of the present invention may contain about 20% to about 50% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof). The orodispersible tablets of the present invention may contain about 25% to about 50% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof). The orodispersible tablets of the present invention may contain about 26% to about 50% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof). The orodispersible tablets of the present invention may contain about 25% to about 40% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof). The orodispersible tablets of the present invention may contain about 26% to about 40% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof). The orodispersible tablets of the present invention may contain about 25% to about 35% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof). The orodispersible tablets of the present invention may contain about 26% to about 35% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof). The orodispersible tablets of the present invention may contain about 25% to about 30% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof). The orodispersible tablets of the present invention may contain about 26% to about 30% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof). The orodispersible tablet of the present invention may contain about 15% to about 25% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof). The orodispersible tablet of the present invention may contain about 30% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof).
[0077] The orodispersible tablet of the present invention may contain one or more of a filler, a binder, a disintegrant, a lubricant, a flow enhancer, a sweetener and a flavoring agent.
[0078] The orodispersible tablets of the present invention may further comprise a filler. The orodispersible tablets of the present invention may further comprise one or more fillers. The filler may be selected from the group consisting of isomalt, lactose and its derivatives (e.g., lactose monohydrate, spray-dried lactose, anhydrous lactose), mannitol (e.g., granulated mannitol, powdered mannitol, spray-dried mannitol (e.g., Mannogem )), sorbitol, sucrose, starch, pregelatinized starch and mixtures thereof. Preferably, the filler may be selected from the group consisting of isomalt, lactose and its derivatives (e.g., lactose monohydrate, spray-dried lactose, anhydrous lactose), mannitol (e.g., granulated mannitol, powdered mannitol, spray-dried mannitol (e.g., Mannogem )), sorbitol and pregelatinized starch. The one or more fillers can be mannitol (e.g., granulated mannitol, powdered mannitol, spray-dried mannitol (e.g., Mannogem Even more preferably, the one or more fillers may be selected from granulated mannitol and spray-dried mannitol (e.g., Mannogem ). One or more fillers can be granulated mannitol. One or more fillers can be spray dried mannitol (e.g., Mannogem ).
[0079] The one or more fillers may be present in about 30% to about 80% by weight of the orodispersible tablet. The one or more fillers may be present in about 40% to about 70% by weight of the orodispersible tablet. The one or more fillers may be present in about 40% to about 65% by weight of the orodispersible tablet. The one or more fillers may be present in about 50% to about 65% by weight of the orodispersible tablet. The one or more fillers may be present in about 50% to about 60% by weight of the orodispersible tablet. The one or more fillers may be present in about 50% to about 55% by weight of the orodispersible tablet. The one or more fillers may be present in about 53% to about 54% by weight of the orodispersible tablet. Preferably, the one or more fillers may be present in about 53.7% by weight of the orodispersible tablet.
[0080] The orodispersible tablets of the present invention may further comprise a binder. The orodispersible tablets of the present invention may further comprise one or more binders. The binder may also be selected from: sugars (such as glucose, sucrose, fructose, dextrose, lactose), sugar alcohols (such as xylitol, maltitol, erythritol, sorbitol), polysaccharides (such as crystalline cellulose, microcrystalline cellulose (e.g., silicified microcrystalline cellulose), powdered cellulose, methylcellulose, carboxymethylcellulose and salts, hydroxypropyl methylcellulose), corn starch, starch 1500, gum arabic, other natural polymers (such as gelatin), polyethylene glycol, cross-linked acrylic acid and acrylic acid copolymers (e.g., ), inorganic compounds (such as calcium carbonate), calcium phosphate (e.g., anhydrous calcium hydrogen phosphate, calcium hydrogen phosphate, tricalcium phosphate), tricalcium citrate and mixtures thereof. More specifically, the binder may be selected from the group consisting of glucose, lactose, corn starch, starch 1500, gelatin, gum arabic, methylcellulose, carboxymethylcellulose and salts, hydroxypropyl methylcellulose, microcrystalline cellulose (e.g., silicified microcrystalline cellulose) and mixtures thereof. Preferably, the binder is microcrystalline cellulose or hydroxypropyl methylcellulose. Even more preferably, the binder is silicified microcrystalline cellulose.
[0081] One or more adhesives may be present in about 5% to about 40% by weight of the orodispersible tablet. One or more adhesives may be present in about 5% to about 30% by weight of the orodispersible tablet. One or more adhesives may be present in about 5% to about 20% by weight of the orodispersible tablet. One or more adhesives may be present in about 5% to about 15% by weight of the orodispersible tablet. One or more adhesives may be present in about 5% to about 10% by weight of the orodispersible tablet. One or more adhesives may be present in about 8% to about 10% by weight of the orodispersible tablet. Preferably, one or more adhesives may be present in about 10% by weight (e.g., 10.01%, 9.74%, or 9.69% by weight) of the orodispersible tablet.
[0082] In the orodispersible tablets of the present invention, the one or more fillers and the one or more binders may be present in about 50% to about 90% by weight of the orodispersible tablet. In the orodispersible tablets of the present invention, the one or more fillers and the one or more binders may be present in about 50% to about 70% by weight of the orodispersible tablet. In the orodispersible tablets of the present invention, the one or more fillers and the one or more binders may be present in about 50% to about 65% by weight of the orodispersible tablet. In the orodispersible tablets of the present invention, the one or more fillers and the one or more binders may be present in about 55% to about 65% by weight of the orodispersible tablet. Preferably, the one or more fillers and the one or more binders may be present in about 64% by weight of the orodispersible tablet. Even more preferably, the one or more fillers and the one or more binders may be present in about 63.7% by weight of the orodispersible tablet.
[0083] In the orodispersible tablets of the present invention, the weight % ratio of one or more fillers to one or more binders may be from about 3:1 to about 8:1. In the orodispersible tablets of the present invention, the weight % ratio of one or more fillers to one or more binders may be from about 4:1 to about 7:1. In the orodispersible tablets of the present invention, the weight % ratio of one or more fillers to one or more binders may be from about 4:1 to about 6:1. In the orodispersible tablets of the present invention, the weight % ratio of one or more fillers to one or more binders may be from about 5:1 to about 6:1. In the orodispersible tablets of the present invention, the weight % ratio of one or more fillers to one or more binders may be from about 4:1 to about 7:1. Preferably, in the orodispersible tablets of the present invention, the weight % ratio of one or more fillers to one or more binders may be from about 5:1 to about 5.5:1, more specifically from about 5.3:1 to about 5.4:1 (e.g., 5.37:1).
[0084] More specifically, in the orodispersible tablets of the present invention, the weight % ratio of mannitol to microcrystalline cellulose is about 3: 1 to about 8: 1, about 4: 1 to about 7: 1, about 4: 1 to about 6: 1, about 5: 1 to about 6: 1, or about 4: 1 to about 7: 1. Preferably, in the orodispersible tablets of the present invention, the weight % ratio of mannitol to microcrystalline cellulose is about 5: 1 to about 5.5: 1, more specifically about 5.3: 1 to about 5.4: 1 (e.g., 5.37: 1).
[0085] The orodispersible tablets of the present invention may also contain a disintegrant. The orodispersible tablets of the present invention may also contain one or more disintegrants. The disintegrant may be starch USP, starch 1500, cellulose derivatives (e.g., carboxymethyl cellulose and salts, hydroxypropyl methyl cellulose), guar gum, alginic acid and salts, sodium starch glycolate, cross-linked cellulose (e.g., cross-linked sodium carboxymethyl cellulose, such as the product sold under the trade name Nymce those of the type 2, 3 or 4), synthetic polymers such as cross-linked polyvinyl pyrrolidone (e.g., crospovidone, Crospovidone ), soybean polysaccharide, calcium silicate, pearlitol Flash (co-processed mannitol / corn starch) and mixtures thereof. More specifically, the disintegrant is selected from: cross-linked cellulose (e.g., ), synthetic polymers such as cross-linked polyvinyl pyrrolidone (e.g., crospovidone, Crospovidone ), sodium starch glycolate, and mixtures thereof. Preferably, the disintegrant is selected from polyvinyl pyrrolidone (crospovidone), sodium starch glycolate, cross-linked sodium carboxymethyl cellulose. Even more preferably, the disintegrant is polyvinyl pyrrolidone (crospovidone).
[0086] One or more disintegrants may be present at about 1% to about 15% by weight of the orodispersible tablet. One or more disintegrants may be present at about 1% to about 14% by weight of the orodispersible tablet. One or more disintegrants may be present at about 1% to about 10% by weight of the orodispersible tablet. One or more disintegrants may be present at about 5% to about 10% by weight of the orodispersible tablet. One or more disintegrants may be present at about 1% to about 9% by weight of the orodispersible tablet. One or more disintegrants may be present at about 2% to about 8% by weight of the orodispersible tablet. One or more disintegrants may be present at about 2% to about 7% by weight of the orodispersible tablet. One or more disintegrants may be present at about 3% to about 6% by weight of the orodispersible tablet. One or more disintegrants may be present at about 4% to about 6% by weight of the orodispersible tablet. One or more disintegrants may be present at about 4% to about 5% by weight of the orodispersible tablet. Preferably, one or more disintegrants may be present at about 5% by weight of the orodispersible tablet.
[0087] The orodispersible tablets of the present invention may also contain a lubricant. The orodispersible tablets of the present invention may also be free of lubricants. The orodispersible tablets of the present invention may also contain a lubricant. The lubricant may be selected from the group consisting of magnesium stearate, calcium stearate, stearic acid, hydrogenated vegetable oils, mineral oils, glyceryl behenate, glyceryl palmitostearate, polyethylene glycol, polyoxyethylene stearate, lauryl sulfate, talc, paraffin, sodium stearyl fumarate, and mixtures thereof. Preferably, the lubricant is selected from the group consisting of magnesium stearate, sodium stearyl fumarate, and talc. Even more preferably, the lubricant is magnesium stearate.
[0088] The lubricant may be an internal lubricant or an external lubricant. Preferably, the lubricant is an external lubricant. As used herein, an external lubricant means a lubricant that aids flow during the manufacturing process and therefore may be present in trace amounts in the final ODT, but is not actively added to the blend / mixture. Even more preferably, the only lubricant used in the orodispersible tablet of the present invention is an external lubricant.
[0089] One or more lubricants may be present in about 0% to about 3% by weight of the orodispersible tablet. One or more lubricants may be present in about 0.5% to about 3% by weight of the orodispersible tablet. One or more lubricants may be present in about 0.5% to about 1% by weight of the orodispersible tablet. One or more lubricants may be present in about 0.5% to about 1% by weight of the orodispersible tablet. One or more lubricants may be present in about 0.5% to about 1.25% by weight of the orodispersible tablet. One or more lubricants may be present in about 0.75% to about 1.25% by weight of the orodispersible tablet. One or more lubricants may be present in about 1% to about 2% by weight of the orodispersible tablet. One or more lubricants may be present in about 0.5% to about 1% by weight of the orodispersible tablet. Preferably, one or more lubricants are present in trace amounts. Even more preferably, there is a lubricant that is present in trace amounts (e.g., less than 0.05% by weight).
[0090] In preferred orodispersible tablets of the invention, the lubricant is an external lubricant, present in trace amounts (eg, less than 0.05% by weight).
[0091] The orodispersible tablet of the present invention may also contain a flow enhancer. Preferably, the flow enhancer is silicon dioxide.
[0092] The flow enhancer may be present at about 0.5% to about 3% by weight of the orodispersible tablet. The flow enhancer may be present at about 0.5% to about 2% by weight of the orodispersible tablet. The flow enhancer may be present at about 0.5% to about 1% by weight of the orodispersible tablet. The flow enhancer may be present at about 0.6% to about 0.9% by weight of the orodispersible tablet. The flow enhancer may be present at about 0.6% to about 0.8% by weight of the orodispersible tablet. The flow enhancer may be present at about 0.7% to about 0.8% by weight of the orodispersible tablet. The flow enhancer may be present at about 0.6% to about 0.75% by weight of the orodispersible tablet. The flow enhancer may be present at about 0.75% to about 0.8% by weight of the orodispersible tablet. Preferably, the flow enhancer may be present at about 0.75% by weight of the orodispersible tablet.
[0093] The orodispersible tablet of the present invention may further comprise a sweetener. The orodispersible tablet of the present invention may further comprise one or more sweeteners. The sweetener may be selected from the group consisting of sucralose, aspartame, sugar derivatives, glucose, polydextrose, xylitol, fructose, sucrose, lactitol, maltitol and saccharin sodium (and mixtures thereof). Preferably, the sweetener is selected from the group consisting of sucralose, aspartame, sugar derivatives, glucose, polydextrose, fructose, lactitol and maltitol. Even more preferably, the sweetener is sucralose.
[0094] One or more sweeteners may be present in an amount of about 0.1% to about 10% by weight of the orodispersible tablet. One or more sweeteners may be present in an amount of about 0.1% to about 7% by weight of the orodispersible tablet. One or more sweeteners may be present in an amount of about 0.1% to about 4% by weight of the orodispersible tablet. One or more sweeteners may be present in an amount of about 0.1% to about 3% by weight of the orodispersible tablet. One or more sweeteners may be present in an amount of about 0.1% to about 2% by weight of the orodispersible tablet. One or more sweeteners may be present in an amount of about 0.1% to about 1% by weight of the orodispersible tablet. One or more sweeteners may be present in an amount of about 0.2% to about 1% by weight of the orodispersible tablet. One or more sweeteners may be present in an amount of about 0.2% to about 0.9% by weight of the orodispersible tablet. One or more sweeteners may be present in an amount of about 0.2% to about 0.8% by weight of the orodispersible tablet. One or more sweeteners may be present in an amount of about 0.2% to about 0.7% by weight of the orodispersible tablet. One or more sweeteners may be present in an amount of about 0.3% to about 0.7% by weight of an orodispersible tablet. One or more sweeteners may be present in an amount of about 0.3% to about 0.6% by weight of an orodispersible tablet. One or more sweeteners may be present in an amount of about 0.4% to about 0.6% by weight of an orodispersible tablet. One or more sweeteners may be present in an amount of about 0.4% to about 0.5% by weight of an orodispersible tablet. One or more sweeteners may be present in an amount of about 0.5% to about 0.6% by weight of an orodispersible tablet. One or more sweeteners may be present in an amount of about 0.45% to about 0.55% by weight of an orodispersible tablet. Preferably, one or more sweeteners may be present in an amount of about 0.5% by weight of an orodispersible tablet.
[0095] The orodispersible tablet of the present invention may also include a flavoring agent. The orodispersible tablet of the present invention may also include one or more flavoring agents. The flavoring agent may be selected from: lemon flavoring agent, mixed berry flavoring agent, grape flavoring agent, mint flavoring agent, mint flavoring agent, banana flavoring agent, chocolate flavoring agent, maple flavoring agent, strawberry flavoring agent, raspberry flavoring agent, cherry flavoring agent, orange flavoring agent and vanilla flavoring agent and mixtures thereof. The flavoring agent may be selected from: lemon flavoring agent, mixed berry flavoring agent, grape flavoring agent, mint flavoring agent, mint flavoring agent, banana flavoring agent, chocolate flavoring agent, maple flavoring agent and orange flavoring agent. In one embodiment, the flavoring agent is a mint flavoring agent. In another embodiment, the flavoring agent is a lemon flavoring agent. Preferably, the flavoring agent is a grape flavoring agent. Even more preferably, the flavoring agent is a mixed berry flavoring agent. Alternatively, the orodispersible tablet may be unflavored.
[0096] One or more flavoring agents may be present at about 0.03% to about 1% by weight of the orodispersible tablet. One or more flavoring agents may be present at about 0.03% to about 0.8% by weight of the orodispersible tablet. One or more flavoring agents may be present at about 0.03% to about 0.5% by weight of the orodispersible tablet. One or more flavoring agents may be present at about 0.03% to about 0.4% by weight of the orodispersible tablet. One or more flavoring agents may be present at about 0.03% to about 0.3% by weight of the orodispersible tablet. One or more flavoring agents may be present at about 0.05% to about 0.2% by weight of the orodispersible tablet. One or more flavoring agents may be present at about 0.05% to about 0.1% by weight of the orodispersible tablet. One or more flavoring agents may be present at about 0.03% to about 0.09% by weight of the orodispersible tablet. One or more flavoring agents may be present at about 0.03% to about 0.08% by weight of the orodispersible tablet. One or more flavoring agents may be present at about 0.03% to about 0.07% by weight of the orodispersible tablet. One or more flavoring agents may be present at about 0.03% to about 0.06% by weight of the orodispersible tablet. One or more flavoring agents may be present at about 0.04% to about 0.06% by weight of the orodispersible tablet. One or more flavoring agents may be present at about 0.04% to about 0.05% by weight of the orodispersible tablet. One or more flavoring agents may be present at about 0.05% to about 0.06% by weight of the orodispersible tablet. One or more flavoring agents may be present at about 0.045% to about 0.055% by weight of the orodispersible tablet. Preferably, one or more flavoring agents may be present at about 0.05% by weight of the orodispersible tablet.
[0097] For example, when the flavoring agent is selected from a lemon flavoring agent or a mixed berry flavoring agent, the flavoring agent may be present at about 0.2% to about 0.5% by weight of the orodispersible tablet. The flavoring agent may be present at about 0.2% to about 0.4% by weight of the orodispersible tablet. The flavoring agent may be present at about 0.3% to about 0.4% by weight of the orodispersible tablet. One or more flavoring agents may be present at about 0.36% by weight of the orodispersible tablet. One or more flavoring agents may be present at about 0.31% by weight of the orodispersible tablet.
[0098] The orodispersible tablets of the present invention may contain about 0.2% to about 0.5% by weight of grape flavoring. The orodispersible tablets of the present invention may contain about 0.36% by weight of lemon flavoring. The orodispersible tablets of the present invention may contain about 0.31% by weight of mixed berry flavoring.
[0099] The orodispersible tablets of the present invention may contain mannitol (e.g., granulated mannitol and / or spray-dried mannitol (e.g., Mannogem )), one or more of microcrystalline cellulose (e.g., silicified microcrystalline cellulose) as a binder and polyvinyl pyrrolidone (crospovidone) as a disintegrant.
[0100] The orodispersible tablets of the present invention may contain mannitol (e.g., granulated mannitol and / or spray-dried mannitol (e.g., Mannogem )), two or more of microcrystalline cellulose (e.g., silicified microcrystalline cellulose) as a binder and polyvinyl pyrrolidone (crospovidone) as a disintegrant.
[0101] The orodispersible tablets of the present invention may contain mannitol (e.g., granulated mannitol and / or spray-dried mannitol (e.g., Mannogem )), microcrystalline cellulose (e.g., silicified microcrystalline cellulose) as a binder, and polyvinyl pyrrolidone (crospovidone) as a disintegrant.
[0102] The orodispersible tablets of the present invention may contain mannitol (e.g., granulated mannitol and / or spray-dried mannitol (e.g., Mannogem )), microcrystalline cellulose (e.g., silicified microcrystalline cellulose) as a binder, polyvinyl pyrrolidone (crospovidone) as a disintegrant, silicon dioxide as a flow enhancer, sucralose as a sweetener, and one or more of a mint-flavored natural flavoring as a flavoring agent.
[0103] The orodispersible tablets of the present invention may contain mannitol (e.g., granulated mannitol and / or spray-dried mannitol (e.g., Mannogem )), microcrystalline cellulose (e.g., silicified microcrystalline cellulose) as a binder, polyvinyl pyrrolidone (crospovidone) as a disintegrant, silicon dioxide as a flow enhancer, sucralose as a sweetener, and one or more of a lemon flavoring as a flavoring.
[0104] The orodispersible tablets of the present invention may contain mannitol (e.g., granulated mannitol and / or spray-dried mannitol (e.g., Mannogem )), one or more of microcrystalline cellulose (e.g., silicified microcrystalline cellulose) as a binder, polyvinyl pyrrolidone (crospovidone) as a disintegrant, silicon dioxide as a flow enhancer, sucralose as a sweetener, and mixed berry flavoring as a flavoring.
[0105] The orodispersible tablets of the present invention may contain mannitol (e.g., granulated mannitol and / or spray-dried mannitol (e.g., Mannogem )), microcrystalline cellulose (e.g., silicified microcrystalline cellulose) as a binder, polyvinyl pyrrolidone (crospovidone) as a disintegrant, silicon dioxide as a flow enhancer, sucralose as a sweetener, and one or more of a grape flavoring as a flavoring.
[0106] The orodispersible tablets of the present invention may contain mannitol (e.g., granulated mannitol and / or spray-dried mannitol (e.g., Mannogem )), microcrystalline cellulose (e.g., silicified microcrystalline cellulose) as a binder, polyvinyl pyrrolidone (crospovidone) as a disintegrant, silicon dioxide as a flow enhancer, sucralose as a sweetener, and two or more of a mint-flavored natural flavoring as a flavoring.
[0107] The orodispersible tablets of the present invention may contain mannitol (e.g., granulated mannitol and / or spray-dried mannitol (e.g., Mannogem )), microcrystalline cellulose (e.g., silicified microcrystalline cellulose) as a binder, polyvinyl pyrrolidone (crospovidone) as a disintegrant, silicon dioxide as a flow enhancer, sucralose as a sweetener, and two or more of a lemon flavoring as a flavoring.
[0108] The orodispersible tablets of the present invention may contain mannitol (e.g., granulated mannitol and / or spray-dried mannitol (e.g., Mannogem )), microcrystalline cellulose (e.g., silicified microcrystalline cellulose) as a binder, polyvinyl pyrrolidone (crospovidone) as a disintegrant, silicon dioxide as a flow enhancer, sucralose as a sweetener, and two or more of a mixed berry flavor as a flavoring.
[0109] The orodispersible tablets of the present invention may contain mannitol (e.g., granulated mannitol and / or spray-dried mannitol (e.g., Mannogem )), microcrystalline cellulose (e.g., silicified microcrystalline cellulose) as a binder, polyvinyl pyrrolidone (crospovidone) as a disintegrant, silicon dioxide as a flow enhancer, sucralose as a sweetener, and two or more of a grape flavoring as a flavoring.
[0110] The orodispersible tablets of the present invention may contain mannitol (e.g., granulated mannitol and / or spray-dried mannitol (e.g., Mannogem )), microcrystalline cellulose (e.g., silicified microcrystalline cellulose) as a binder, polyvinyl pyrrolidone (crospovidone) as a disintegrant, silicon dioxide as a flow enhancer, sucralose as a sweetener, and three or more of a mint-flavored natural flavoring as a flavoring.
[0111] The orodispersible tablets of the present invention may contain mannitol (e.g., granulated mannitol and / or spray-dried mannitol (e.g., Mannogem )), microcrystalline cellulose (e.g., silicified microcrystalline cellulose) as a binder, polyvinyl pyrrolidone (crospovidone) as a disintegrant, silicon dioxide as a flow enhancer, sucralose as a sweetener, and three or more of a lemon flavoring as a flavoring.
[0112] The orodispersible tablets of the present invention may contain mannitol (e.g., granulated mannitol and / or spray-dried mannitol (e.g., Mannogem )), microcrystalline cellulose (e.g., silicified microcrystalline cellulose) as a binder, polyvinyl pyrrolidone (crospovidone) as a disintegrant, silicon dioxide as a flow enhancer, sucralose as a sweetener, and three or more of a mixed berry flavor as a flavoring.
[0113] The orodispersible tablets of the present invention may contain mannitol (e.g., granulated mannitol and / or spray-dried mannitol (e.g., Mannogem )), microcrystalline cellulose (e.g., silicified microcrystalline cellulose) as a binder, polyvinyl pyrrolidone (crospovidone) as a disintegrant, silicon dioxide as a flow enhancer, sucralose as a sweetener, and three or more of a grape flavoring as a flavoring.
[0114] The orodispersible tablets of the present invention may contain mannitol (e.g., granulated mannitol and / or spray-dried mannitol (e.g., Mannogem )), microcrystalline cellulose (e.g., silicified microcrystalline cellulose) as a binder, polyvinyl pyrrolidone (crospovidone) as a disintegrant, magnesium stearate as a lubricant, silicon dioxide as a flow enhancer, sucralose as a sweetener, and one or more of a mint-flavored natural flavoring as a flavoring.
[0115] The orodispersible tablets of the present invention may contain mannitol (e.g., granulated mannitol and / or spray-dried mannitol (e.g., Mannogem )), microcrystalline cellulose (e.g., silicified microcrystalline cellulose) as a binder, polyvinyl pyrrolidone (crospovidone) as a disintegrant, magnesium stearate as a lubricant, silicon dioxide as a flow enhancer, sucralose as a sweetener, and one or more of a lemon flavoring as a flavoring.
[0116] The orodispersible tablets of the present invention may contain mannitol (e.g., granulated mannitol and / or spray-dried mannitol (e.g., Mannogem )), microcrystalline cellulose (e.g., silicified microcrystalline cellulose) as a binder, polyvinyl pyrrolidone (crospovidone) as a disintegrant, magnesium stearate as a lubricant, silicon dioxide as a flow enhancer, sucralose as a sweetener, and one or more of a mixed berry flavor as a flavoring.
[0117] The orodispersible tablets of the present invention may contain mannitol (e.g., granulated mannitol and / or spray-dried mannitol (e.g., Mannogem )), microcrystalline cellulose (e.g., silicified microcrystalline cellulose) as a binder, polyvinyl pyrrolidone (crospovidone) as a disintegrant, magnesium stearate as a lubricant, silicon dioxide as a flow enhancer, sucralose as a sweetener, and one or more of a grape flavoring as a flavoring.
[0118] The orodispersible tablets of the present invention may contain mannitol (e.g., granulated mannitol and / or spray-dried mannitol (e.g., Mannogem )), microcrystalline cellulose (e.g., silicified microcrystalline cellulose) as a binder, polyvinyl pyrrolidone (crospovidone) as a disintegrant, magnesium stearate as a lubricant, silicon dioxide as a flow enhancer, sucralose as a sweetener, and two or more of a mint-flavored natural flavoring as a flavoring.
[0119] The orodispersible tablets of the present invention may contain mannitol (e.g., granulated mannitol and / or spray-dried mannitol (e.g., Mannogem )), microcrystalline cellulose (e.g., silicified microcrystalline cellulose) as a binder, polyvinyl pyrrolidone (crospovidone) as a disintegrant, magnesium stearate as a lubricant, silicon dioxide as a flow enhancer, sucralose as a sweetener, and two or more of a lemon flavoring as a flavoring.
[0120] The orodispersible tablets of the present invention may contain mannitol (e.g., granulated mannitol and / or spray-dried mannitol (e.g., Mannogem )), microcrystalline cellulose (e.g., silicified microcrystalline cellulose) as a binder, polyvinyl pyrrolidone (crospovidone) as a disintegrant, magnesium stearate as a lubricant, silicon dioxide as a flow enhancer, sucralose as a sweetener, and two or more of a mixed berry flavoring as a flavoring.
[0121] The orodispersible tablets of the present invention may contain mannitol (e.g., granulated mannitol and / or spray-dried mannitol (e.g., Mannogem )), microcrystalline cellulose (e.g., silicified microcrystalline cellulose) as a binder, polyvinyl pyrrolidone (crospovidone) as a disintegrant, magnesium stearate as a lubricant, silicon dioxide as a flow enhancer, sucralose as a sweetener, and two or more of a grape flavoring as a flavoring.
[0122] The orodispersible tablets of the present invention may contain mannitol (e.g., granulated mannitol and / or spray-dried mannitol (e.g., Mannogem )) and three or more of microcrystalline cellulose (e.g., silicified microcrystalline cellulose) as a binder, polyvinyl pyrrolidone (crospovidone) as a disintegrant, magnesium stearate as a lubricant, silicon dioxide as a flow enhancer, sucralose as a sweetener, and mint-flavored natural flavoring as a flavoring.
[0123] The orodispersible tablets of the present invention may contain mannitol (e.g., granulated mannitol and / or spray-dried mannitol (e.g., Mannogem )) and three or more of microcrystalline cellulose (e.g., silicified microcrystalline cellulose) as a binder, polyvinyl pyrrolidone (crospovidone) as a disintegrant, magnesium stearate as a lubricant, silicon dioxide as a flow enhancer, sucralose as a sweetener, and lemon flavoring as a flavoring.
[0124] The orodispersible tablets of the present invention may contain mannitol (e.g., granulated mannitol and / or spray-dried mannitol (e.g., Mannogem )) and three or more of microcrystalline cellulose (e.g., silicified microcrystalline cellulose) as a binder, polyvinyl pyrrolidone (crospovidone) as a disintegrant, magnesium stearate as a lubricant, silicon dioxide as a flow enhancer, sucralose as a sweetener, and mixed berry flavor as a flavoring.
[0125] The orodispersible tablets of the present invention may contain mannitol (e.g., granulated mannitol and / or spray-dried mannitol (e.g., Mannogem )) and three or more of microcrystalline cellulose (e.g., silicified microcrystalline cellulose) as a binder, polyvinyl pyrrolidone (crospovidone) as a disintegrant, magnesium stearate as a lubricant, silicon dioxide as a flow enhancer, sucralose as a sweetener, and grape flavoring as a flavoring.
[0126] The orodispersible tablets of the present invention may comprise granulated mannitol, spray-dried mannitol (e.g., Mannogem ), microcrystalline cellulose (e.g., silicified microcrystalline cellulose), polyvinyl pyrrolidone (crospovidone), silicon dioxide, sucralose, and one or more of a mint-flavored natural flavoring agent.
[0127] The orodispersible tablets of the present invention may comprise granulated mannitol, spray-dried mannitol (e.g., Mannogem ), microcrystalline cellulose (e.g., silicified microcrystalline cellulose), polyvinyl pyrrolidone (crospovidone), silicon dioxide, sucralose, and one or more of a lemon flavoring.
[0128] The orodispersible tablets of the present invention may comprise granulated mannitol, spray-dried mannitol (e.g., Mannogem ), microcrystalline cellulose (e.g., silicified microcrystalline cellulose), polyvinylpyrrolidone (crospovidone), silicon dioxide, sucralose, and mixed berry flavoring.
[0129] The orodispersible tablets of the present invention may comprise granulated mannitol, spray-dried mannitol (e.g., Mannogem ), microcrystalline cellulose (e.g., silicified microcrystalline cellulose), polyvinyl pyrrolidone (crospovidone), silicon dioxide, sucralose, and grape flavoring.
[0130] The orodispersible tablets of the present invention may comprise granulated mannitol, spray-dried mannitol (e.g., Mannogem ), microcrystalline cellulose (e.g., silicified microcrystalline cellulose), polyvinyl pyrrolidone (crospovidone), magnesium stearate, silicon dioxide, sucralose, and one or more of a mint-flavored natural flavoring.
[0131] The orodispersible tablets of the present invention may comprise granulated mannitol, spray-dried mannitol (e.g., Mannogem ), microcrystalline cellulose (e.g., silicified microcrystalline cellulose), polyvinyl pyrrolidone (crospovidone), magnesium stearate, silicon dioxide, sucralose, and one or more of a lemon flavoring.
[0132] The orodispersible tablets of the present invention may comprise granulated mannitol, spray-dried mannitol (e.g., Mannogem ), microcrystalline cellulose (e.g., silicified microcrystalline cellulose), polyvinylpyrrolidone (crospovidone), magnesium stearate, silicon dioxide, sucralose, and one or more of mixed berry flavoring.
[0133] The orodispersible tablets of the present invention may comprise granulated mannitol, spray-dried mannitol (e.g., Mannogem ), microcrystalline cellulose (e.g., silicified microcrystalline cellulose), polyvinyl pyrrolidone (crospovidone), magnesium stearate, silicon dioxide, sucralose, and grape flavoring.
[0134] The orodispersible tablets of the present invention may comprise granulated mannitol, spray-dried mannitol (e.g., Mannogem ), one or more of silicified microcrystalline cellulose, polyvinyl pyrrolidone (crospovidone), silicon dioxide, sucralose and mint-flavored natural flavoring.
[0135] The orodispersible tablets of the present invention may comprise granulated mannitol, spray-dried mannitol (e.g., Mannogem ), one or more of silicified microcrystalline cellulose, polyvinyl pyrrolidone (crospovidone), silicon dioxide, sucralose and lemon flavor.
[0136] The orodispersible tablets of the present invention may comprise granulated mannitol, spray-dried mannitol (e.g., Mannogem ), one or more of silicified microcrystalline cellulose, polyvinyl pyrrolidone (crospovidone), silicon dioxide, sucralose and mixed berry flavoring.
[0137] The orodispersible tablets of the present invention may comprise granulated mannitol, spray-dried mannitol (e.g., Mannogem ), one or more of silicified microcrystalline cellulose, polyvinyl pyrrolidone (crospovidone), silicon dioxide, sucralose and grape flavoring.
[0138] The orodispersible tablets of the present invention may comprise granulated mannitol, spray-dried mannitol (e.g., Mannogem ), one or more of silicified microcrystalline cellulose, polyvinyl pyrrolidone (crospovidone), magnesium stearate, silicon dioxide, sucralose and mint-flavored natural flavoring.
[0139] The orodispersible tablets of the present invention may comprise granulated mannitol, spray-dried mannitol (e.g., Mannogem ), one or more of silicified microcrystalline cellulose, polyvinyl pyrrolidone (crospovidone), magnesium stearate, silicon dioxide, sucralose and lemon flavor.
[0140] The orodispersible tablets of the present invention may comprise granulated mannitol, spray-dried mannitol (e.g., Mannogem ), one or more of silicified microcrystalline cellulose, polyvinyl pyrrolidone (crospovidone), magnesium stearate, silicon dioxide, sucralose and mixed berry flavoring.
[0141] The orodispersible tablets of the present invention may comprise granulated mannitol, spray-dried mannitol (e.g., Mannogem ), one or more of silicified microcrystalline cellulose, polyvinyl pyrrolidone (crospovidone), magnesium stearate, silicon dioxide, sucralose and grape flavoring.
[0142] The orodispersible tablets of the present invention may comprise about 25% to about 50% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof) and one or more fillers (e.g., granular mannitol and / or spray-dried mannitol) present at about 30% to 80% by weight of the orodispersible tablet.
[0143] The orodispersible tablets of the present invention may comprise about 25% to about 50% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof) and one or more binders (e.g., silicified microcrystalline cellulose) present at about 5% to about 30% by weight of the orodispersible tablet.
[0144] The orodispersible tablets of the present invention may comprise from about 25% to about 50% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof) and one or more disintegrants (e.g., polyvinylpyrrolidone (crospovidone)) present at 1% to about 10% by weight of the orodispersible tablet.
[0145] The orodispersible tablets of the present invention may comprise about 25% to about 50% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof), one or more fillers (e.g., granular mannitol and / or spray-dried mannitol) present at about 30% to 80% by weight of the orodispersible tablet, one or more binders (e.g., silicified microcrystalline cellulose) present at about 5% to about 30% by weight of the orodispersible tablet, and one or more disintegrants (e.g., polyvinyl pyrrolidone (crospovidone)) present at 1% to about 10% by weight of the orodispersible tablet.
[0146] The orodispersible tablets of the present invention may comprise from about 26 wt % to about 50 wt % of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof) and one or more fillers (e.g., granular mannitol and / or spray-dried mannitol) present at about 30 wt % to 80 wt % of the orodispersible tablet.
[0147] The orodispersible tablets of the present invention may comprise about 26 wt % to about 50 wt % of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof) and one or more binders (e.g., silicified microcrystalline cellulose) present at about 5 wt % to about 30 wt % of the orodispersible tablet.
[0148] The orodispersible tablets of the present invention may comprise from about 26 wt % to about 50 wt % of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof) and one or more disintegrants (e.g., polyvinylpyrrolidone (crospovidone)) present at 1 wt % to about 10 wt % of the orodispersible tablet.
[0149] The orodispersible tablets of the present invention may comprise about 26 wt % to about 50 wt % of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof), one or more fillers (e.g., granular mannitol and / or spray-dried mannitol) present at about 30 wt % to 80 wt % of the orodispersible tablet, one or more binders (e.g., silicified microcrystalline cellulose) present at about 5 wt % to about 30 wt % of the orodispersible tablet, and one or more disintegrants (e.g., polyvinyl pyrrolidone (crospovidone)) present at 1 wt % to about 10 wt % of the orodispersible tablet.
[0150] The orodispersible tablets of the present invention may comprise about 25% to about 40% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof) and one or more fillers (e.g., granular mannitol and / or spray-dried mannitol) present at about 40% to about 70% by weight of the orodispersible tablet.
[0151] The orodispersible tablets of the present invention may comprise about 25% to about 40% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof) and one or more binders (e.g., silicified microcrystalline cellulose) present at about 5% to about 20% by weight of the orodispersible tablet.
[0152] The orodispersible tablets of the present invention may comprise from about 25% to about 40% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof) and one or more disintegrants (e.g., polyvinylpyrrolidone (crospovidone)) present at 1% to about 7% by weight of the orodispersible tablet.
[0153] The orodispersible tablets of the present invention may comprise about 25% to about 40% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof), one or more fillers (e.g., granular mannitol and / or spray-dried mannitol) present at about 40% to about 70% by weight of the orodispersible tablet, one or more binders (e.g., silicified microcrystalline cellulose) present at about 5% to about 20% by weight of the orodispersible tablet, and one or more disintegrants (e.g., polyvinyl pyrrolidone (crospovidone)) present at 1% to about 7% by weight of the orodispersible tablet.
[0154] The orodispersible tablets of the present invention may comprise from about 26 wt % to about 40 wt % of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof) and one or more fillers (e.g., granular mannitol and / or spray-dried mannitol) present at about 40 wt % to about 70 wt % of the orodispersible tablet.
[0155] The orodispersible tablets of the present invention may comprise about 26 wt % to about 40 wt % of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof) and one or more binders (e.g., silicified microcrystalline cellulose) present at about 5 wt % to about 20 wt % of the orodispersible tablet.
[0156] The orodispersible tablets of the present invention may comprise from about 26 wt % to about 40 wt % of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof) and one or more disintegrants (e.g., polyvinylpyrrolidone (crospovidone)) present at 1 wt % to about 7 wt % of the orodispersible tablet.
[0157] The orodispersible tablets of the present invention may comprise about 26 wt % to about 40 wt % of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof), one or more fillers (e.g., granular mannitol and / or spray-dried mannitol) present at about 40 wt % to 70 wt % of the orodispersible tablet, one or more binders (e.g., silicified microcrystalline cellulose) present at about 5 wt % to about 20 wt % of the orodispersible tablet, and one or more disintegrants (e.g., polyvinyl pyrrolidone (crospovidone)) present at 1 wt % to about 7 wt % of the orodispersible tablet.
[0158] The orodispersible tablets of the present invention may comprise about 25% to about 35% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof) and one or more fillers (e.g., granular mannitol and / or spray-dried mannitol) present at about 50% to about 60% by weight of the orodispersible tablet.
[0159] The orodispersible tablets of the present invention may comprise about 25 wt % to about 35 wt % of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof) and one or more binders (e.g., silicified microcrystalline cellulose) present at about 5 wt % to about 15 wt % of the orodispersible tablet.
[0160] The orodispersible tablets of the present invention may comprise from about 25% to about 35% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof) and one or more disintegrants (e.g., polyvinylpyrrolidone (crospovidone)) present at from about 4% to about 6% by weight of the orodispersible tablet.
[0161] The orodispersible tablets of the present invention may comprise about 25% to about 35% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof), one or more fillers (e.g., granular mannitol and / or spray-dried mannitol) present at about 50% to about 60% by weight of the orodispersible tablet, one or more binders (e.g., silicified microcrystalline cellulose) present at about 5% to about 15% by weight of the orodispersible tablet, and one or more disintegrants (e.g., polyvinyl pyrrolidone (crospovidone)) present at about 4% to 6% by weight of the orodispersible tablet.
[0162] The orodispersible tablets of the present invention may comprise about 25% to about 30% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof) and one or more fillers (e.g., granular mannitol and / or spray-dried mannitol) present at about 50% to about 55% by weight of the orodispersible tablet.
[0163] The orodispersible tablets of the present invention may comprise about 25% to about 30% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof) and one or more binders (e.g., silicified microcrystalline cellulose) present at about 5% to about 10% by weight of the orodispersible tablet.
[0164] The orodispersible tablets of the present invention may comprise about 25 wt % to about 30 wt % of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof) and one or more disintegrants (e.g., polyvinylpyrrolidone (crospovidone)) present at about 4 wt % to about 5 wt % of the orodispersible tablet.
[0165] The orodispersible tablets of the present invention may comprise about 25% to about 30% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof), one or more fillers (e.g., granular mannitol and / or spray-dried mannitol) present at about 50% to about 55% by weight of the orodispersible tablet, one or more binders (e.g., silicified microcrystalline cellulose) present at about 5% to about 10% by weight of the orodispersible tablet, and one or more disintegrants (e.g., polyvinyl pyrrolidone (crospovidone)) present at about 4% to about 5% by weight of the orodispersible tablet.
[0166] The orodispersible tablet of the present invention may contain about 30% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof).
[0167] The orodispersible tablets of the present invention may comprise about 30 wt % KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof) and one or more fillers (e.g., granular mannitol and / or spray-dried mannitol) present at about 54 wt % (e.g., 53.7 wt %) of the orodispersible tablet.
[0168] The orodispersible tablets of the present invention may comprise about 30% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof) and one or more binders (eg, silicified microcrystalline cellulose) present at about 10% by weight of the orodispersible tablet.
[0169] The orodispersible tablets of the present invention may comprise about 30 wt % KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof) and one or more disintegrants (eg, polyvinylpyrrolidone (crospovidone)) present at about 5 wt % of the orodispersible tablet.
[0170] The orodispersible tablets of the present invention may comprise about 30% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof), one or more fillers (e.g., granular mannitol and / or spray-dried mannitol) present at about 54% by weight (e.g., 53.7% by weight) of the orodispersible tablet, one or more binders (e.g., silicified microcrystalline cellulose) present at about 10% by weight of the orodispersible tablet, and one or more disintegrants (e.g., polyvinyl pyrrolidone (crospovidone)) present at about 5% by weight of the orodispersible tablet.
[0171] The orodispersible tablet of the present invention may contain about 15 wt % to about 25 wt % of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof).
[0172] The orodispersible tablets of the present invention may comprise from about 15 wt % to about 25 wt % of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof) and one or more fillers (e.g., granular mannitol and / or spray-dried mannitol) present at about 54 wt % (e.g., 53.7 wt %) of the orodispersible tablet.
[0173] The orodispersible tablets of the present invention may comprise about 15% to about 25% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof) and one or more binders (eg, silicified microcrystalline cellulose) present at about 10% by weight of the orodispersible tablet.
[0174] The orodispersible tablets of the present invention may comprise about 15% to about 25% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof) and one or more disintegrants (e.g., polyvinylpyrrolidone (crospovidone)) present at about 5% by weight of the orodispersible tablet.
[0175] The orodispersible tablets of the present invention may comprise about 15% to about 25% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof), one or more fillers (e.g., granular mannitol and / or spray-dried mannitol) present at about 54% by weight (e.g., 53.7% by weight) of the orodispersible tablet, one or more binders (e.g., silicified microcrystalline cellulose) present at about 10% by weight of the orodispersible tablet, and one or more disintegrants (e.g., polyvinyl pyrrolidone (crospovidone)) present at about 5% by weight of the orodispersible tablet.
[0176] The orodispersible tablets of the present invention may comprise about 25% to about 50% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof), one or more fillers (e.g., granular mannitol and / or spray-dried mannitol) present at about 30% to 80% by weight of the orodispersible tablet, one or more binders (e.g., silicified microcrystalline cellulose) present at about 5% to about 30% by weight of the orodispersible tablet, one or more disintegrants (e.g., polyvinyl pyrrolidone (crospovidone)) present at 1% to about 10% by weight of the orodispersible tablet, and a flow enhancer (e.g., silicon dioxide) present at about 0.1% to about 5% by weight of the orodispersible tablet.
[0177] The orodispersible tablets of the present invention may comprise about 25% to about 50% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof), one or more fillers (e.g., granular mannitol and / or spray-dried mannitol) present at about 30% to 80% by weight of the orodispersible tablet, one or more binders (e.g., silicified microcrystalline cellulose) present at about 5% to about 30% by weight of the orodispersible tablet, one or more disintegrants (e.g., polyvinyl pyrrolidone (crospovidone)) present at 1% to about 10% by weight of the orodispersible tablet, a flow enhancer (e.g., silicon dioxide) present at about 0.1% to about 1% by weight of the orodispersible tablet, and one or more sweeteners (e.g., sucralose) present at about 0.1% to about 5% by weight of the orodispersible tablet.
[0178] The orodispersible tablets of the present invention may include about 25% to about 50% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof), one or more fillers (e.g., granular mannitol and / or spray-dried mannitol) present at about 30% to 80% by weight of the orodispersible tablet, one or more binders (e.g., silicified microcrystalline cellulose) present at about 5% to about 30% by weight of the orodispersible tablet, one or more disintegrants (e.g., polyvinylpyrrolidone (crospovidone)) present at 1% to about 10% by weight of the orodispersible tablet, a flow enhancer (e.g., silicon dioxide) present at about 0.1% to about 5% by weight of the orodispersible tablet, one or more sweeteners (e.g., sucralose) present at about 0.1% to about 5% by weight of the orodispersible tablet, and one or more flavoring agents (e.g., lemon flavor, mixed berry flavor, grape flavor, or mint flavor) present at 0.01% to about 1% by weight of the orodispersible tablet.
[0179] The orodispersible tablets of the present invention may comprise about 25% to about 40% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof), one or more fillers (e.g., granular mannitol and / or spray-dried mannitol) present at about 40% to 70% by weight of the orodispersible tablet, one or more binders (e.g., silicified microcrystalline cellulose) present at about 5% to about 20% by weight of the orodispersible tablet, one or more disintegrants (e.g., polyvinyl pyrrolidone (crospovidone)) present at 1% to about 7% by weight of the orodispersible tablet, and a flow enhancer (e.g., silicon dioxide) present at about 0.5% to about 1% by weight of the orodispersible tablet.
[0180] The orodispersible tablets of the present invention may include about 25% to about 40% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof), one or more fillers (e.g., granular mannitol and / or spray-dried mannitol) present at about 40% to 70% by weight of the orodispersible tablet, one or more binders (e.g., silicified microcrystalline cellulose) present at about 5% to about 20% by weight of the orodispersible tablet, one or more disintegrants (e.g., polyvinylpyrrolidone (crospovidone)) present at 1% to about 7% by weight of the orodispersible tablet, a flow enhancer (e.g., silicon dioxide) present at about 0.5% to about 1% by weight of the orodispersible tablet, and one or more sweeteners (e.g., sucralose) present at about 0.3% to about 0.7% by weight of the orodispersible tablet.
[0181] The orodispersible tablets of the present invention may include about 25% to about 40% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof), one or more fillers (e.g., granular mannitol and / or spray-dried mannitol) present at about 40% to 70% by weight of the orodispersible tablet, one or more binders (e.g., silicified microcrystalline cellulose) present at about 5% to about 20% by weight of the orodispersible tablet, one or more disintegrants (e.g., polyvinylpyrrolidone (crospovidone)) present at 1% to about 7% by weight of the orodispersible tablet, a flow enhancer (e.g., silicon dioxide) present at about 0.5% to about 1% by weight of the orodispersible tablet, one or more sweeteners (e.g., sucralose) present at about 0.3% to about 0.7% by weight of the orodispersible tablet, and one or more flavoring agents (e.g., mint-flavored natural flavoring) present at about 0.03% to about 0.06% by weight of the orodispersible tablet.
[0182] The orodispersible tablets of the present invention may include about 25% to about 40% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof), one or more fillers (e.g., granular mannitol and / or spray-dried mannitol) present at about 40% to 70% by weight of the orodispersible tablet, one or more binders (e.g., silicified microcrystalline cellulose) present at about 5% to about 20% by weight of the orodispersible tablet, one or more disintegrants (e.g., polyvinylpyrrolidone (crospovidone)) present at 1% to about 7% by weight of the orodispersible tablet, a flow enhancer (e.g., silicon dioxide) present at about 0.5% to about 1% by weight of the orodispersible tablet, one or more sweeteners (e.g., sucralose) present at about 0.3% to about 0.7% by weight of the orodispersible tablet, and one or more flavoring agents (e.g., lemon flavor, mixed berry flavor, or grape flavor) present at about 0.2% to about 0.5% by weight of the orodispersible tablet.
[0183] The orodispersible tablets of the present invention may comprise about 30% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof), one or more fillers (e.g., granular mannitol and / or spray-dried mannitol) present at about 54% by weight (e.g., 53.7% by weight) of the orodispersible tablet, one or more binders (e.g., silicified microcrystalline cellulose) present at about 10% by weight of the orodispersible tablet, one or more disintegrants (e.g., polyvinyl pyrrolidone (crospovidone)) present at about 5% by weight of the orodispersible tablet, and a flow enhancer (e.g., silicon dioxide) present at about 0.75% by weight of the orodispersible tablet.
[0184] The orodispersible tablets of the present invention may include about 30% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof), one or more fillers (e.g., granular mannitol and / or spray-dried mannitol) present at about 54% by weight (e.g., 53.7% by weight) of the orodispersible tablet, one or more binders (e.g., silicified microcrystalline cellulose) present at about 10% by weight of the orodispersible tablet, one or more disintegrants (e.g., polyvinyl pyrrolidone (crospovidone)) present at about 5% by weight of the orodispersible tablet, a flow enhancer (e.g., silicon dioxide) present at about 0.75% by weight of the orodispersible tablet, and one or more sweeteners (e.g., sucralose) present at about 0.5% by weight of the orodispersible tablet.
[0185] The orodispersible tablets of the present invention may include about 30% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof), one or more fillers (e.g., granular mannitol and / or spray-dried mannitol) present at about 54% by weight (e.g., 53.7% by weight) of the orodispersible tablet, one or more binders (e.g., silicified microcrystalline cellulose) present at about 10% by weight of the orodispersible tablet, one or more disintegrants (e.g., polyvinylpyrrolidone (crospovidone)) present at about 5% by weight of the orodispersible tablet, a flow enhancer (e.g., silicon dioxide) present at about 0.75% by weight of the orodispersible tablet, one or more sweeteners (e.g., sucralose) present at about 0.5% by weight of the orodispersible tablet, and one or more flavoring agents (e.g., mint-flavored natural flavoring) present at about 0.05% by weight of the orodispersible tablet.
[0186] The orodispersible tablets of the present invention may include about 30% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof), one or more fillers (e.g., granular mannitol and / or spray-dried mannitol) present at about 54% by weight (e.g., 53.7% by weight) of the orodispersible tablet, one or more binders (e.g., silicified microcrystalline cellulose) present at about 10% by weight of the orodispersible tablet, one or more disintegrants (e.g., polyvinylpyrrolidone (crospovidone)) present at about 5% by weight of the orodispersible tablet, a flow enhancer (e.g., silicon dioxide) present at about 0.75% by weight of the orodispersible tablet, one or more sweeteners (e.g., sucralose) present at about 0.5% by weight of the orodispersible tablet, and one or more flavoring agents (e.g., lemon flavor or mixed berry flavor) present at about 0.3% to about 0.4% by weight of the orodispersible tablet.
[0187] The orodispersible tablet of the present invention may comprise about 27% by weight of granulated mannitol. The orodispersible tablet of the present invention may comprise about 26.87% by weight of granulated mannitol. Preferably, the orodispersible tablet of the present invention may comprise about 26.85% by weight of granulated mannitol.
[0188] The orodispersible tablets of the present invention may comprise about 27% by weight of spray-dried mannitol (e.g., Mannogem The orodispersible tablets of the present invention may comprise about 26.87% by weight of spray-dried mannitol (e.g., Mannogem Preferably, the orodispersible tablet of the present invention may comprise about 26.85% by weight of spray-dried mannitol (eg, Mannogem ).
[0189] The orodispersible tablet of the present invention may comprise about 10 wt% microcrystalline cellulose.Preferably, the orodispersible tablet of the present invention may comprise about 10 wt% (eg, 10.01 wt%, 9.74 wt% or 9.69 wt%) silicified microcrystalline cellulose.
[0190] The orodispersible tablet of the present invention may comprise about 5% by weight of polyvinylpyrrolidone (crospovidone).
[0191] The orodispersible tablets of the present invention may contain about 0.75% by weight silicon dioxide.
[0192] The orodispersible tablet of the present invention may contain about 0.5% by weight sucralose.
[0193] The orodispersible tablets of the present invention may contain about 0.05% by weight of a mint-flavored natural flavoring.
[0194] The orodispersible tablets of the present invention may contain from about 0.2% to about 0.5% by weight of grape flavoring.
[0195] The orodispersible tablet of the present invention may contain about 0.36% by weight of lemon flavoring.
[0196] The orodispersible tablet of the present invention may contain about 0.31% by weight of mixed berry flavoring.
[0197] The orodispersible tablets of the present invention may contain trace amounts of magnesium stearate.
[0198] The orodispersible tablet of the present invention may comprise about 30 wt % of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof), about 26.85 wt % of granulated mannitol, about 26.85 wt % of spray-dried mannitol (e.g., Mannogem ), about 10% by weight silicified microcrystalline cellulose and about 5% by weight polyvinyl pyrrolidone (crospovidone).
[0199] The orodispersible tablet of the present invention may comprise about 30 wt % of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof), about 26.87 wt % of granulated mannitol, about 26.87 wt % of spray-dried mannitol (e.g., Mannogem ), about 10 wt % (e.g., 10.01 wt %) silicified microcrystalline cellulose, about 5 wt % polyvinylpyrrolidone (crospovidone), about 0.75 wt % silicon dioxide, and about 0.5 wt % sucralose.
[0200] The orodispersible tablet of the present invention may comprise about 30 wt % of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof), about 26.85 wt % of granulated mannitol, about 26.85 wt % of spray-dried mannitol (e.g., Mannogem ), about 10 wt % silicified microcrystalline cellulose, about 5 wt % polyvinylpyrrolidone (crospovidone), about 0.75 wt % silicon dioxide, about 0.5 wt % sucralose and about 0.05 wt % peppermint flavoring.
[0201] The orodispersible tablet of the present invention may comprise about 30 wt % of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof), about 26.85 wt % of granulated mannitol, about 26.85 wt % of spray-dried mannitol (e.g., Mannogem ), about 10 wt % (e.g., 9.69 wt %) silicified microcrystalline cellulose, about 5 wt % polyvinylpyrrolidone (crospovidone), about 0.75 wt % silicon dioxide, about 0.5 wt % sucralose, and about 0.36 wt % lemon flavoring.
[0202] The orodispersible tablet of the present invention may comprise about 30 wt % of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof), about 26.85 wt % of granulated mannitol, about 26.85 wt % of spray-dried mannitol (e.g., Mannogem ), about 10 wt % (e.g., 9.74 wt %) silicified microcrystalline cellulose, about 5 wt % polyvinylpyrrolidone (crospovidone), about 0.75 wt % silicon dioxide, about 0.5 wt % sucralose, and about 0.31 wt % mixed berry flavoring.
[0203] The orodispersible tablet of the present invention may comprise about 30 wt % of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof), about 26.85 wt % of granulated mannitol, about 26.85 wt % of spray-dried mannitol (e.g., Mannogem ), about 10 wt % silicified microcrystalline cellulose, about 5 wt % polyvinylpyrrolidone (crospovidone), about 0.75 wt % silicon dioxide, about 0.5 wt % sucralose, about 0.05 wt % mint flavoring and a trace amount of magnesium stearate.
[0204] The orodispersible tablet of the present invention may comprise about 30 wt % of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof), about 26.85 wt % of granulated mannitol, about 26.85 wt % of spray-dried mannitol (e.g., Mannogem ), about 10 wt % (e.g., 9.69 wt %) of silicified microcrystalline cellulose, about 5 wt % of polyvinyl pyrrolidone (crospovidone), about 0.75 wt % of silicon dioxide, about 0.5 wt % of sucralose, about 0.36 wt % of lemon flavor and a trace amount of magnesium stearate.
[0205] The orodispersible tablet of the present invention may comprise about 30 wt % of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof), about 26.85 wt % of granulated mannitol, about 26.85 wt % of spray-dried mannitol (e.g., Mannogem ), about 10 wt % (e.g., 9.74 wt %) of silicified microcrystalline cellulose, about 5 wt % of polyvinylpyrrolidone (crospovidone), about 0.75 wt % of silicon dioxide, about 0.5 wt % of sucralose, about 0.31 wt % of mixed berry flavoring, and a trace amount of magnesium stearate.
[0206] The orodispersible tablets of the present invention may be round, oval, caplet-shaped or elliptical. The orodispersible tablets of the present invention may be round. The orodispersible tablets of the present invention may be oval. The orodispersible tablets of the present invention may be caplet-shaped. The orodispersible tablets of the present invention may contain 300 mg of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof) and may be round. The orodispersible tablets of the present invention may contain 150 mg of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof) and may be oval. The orodispersible tablets of the present invention may contain about 25 mg to about 75 mg (e.g., 25 mg, 50 mg or 75 mg) of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof) and may be caplet-shaped or elliptical. The orodispersible tablets of the present invention may contain about 25 mg and may be caplet-shaped. The orodispersible tablets of the present invention may contain about 50 mg and may be caplet-shaped. The orodispersible tablets of the present invention may contain about 75 mg and may be caplet-shaped.
[0207] A particular advantage of the orodispersible tablets of the present invention is that they can be indented. The orodispersible tablets of the present invention can be indented with a logo, tablet strength and / or one or more score lines. The orodispersible tablets of the present invention can be indented with a logo. The orodispersible tablets of the present invention can be indented with a tablet strength. The orodispersible tablets of the present invention can be indented with a logo and a tablet strength. Preferably, the orodispersible tablets of the present invention can be indented with one or more score lines. The orodispersible tablets of the present invention can be indented with a logo and one or more score lines. The orodispersible tablets of the present invention can be indented with a logo and a score line. The phrase "indented with one or more score lines" means that the orodispersible tablets of the present invention are indented with one or more markings on the plane of the orodispersible tablet, which enables the orodispersible tablet to be easily, accurately and evenly divided into a plurality of sub-tablets. The orodispersible tablets of the present invention can be indented with one score line. The orodispersible tablets of the present invention can be indented with two score lines. The orodispersible tablets of the present invention can be indented with two score lines to form a cross.
[0208] The orodispersible tablets of the present invention may be scored and then split. Tablet splitting is the practice of dividing a single higher concentration tablet into multiple sub-tablets to obtain the desired dose of active ingredient. Tablet splitting facilitates dosage adjustment, which is particularly useful for dosage administration that is beneficial to certain populations.
[0209] More specifically, the orodispersible tablet of the present invention can be used to be divided into a plurality of subdivided tablets by a concave score line. The orodispersible tablet of the present invention can be used to be divided into four subdivided tablets by a concave score line. The orodispersible tablet of the present invention can be used to be divided into two subdivided tablets by a concave score line. The orodispersible tablet of the present invention can be used to be divided into two subdivided tablets of approximately equal halves by a concave score line.
[0210] An advantage of the orodispersible tablets of the present invention with indented score lines is that multiple subdivided tablets maintain acceptable content uniformity when they are split. For example, when an orodispersible tablet of the present invention (which is used to be split into two approximately equal subdivided tablets by indented score lines) is split into two halves, each half maintains acceptable content uniformity.
[0211] Thus, the present invention also provides subdivided tablets produced by dividing an orodispersible tablet of the present invention along one or more score lines.
[0212] The orodispersible tablets of the present invention may contain about 300 mg, may be round, and may be debossed with a logo and a score line. The orodispersible tablets of the present invention may contain about 150 mg, may be oval, and may be debossed with a logo and a score line. The orodispersible tablets of the present invention may contain about 25 mg, may be caplet-shaped, and may be debossed with a score line. The orodispersible tablets of the present invention may contain about 50 mg, may be caplet-shaped, and may be debossed with a score line. The orodispersible tablets of the present invention may contain about 75 mg, may be caplet-shaped, and may be debossed with a score line.
[0213] Disintegration and dissolution
[0214] As used herein, disintegration specifications are according to USP <701> and Ph Eur 2.9.1 (measured in USP purified water). The disintegration specification can be achieved in less than about 3 minutes> 80%. More specifically, the disintegration specification can be achieved in less than about 2 minutes> 80%. More specifically, the disintegration specification can be achieved in less than about 1 minute> 80%. The disintegration specification can be achieved in less than about 45 seconds> 80%. Preferably, the disintegration specification can be achieved in less than about 30 seconds> 80%. Even more preferably, the disintegration specification can be achieved in less than about 20 seconds> 80%. The disintegration specification can be achieved in less than about 15 to about 20 seconds> 80%. The disintegration specification can be achieved in less than about 15 seconds> 80%.
[0215] As used herein, dissolution specifications are according to USP <711> and Ph Eur 2.9.3. The dissolution specification can be achieved in less than about 45 minutes ≥ 99%. The dissolution specification can be achieved in less than about 45 minutes ≥ 97%. The dissolution specification can be achieved in less than about 45 minutes ≥ 95%. The dissolution specification can be achieved in less than about 45 minutes ≥ 90%. The dissolution specification can be achieved in less than about 45 minutes ≥ 80%. More specifically, the dissolution specification can be achieved in less than about 45 minutes ≥ 80%. More specifically, the dissolution specification can be achieved in less than about 30 minutes ≥ 80%. More specifically, the dissolution specification can be achieved in less than about 20 minutes ≥ 80%. More specifically, the dissolution specification can be achieved in less than about 10 minutes ≥ 80%. More specifically, the dissolution specification can be achieved in less than about 5 minutes ≥ 80%.
[0216] The disintegration specification can reach >80% in less than about 20 seconds, and the dissolution specification can reach about ≥99% in less than about 45 minutes. The disintegration specification can reach >80% in less than about 15 to about 20 seconds, and the dissolution specification can reach about ≥97% in less than about 45 minutes. The disintegration specification can reach >80% in less than about 30 seconds, and the dissolution specification can reach ≥95% in less than about 45 minutes. The disintegration specification can reach >80% in less than about 20 seconds, and the dissolution specification can reach ≥90% in less than about 45 minutes. The disintegration specification can reach >80% in less than about 15 seconds, and the dissolution specification can reach ≥80% in less than about 45 minutes. The disintegration specification can reach >80% in less than about 30 seconds, and the dissolution specification can reach ≥80% in less than about 20 minutes. The disintegration specification can reach >80% in less than about 20 seconds, and the dissolution specification can reach ≥80% in less than about 10 minutes. Disintegration specifications can be achieved to >80% in less than about 15 seconds, and dissolution specifications can be achieved to ≥80% in less than about 5 minutes.
[0217] The present invention also provides ODTs that are bioequivalent to those described herein. Accordingly, the present invention provides an ODT comprising KVD900 as described herein, or a bioequivalent formulation thereof.
[0218] The mixture of the present invention
[0219] The present invention also provides a mixture used in a manufacturing process to provide an orodispersible tablet of the present invention. The mixture of the present invention has improved flowability, compressibility and processability, for example, they can be compressed into a stable orodispersible tablet. In addition, the mixture of the present invention can be prepared on a large scale because the blend has excellent flowability and compressibility.
[0220] The mixtures of the present invention are particularly advantageous due to their versatility. Specifically, the mixtures of the present invention can be used to make orodispersible tablets of varying sizes and / or strengths without compromising the rapid disintegration time or uniformity of the dosage unit achieved with the orodispersible tablets of the present invention.
[0221] It is challenging to use the same blend to make orodispersible tablets of different sizes and / or concentrations because, for example, the compression force tolerance may be narrower for tablets of lower concentrations. The present applicants have overcome these difficulties and have provided blends of the present invention that can withstand compression even for lower concentrations (e.g., 75 mg, 50 mg, or 25 mg), such that these blends can be used to make orodispersible tablets of lower concentrations with suitable compression forces and resulting hardness while maintaining fast disintegration times.
[0222] The present invention provides a mixture comprising KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof). The present invention provides a mixture comprising about 25 mg to about 1000 mg of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof). The mixture of the present invention may contain about 100 mg to about 1000 mg of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof). The mixture of the present invention may contain about 150 mg to about 1000 mg of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof). The mixture of the present invention may contain about 100 mg to about 700 mg of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof). The mixture of the present invention may contain about 200 mg to about 600 mg of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof). The mixture of the present invention may contain about 250 mg of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof). Alternatively, the mixture of the present invention may contain about 275 mg of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof). Alternatively, the mixture of the present invention may contain about 300 mg of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof).
[0223] The mixture of the present invention may contain about 25 mg to about 500 mg of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof). The mixture of the present invention may contain about 25 mg to about 200 mg of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof). The mixture of the present invention may contain about 25 mg to about 150 mg of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof). The mixture of the present invention may contain about 150 mg of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof).
[0224] The mixture of the present invention may contain about 25 mg to about 100 mg of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof). The mixture of the present invention may contain about 25 mg to about 80 mg of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof). The mixture of the present invention may contain about 25 mg to about 75 mg of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof). The mixture of the present invention may contain about 75 mg of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof). Alternatively, the mixture of the present invention may contain about 50 mg of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof). Alternatively, the mixture of the present invention may contain about 25 mg of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof).
[0225] The mixture of the present invention may contain about 10% to about 70% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof). The mixture of the present invention may contain about 15% to about 60% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof). The mixture of the present invention may contain about 15% to about 50% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof). The mixture of the present invention may contain about 20% to about 50% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof). The mixture of the present invention may contain about 25% to about 50% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof). The mixture of the present invention may contain about 26% to about 50% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof). The mixture of the present invention may contain about 25% to about 40% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof). The mixture of the present invention may contain about 26% to about 40% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof). The mixture of the present invention may contain about 25% to about 35% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof). The mixture of the present invention may contain about 26% to about 35% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof). The mixture of the present invention may contain about 25% to about 30% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof). The mixture of the present invention may contain about 26% to about 30% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof). The mixture of the present invention may contain about 15% to about 25% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof). The mixture of the present invention may contain about 30% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof).
[0226] The mixture of the present invention may contain one or more of a filler, a binder, a disintegrant, a lubricant, a flow enhancer, a sweetener and a flavoring agent.
[0227] The mixtures according to the invention may also contain fillers.The mixtures according to the invention may also contain one or more fillers.
[0228] The filler may be selected from the group consisting of isomalt, lactose and its derivatives (e.g., lactose monohydrate, spray-dried lactose, anhydrous lactose), sorbitol, mannitol (e.g., granulated mannitol, powdered mannitol, spray-dried mannitol (e.g., Mannogem )), sorbitol, sucrose, starch, pregelatinized starch and mixtures thereof. Preferably, the filler may be selected from the group consisting of isomalt, lactose and its derivatives (e.g., lactose monohydrate, spray-dried lactose, anhydrous lactose), mannitol (e.g., granulated mannitol, powdered mannitol, spray-dried mannitol (e.g., Mannogem )), sorbitol and pregelatinized starch. The one or more fillers can be mannitol (e.g., granulated mannitol, powdered mannitol, spray-dried mannitol (e.g., Mannogem Even more preferably, the one or more fillers may be selected from granulated mannitol and spray-dried mannitol (e.g., Mannogem ). One or more fillers can be granulated mannitol. One or more fillers can be spray dried mannitol (e.g., Mannogem ).
[0229] One or more fillers may be present in about 30% to about 80% by weight of the mixture. One or more fillers may be present in about 40% to about 70% by weight of the mixture. One or more fillers may be present in about 40% to about 65% by weight of the mixture. One or more fillers may be present in about 50% to about 65% by weight of the mixture. One or more fillers may be present in about 50% to about 60% by weight of the mixture. One or more fillers may be present in about 50% to about 55% by weight of the mixture. One or more fillers may be present in about 53% to about 54% by weight of the mixture. Preferably, one or more fillers may be present in about 53.7% by weight of the mixture.
[0230] The mixture of the present invention may also contain a binder. The mixture of the present invention may also contain one or more binders. The binder may also be selected from: sugars (such as glucose, sucrose, fructose, dextrose, lactose), sugar alcohols (such as xylitol, maltitol, erythritol, sorbitol), polysaccharides (such as crystalline cellulose, microcrystalline cellulose (e.g., silicified microcrystalline cellulose), powdered cellulose, methylcellulose, carboxymethylcellulose and salts, hydroxypropyl methylcellulose), corn starch, starch 1500, gum arabic, other natural polymers (such as gelatin), polyethylene glycol, cross-linked acrylic acid and acrylic acid copolymers (e.g., ), inorganic compounds (such as calcium carbonate), calcium phosphate (e.g., anhydrous calcium hydrogen phosphate, calcium hydrogen phosphate, tricalcium phosphate), tricalcium citrate and mixtures thereof. More specifically, the binder may be selected from the group consisting of glucose, lactose, corn starch, starch 1500, gelatin, gum arabic, methylcellulose, carboxymethylcellulose and salts, hydroxypropyl methylcellulose, microcrystalline cellulose, silicified microcrystalline cellulose and mixtures thereof. Preferably, the binder is microcrystalline cellulose or hydroxypropyl methylcellulose. Even more preferably, the binder is silicified microcrystalline cellulose.
[0231] One or more adhesives may be present in about 5% to about 40% by weight of the mixture. One or more adhesives may be present in about 5% to about 40% by weight of the mixture. One or more adhesives may be present in about 5% to about 20% by weight of the mixture. One or more adhesives may be present in about 5% to about 15% by weight of the mixture. One or more adhesives may be present in about 5% to about 14% by weight of the mixture. One or more adhesives may be present in about 5% to about 10% by weight of the mixture. One or more adhesives may be present in about 8% to about 10% by weight of the mixture. One or more adhesives may be present in about 10% by weight (e.g., 10.01%, 9.74% or 9.69% by weight) of an orodispersible tablet. Preferably, one or more adhesives may be present in about 10% by weight of the mixture.
[0232] In the mixture of the present invention, one or more fillers and one or more adhesives can exist with about 50% by weight to about 90% by weight of the mixture. In the mixture of the present invention, one or more fillers and one or more adhesives can exist with about 50% by weight to about 70% by weight of the mixture. In the mixture of the present invention, one or more fillers and one or more adhesives can exist with about 50% by weight to about 65% by weight of the mixture. In the mixture of the present invention, one or more fillers and one or more adhesives can exist with about 55% by weight to about 65% by weight of the mixture. Preferably, one or more fillers and one or more adhesives can exist with about 64% by weight of the mixture. Even more preferably, one or more fillers and one or more adhesives can exist with about 63.7% by weight of the mixture.
[0233] In the mixture of the present invention, the weight % ratio of one or more fillers to one or more binders may be from about 3:1 to about 8:1. In the mixture of the present invention, the weight % ratio of one or more fillers to one or more binders may be from about 4:1 to about 7:1. In the mixture of the present invention, the weight % ratio of one or more fillers to one or more binders may be from about 4:1 to about 6:1. In the mixture of the present invention, the weight % ratio of one or more fillers to one or more binders may be from about 5:1 to about 6:1. In the mixture of the present invention, the weight % ratio of one or more fillers to one or more binders may be from about 4:1 to about 7:1. Preferably, in the mixture of the present invention, the weight % ratio of one or more fillers to one or more binders may be from about 5:1 to about 5.5:1, more specifically from about 5.3:1 to about 5.4:1 (e.g., 5.37:1).
[0234] More specifically, in the mixture of the present invention, the weight % ratio of mannitol to microcrystalline cellulose is about 3: 1 to about 8: 1, about 4: 1 to about 7: 1, about 4: 1 to about 6: 1, about 5: 1 to about 6: 1, or about 4: 1 to about 7: 1. Preferably, in the mixture of the present invention, the weight % ratio of mannitol to microcrystalline cellulose is about 5: 1 to about 5.5: 1, more specifically about 5.3: 1 to about 5.4: 1 (e.g., 5.37: 1).
[0235] The mixture of the present invention may also contain a disintegrant. The mixture of the present invention may also contain one or more disintegrants. The disintegrant is selected from: cross-linked cellulose (e.g., Nymce ), synthetic polymers such as cross-linked polyvinyl pyrrolidone (e.g., crospovidone, Crospovidone ), sodium starch glycolate, and mixtures thereof. More specifically, the disintegrant can be starch USP, starch 1500, cellulose derivatives (e.g., carboxymethyl cellulose and salts, hydroxypropyl methyl cellulose), guar gum, alginic acid and salts, sodium starch glycolate, cross-linked cellulose (e.g., cross-linked sodium carboxymethyl cellulose, such as cellulose sold under the trade name Nymce those of the type 2), cross-linked polyvinyl pyrrolidone (e.g., crospovidone, Crospovidone ), soy polysaccharide, calcium silicate, pearlitol Flash (co-processed mannitol / corn starch) and mixtures thereof. Preferably, the disintegrant is selected from polyvinyl pyrrolidone (crospovidone), sodium starch glycolate, cross-linked sodium carboxymethyl cellulose. Even more preferably, the disintegrant is polyvinyl pyrrolidone (crospovidone).
[0236] One or more disintegrants may be present in about 1% to about 15% by weight of the mixture. One or more disintegrants may be present in about 1% to about 14% by weight of the mixture. One or more disintegrants may be present in about 1% to about 10% by weight of the mixture. One or more disintegrants may be present in about 1% to about 9% by weight of the mixture. One or more disintegrants may be present in about 2% to about 8% by weight of the mixture. One or more disintegrants may be present in about 1% to about 7% by weight of the mixture. One or more disintegrants may be present in about 2% to about 7% by weight of the mixture. One or more disintegrants may be present in about 3% to about 6% by weight of the mixture. One or more disintegrants may be present in about 4% to about 6% by weight of the mixture. One or more disintegrants may be present in about 4% to about 5% by weight of the mixture. Preferably, one or more disintegrants may be present in about 5% by weight of the mixture.
[0237] The mixture of the present invention may also contain a flow enhancer. Preferably, the flow enhancer is silicon dioxide.
[0238] The flow enhancer may be present at about 0.5% to about 3% by weight of the mixture. The flow enhancer may be present at about 0.5% to about 2% by weight of the mixture. The flow enhancer may be present at about 0.5% to about 1% by weight of the mixture. The flow enhancer may be present at about 0.6% to about 0.9% by weight of the mixture. The flow enhancer may be present at about 0.6% to about 0.8% by weight of the mixture. The flow enhancer may be present at about 0.7% to about 0.8% by weight of the mixture. The flow enhancer may be present at about 0.6% to about 0.75% by weight of the mixture. The flow enhancer may be present at about 0.75% to about 0.8% by weight of the mixture. Preferably, the flow enhancer may be present at about 0.75% by weight of the mixture.
[0239] The mixture of the present invention may also contain a sweetener. The mixture of the present invention may also contain one or more sweeteners. The sweetener may be selected from: sucralose, aspartame, sugar derivatives, glucose, polydextrose, xylitol, fructose, sucrose, lactitol, maltitol and saccharin sodium (and mixtures thereof). Preferably, the sweetener is selected from: sucralose, aspartame, sugar derivatives, glucose, polydextrose, fructose, lactitol and maltitol. Even more preferably, the sweetener is sucralose.
[0240] One or more sweeteners may be present in an amount of about 0.1% to about 10% by weight of the mixture. One or more sweeteners may be present in an amount of about 0.1% to about 7% by weight of the mixture. One or more sweeteners may be present in an amount of about 0.1% to about 4% by weight of the mixture. One or more sweeteners may be present in an amount of about 0.1% to about 3% by weight of the mixture. One or more sweeteners may be present in an amount of about 0.1% to about 2% by weight of the mixture. One or more sweeteners may be present in an amount of about 0.1% to about 1% by weight of the mixture. One or more sweeteners may be present in an amount of about 0.2% to about 1% by weight of the mixture. One or more sweeteners may be present in an amount of about 0.2% to about 0.9% by weight of the mixture. One or more sweeteners may be present in an amount of about 0.2% to about 0.8% by weight of the mixture. One or more sweeteners may be present in an amount of about 0.2% to about 0.7% by weight of the mixture. One or more sweeteners may be present in an amount of about 0.3% to about 0.7% by weight of the mixture. One or more sweeteners can exist at about 0.3% by weight to about 0.6% by weight of the mixture. One or more sweeteners can exist at about 0.4% by weight to about 0.6% by weight of the mixture. One or more sweeteners can exist at about 0.4% by weight to about 0.5% by weight of the mixture. One or more sweeteners can exist at about 0.5% by weight to about 0.6% by weight of the mixture. One or more sweeteners can exist at about 0.45% by weight to about 0.55% by weight of the mixture. Preferably, one or more sweeteners can exist at about 0.5% by weight of the mixture.
[0241] The mixtures according to the invention may also contain flavoring agents. The mixtures according to the invention may also contain one or more flavoring agents.
[0242] Flavoring agent can be selected from: lemon flavoring agent, mixed berry flavoring agent, grape flavoring agent, mint flavoring agent, mint flavoring agent, banana flavoring agent, chocolate flavoring agent, maple flavoring agent, strawberry flavoring agent, raspberry flavoring agent, cherry flavoring agent, orange flavoring agent and vanilla flavoring agent and their mixture. Flavoring agent can be selected from: lemon flavoring agent, mixed berry flavoring agent, grape flavoring agent, mint flavoring agent, mint flavoring agent, banana flavoring agent, chocolate flavoring agent, maple flavoring agent and orange flavoring agent. In one embodiment, flavoring agent is mint flavoring agent. In another embodiment, flavoring agent is lemon flavoring agent. Preferably, flavoring agent is grape flavoring agent. Even more preferably, flavoring agent is mixed berry flavoring agent. Alternatively, orodispersible tablet can be unflavored.
[0243] One or more flavoring agents may be present at about 0.03% to about 1% by weight of the mixture. One or more flavoring agents may be present at about 0.03% to about 0.8% by weight of the mixture. One or more flavoring agents may be present at about 0.03% to about 0.5% by weight of the mixture. One or more flavoring agents may be present at about 0.03% to about 0.4% by weight of the mixture. One or more flavoring agents may be present at about 0.03% to about 0.3% by weight of the mixture. One or more flavoring agents may be present at about 0.05% to about 0.2% by weight of the mixture. One or more flavoring agents may be present at about 0.05% to about 0.1% by weight of the mixture. One or more flavoring agents may be present at about 0.03% to about 0.09% by weight of the mixture. One or more flavoring agents may be present at about 0.03% to about 0.08% by weight of the mixture. One or more flavoring agents may be present at about 0.03% to about 0.07% by weight of the mixture. One or more flavoring agents can exist at about 0.03% by weight to about 0.06% by weight of the mixture. One or more flavoring agents can exist at about 0.04% by weight to about 0.06% by weight of the mixture. One or more flavoring agents can exist at about 0.04% by weight to about 0.05% by weight of the mixture. One or more flavoring agents can exist at about 0.05% by weight to about 0.06% by weight of the mixture. One or more flavoring agents can exist at about 0.045% by weight to about 0.055% by weight of the mixture. Preferably, one or more flavoring agents can exist at about 0.05% by weight of the mixture.
[0244] For example, when the flavoring agent is selected from a lemon flavoring agent or a mixed berry flavoring agent, the flavoring agent may be present at about 0.2% to 0.5% by weight of the orodispersible tablet. The flavoring agent may be present at about 0.2% to 0.4% by weight of the orodispersible tablet. The flavoring agent may be present at about 0.3% to 0.4% by weight of the orodispersible tablet. One or more flavoring agents may be present at about 0.36% by weight of the orodispersible tablet. One or more flavoring agents may be present at about 0.31% by weight of the orodispersible tablet.
[0245] The orodispersible tablets of the present invention may contain about 0.2% to about 0.5% by weight of grape flavoring. The orodispersible tablets of the present invention may contain about 0.36% by weight of lemon flavoring. The orodispersible tablets of the present invention may contain about 0.31% by weight of mixed berry flavoring.
[0246] The mixture of the present invention may contain mannitol (e.g., granulated mannitol and / or spray-dried mannitol (e.g., Mannogem )), microcrystalline cellulose (e.g., silicified microcrystalline cellulose) as a binder, polyvinyl pyrrolidone (crospovidone) as a disintegrant, silicon dioxide as a flow enhancer, sucralose as a sweetener, and one or more of a mint-flavored natural flavoring as a flavoring agent.
[0247] The mixture of the present invention may contain mannitol (e.g., granulated mannitol and / or spray-dried mannitol (e.g., Mannogem )), microcrystalline cellulose (e.g., silicified microcrystalline cellulose) as a binder, polyvinyl pyrrolidone (crospovidone) as a disintegrant, silicon dioxide as a flow enhancer, sucralose as a sweetener, and one or more of a lemon flavoring as a flavoring.
[0248] The mixture of the present invention may contain mannitol (e.g., granulated mannitol and / or spray-dried mannitol (e.g., Mannogem )), one or more of microcrystalline cellulose (e.g., silicified microcrystalline cellulose) as a binder, polyvinyl pyrrolidone (crospovidone) as a disintegrant, silicon dioxide as a flow enhancer, sucralose as a sweetener, and mixed berry flavoring as a flavoring.
[0249] The mixture of the present invention may contain mannitol (e.g., granulated mannitol and / or spray-dried mannitol (e.g., Mannogem )), microcrystalline cellulose (e.g., silicified microcrystalline cellulose) as a binder, polyvinyl pyrrolidone (crospovidone) as a disintegrant, silicon dioxide as a flow enhancer, sucralose as a sweetener, and one or more of a grape flavoring as a flavoring.
[0250] The mixture of the present invention may contain mannitol (e.g., granulated mannitol and / or spray-dried mannitol (e.g., Mannogem )), microcrystalline cellulose (e.g., silicified microcrystalline cellulose) as a binder, polyvinyl pyrrolidone (crospovidone) as a disintegrant, silicon dioxide as a flow enhancer, sucralose as a sweetener, and two or more of a mint-flavored natural flavoring as a flavoring.
[0251] The mixture of the present invention may contain mannitol (e.g., granulated mannitol and / or spray-dried mannitol (e.g., Mannogem )), microcrystalline cellulose (e.g., silicified microcrystalline cellulose) as a binder, polyvinyl pyrrolidone (crospovidone) as a disintegrant, silicon dioxide as a flow enhancer, sucralose as a sweetener, and two or more of a lemon flavoring as a flavoring.
[0252] The mixture of the present invention may contain mannitol (e.g., granulated mannitol and / or spray-dried mannitol (e.g., Mannogem )), microcrystalline cellulose (e.g., silicified microcrystalline cellulose) as a binder, polyvinyl pyrrolidone (crospovidone) as a disintegrant, silicon dioxide as a flow enhancer, sucralose as a sweetener, and two or more of a mixed berry flavor as a flavoring.
[0253] The mixture of the present invention may contain mannitol (e.g., granulated mannitol and / or spray-dried mannitol (e.g., Mannogem )), microcrystalline cellulose (e.g., silicified microcrystalline cellulose) as a binder, polyvinyl pyrrolidone (crospovidone) as a disintegrant, silicon dioxide as a flow enhancer, sucralose as a sweetener, and two or more of a grape flavoring as a flavoring.
[0254] The mixture of the present invention may contain mannitol (e.g., granulated mannitol and / or spray-dried mannitol (e.g., Mannogem )) and three or more of microcrystalline cellulose (e.g., silicified microcrystalline cellulose) as a binder, polyvinyl pyrrolidone (crospovidone) as a disintegrant, silicon dioxide as a flow enhancer, sucralose as a sweetener, and peppermint-flavored natural flavoring as a flavoring.
[0255] The mixture of the present invention may contain mannitol (e.g., granulated mannitol and / or spray-dried mannitol (e.g., Mannogem )) and three or more of microcrystalline cellulose (e.g., silicified microcrystalline cellulose) as a binder, polyvinyl pyrrolidone (crospovidone) as a disintegrant, silicon dioxide as a flow enhancer, sucralose as a sweetener, and lemon flavoring as a flavoring.
[0256] The mixture of the present invention may contain mannitol (e.g., granulated mannitol and / or spray-dried mannitol (e.g., Mannogem )) and three or more of microcrystalline cellulose (e.g., silicified microcrystalline cellulose) as a binder, polyvinyl pyrrolidone (crospovidone) as a disintegrant, silicon dioxide as a flow enhancer, sucralose as a sweetener, and mixed berry flavor as a flavoring.
[0257] The mixture of the present invention may contain mannitol (e.g., granulated mannitol and / or spray-dried mannitol (e.g., Mannogem )) and three or more of microcrystalline cellulose (e.g., silicified microcrystalline cellulose) as a binder, polyvinyl pyrrolidone (crospovidone) as a disintegrant, silicon dioxide as a flow enhancer, sucralose as a sweetener, and grape flavoring as a flavoring.
[0258] The mixture of the present invention may comprise granulated mannitol, spray dried mannitol (e.g., Mannogem ), microcrystalline cellulose (e.g., silicified microcrystalline cellulose), polyvinyl pyrrolidone (crospovidone), silicon dioxide, sucralose, and one or more of a mint-flavored natural flavoring.
[0259] The mixture of the present invention may comprise granulated mannitol, spray dried mannitol (e.g., Mannogem ), microcrystalline cellulose (e.g., silicified microcrystalline cellulose), polyvinyl pyrrolidone (crospovidone), silicon dioxide, sucralose, and one or more of a lemon flavoring.
[0260] The mixture of the present invention may comprise granulated mannitol, spray dried mannitol (e.g., Mannogem ), microcrystalline cellulose (e.g., silicified microcrystalline cellulose), polyvinylpyrrolidone (crospovidone), silicon dioxide, sucralose, and mixed berry flavoring.
[0261] The mixture of the present invention may comprise granulated mannitol, spray dried mannitol (e.g., Mannogem ), microcrystalline cellulose (e.g., silicified microcrystalline cellulose), polyvinyl pyrrolidone (crospovidone), silicon dioxide, sucralose, and grape flavoring.
[0262] The mixture of the present invention may comprise granulated mannitol, spray dried mannitol (e.g., Mannogem ), one or more of silicified microcrystalline cellulose, polyvinyl pyrrolidone (crospovidone), silicon dioxide, sucralose and mint-flavored natural flavoring.
[0263] The mixture of the present invention may comprise granulated mannitol, spray dried mannitol (e.g., Mannogem ), one or more of silicified microcrystalline cellulose, polyvinyl pyrrolidone (crospovidone), silicon dioxide, sucralose and lemon flavor.
[0264] The mixture of the present invention may comprise granulated mannitol, spray dried mannitol (e.g., Mannogem ), one or more of silicified microcrystalline cellulose, polyvinyl pyrrolidone (crospovidone), silicon dioxide, sucralose and mixed berry flavoring.
[0265] The mixture of the present invention may comprise granulated mannitol, spray dried mannitol (e.g., Mannogem ), one or more of silicified microcrystalline cellulose, polyvinyl pyrrolidone (crospovidone), silicon dioxide, sucralose and grape flavoring.
[0266] The mixture of the present invention may include about 15% to about 50% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof), one or more fillers (e.g., granulated mannitol and / or spray-dried mannitol) present at about 30% to 80% by weight of the mixture, one or more binders (e.g., silicified microcrystalline cellulose) present at about 5% to about 30% by weight of the mixture, and one or more disintegrants (e.g., polyvinyl pyrrolidone (crospovidone)) present at about 1% to about 10% by weight of the mixture.
[0267] The mixture of the present invention can include about 15% to about 50% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof), one or more fillers (e.g., granulated mannitol and / or spray-dried mannitol) present at about 30% to 80% by weight of the mixture, one or more binders (e.g., silicified microcrystalline cellulose) present at about 5% to about 30% by weight of the mixture, one or more disintegrants (e.g., polyvinyl pyrrolidone (crospovidone)) present at about 1% to about 10% by weight of the mixture, and a flow enhancer (e.g., silicon dioxide) present at about 0.1% to about 5% by weight of the mixture.
[0268] The mixture of the present invention can include about 15% to about 50% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof), one or more fillers (e.g., granulated mannitol and / or spray-dried mannitol) present at about 30% to 80% by weight of the mixture, one or more binders (e.g., silicified microcrystalline cellulose) present at about 5% to about 30% by weight of the mixture, one or more disintegrants (e.g., polyvinyl pyrrolidone (crospovidone)) present at about 1% to about 10% by weight of the mixture, a flow enhancer (e.g., silicon dioxide) present at about 0.1% to about 5% by weight of the mixture, and one or more sweeteners (e.g., sucralose) present at about 0.1% to about 5% by weight of the mixture.
[0269] The mixture of the present invention can include about 15% to about 50% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof), one or more fillers (e.g., granulated mannitol and / or spray-dried mannitol) present at about 30% to 80% by weight of the mixture, one or more binders (e.g., silicified microcrystalline cellulose) present at about 5% to about 30% by weight of the mixture, one or more disintegrants (e.g., polyvinylpyrrolidone (crospovidone)) present at about 1% to about 10% by weight of the mixture, a flow enhancer (e.g., silicon dioxide) present at about 0.1% to about 5% by weight of the mixture, one or more sweeteners (e.g., sucralose) present at about 0.1% to about 5% by weight of the mixture, and one or more flavorings (e.g., lemon flavor, mixed berry flavor, grape flavor, or mint natural flavor) present at 0.01% to about 1% by weight of the mixture.
[0270] The mixture of the present invention may include about 15% to about 50% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof), one or more fillers (e.g., granulated mannitol and / or spray-dried mannitol) present at about 30% to 80% by weight of the mixture, one or more binders (e.g., silicified microcrystalline cellulose) present at about 5% to about 14% by weight of the mixture, and one or more disintegrants (e.g., polyvinyl pyrrolidone (crospovidone)) present at about 1% to about 10% by weight of the mixture.
[0271] The mixture of the present invention can include about 15% to about 50% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof), one or more fillers (e.g., granulated mannitol and / or spray-dried mannitol) present at about 30% to 80% by weight of the mixture, one or more binders (e.g., silicified microcrystalline cellulose) present at about 5% to about 14% by weight of the mixture, and one or more disintegrants (e.g., polyvinyl pyrrolidone (crospovidone)) present at about 1% to about 10% by weight of the mixture, and a flow enhancer (e.g., silicon dioxide) present at about 0.1% to about 5% by weight of the mixture.
[0272] The mixture of the present invention can include about 15% to about 50% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof), one or more fillers (e.g., granulated mannitol and / or spray-dried mannitol) present at about 30% to 80% by weight of the mixture, one or more binders (e.g., silicified microcrystalline cellulose) present at about 5% to about 14% by weight of the mixture, one or more disintegrants (e.g., polyvinyl pyrrolidone (crospovidone)) present at about 1% to about 10% by weight of the mixture, a flow enhancer (e.g., silicon dioxide) present at about 0.1% to about 5% by weight of the mixture, and one or more sweeteners (e.g., sucralose) present at about 0.1% to about 5% by weight of the mixture.
[0273] The mixture of the present invention can include about 15% to about 50% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof), one or more fillers (e.g., granulated mannitol and / or spray-dried mannitol) present at about 30% to 80% by weight of the mixture, one or more binders (e.g., silicified microcrystalline cellulose) present at about 5% to about 14% by weight of the mixture, one or more disintegrants (e.g., polyvinylpyrrolidone (crospovidone)) present at about 1% to about 10% by weight of the mixture, a flow enhancer (e.g., silicon dioxide) present at about 0.1% to about 5% by weight of the mixture, one or more sweeteners (e.g., sucralose) present at about 0.1% to about 5% by weight of the mixture, and one or more flavorings (e.g., lemon flavor, mixed berry flavor, grape flavor, or mint natural flavor) present at 0.01% to about 1% by weight of the mixture.
[0274] The mixture of the present invention may include about 15% to about 50% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof), one or more fillers (e.g., granulated mannitol and / or spray-dried mannitol) present at about 30% to 80% by weight of the mixture, one or more binders (e.g., silicified microcrystalline cellulose) present at about 5% to about 30% by weight of the mixture, and one or more disintegrants (e.g., polyvinyl pyrrolidone (crospovidone)) present at about 1% to about 7% by weight of the mixture.
[0275] The mixture of the present invention can include about 15% to about 50% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof), one or more fillers (e.g., granulated mannitol and / or spray-dried mannitol) present at about 30% to 80% by weight of the mixture, one or more binders (e.g., silicified microcrystalline cellulose) present at about 5% to about 30% by weight of the mixture, one or more disintegrants (e.g., polyvinyl pyrrolidone (crospovidone)) present at about 1% to about 7% by weight of the mixture, and a flow enhancer (e.g., silicon dioxide) present at about 0.1% to about 5% by weight of the mixture.
[0276] The mixture of the present invention can include about 15% to about 50% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof), one or more fillers (e.g., granulated mannitol and / or spray-dried mannitol) present at about 30% to 80% by weight of the mixture, one or more binders (e.g., silicified microcrystalline cellulose) present at about 5% to about 30% by weight of the mixture, one or more disintegrants (e.g., polyvinyl pyrrolidone (crospovidone)) present at about 1% to about 7% by weight of the mixture, a flow enhancer (e.g., silicon dioxide) present at about 0.1% to about 5% by weight of the mixture, and one or more sweeteners (e.g., sucralose) present at about 0.1% to about 5% by weight of the mixture.
[0277] The mixture of the present invention can include about 15% to about 50% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof), one or more fillers (e.g., granular mannitol and / or spray-dried mannitol) present at about 30% to 80% by weight of the mixture, one or more binders (e.g., silicified microcrystalline cellulose) present at about 5% to about 30% by weight of the mixture, one or more disintegrants (e.g., polyvinyl pyrrolidone (crospovidone)) present at about 1% to about 7% by weight of the mixture, a flow enhancer (e.g., silicon dioxide) present at about 0.1% to about 5% by weight of the mixture, one or more sweeteners (e.g., sucralose) present at about 0.1% to about 5% by weight of the mixture, and one or more flavorings (e.g., lemon flavor, mixed berry flavor, grape flavor, or mint natural flavor) present at 0.01% to about 1% by weight of the mixture.
[0278] The mixture of the present invention may include about 15% to about 50% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof), one or more fillers (e.g., granulated mannitol and / or spray-dried mannitol) present at about 30% to 80% by weight of the mixture, one or more binders (e.g., silicified microcrystalline cellulose) present at about 5% to about 14% by weight of the mixture, and one or more disintegrants (e.g., polyvinyl pyrrolidone (crospovidone)) present at about 1% to about 7% by weight of the mixture.
[0279] The mixture of the present invention can include about 15% to about 50% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof), one or more fillers (e.g., granulated mannitol and / or spray-dried mannitol) present at about 30% to 80% by weight of the mixture, one or more binders (e.g., silicified microcrystalline cellulose) present at about 5% to about 14% by weight of the mixture, one or more disintegrants (e.g., polyvinyl pyrrolidone (crospovidone)) present at about 1% to about 7% by weight of the mixture, and a flow enhancer (e.g., silicon dioxide) present at about 0.1% to about 5% by weight of the mixture.
[0280] The mixture of the present invention can include about 15% to about 50% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof), one or more fillers (e.g., granulated mannitol and / or spray-dried mannitol) present at about 30% to 80% by weight of the mixture, one or more binders (e.g., silicified microcrystalline cellulose) present at about 5% to about 14% by weight of the mixture, one or more disintegrants (e.g., polyvinyl pyrrolidone (crospovidone)) present at about 1% to about 7% by weight of the mixture, a flow enhancer (e.g., silicon dioxide) present at about 0.1% to about 5% by weight of the mixture, and one or more sweeteners (e.g., sucralose) present at about 0.1% to about 5% by weight of the mixture.
[0281] The mixture of the present invention can include about 15% to about 50% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof), one or more fillers (e.g., granulated mannitol and / or spray-dried mannitol) present at about 30% to 80% by weight of the mixture, one or more binders (e.g., silicified microcrystalline cellulose) present at about 5% to about 14% by weight of the mixture, one or more disintegrants (e.g., polyvinylpyrrolidone (crospovidone)) present at about 1% to about 7% by weight of the mixture, a flow enhancer (e.g., silicon dioxide) present at about 0.1% to about 5% by weight of the mixture, one or more sweeteners (e.g., sucralose) present at about 0.1% to about 5% by weight of the mixture, and one or more flavorings (e.g., lemon flavor, mixed berry flavor, grape flavor, or mint natural flavor) present at 0.01% to about 1% by weight of the mixture.
[0282] The mixture of the present invention may include about 25% to about 50% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof), one or more fillers (e.g., granulated mannitol and / or spray-dried mannitol) present at about 30% to 80% by weight of the mixture, one or more binders (e.g., silicified microcrystalline cellulose) present at about 5% to about 30% by weight of the mixture, and one or more disintegrants (e.g., polyvinyl pyrrolidone (crospovidone)) present at about 1% to about 10% by weight of the mixture.
[0283] The mixture of the present invention can include about 25% to about 50% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof), one or more fillers (e.g., granulated mannitol and / or spray-dried mannitol) present at about 30% to 80% by weight of the mixture, one or more binders (e.g., silicified microcrystalline cellulose) present at about 5% to about 30% by weight of the mixture, one or more disintegrants (e.g., polyvinyl pyrrolidone (crospovidone)) present at about 1% to about 10% by weight of the mixture, and a flow enhancer (e.g., silicon dioxide) present at about 0.1% to about 5% by weight of the mixture.
[0284] The mixture of the present invention can include about 25% to about 50% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof), one or more fillers (e.g., granulated mannitol and / or spray-dried mannitol) present at about 30% to 80% by weight of the mixture, one or more binders (e.g., silicified microcrystalline cellulose) present at about 5% to about 30% by weight of the mixture, one or more disintegrants (e.g., polyvinyl pyrrolidone (crospovidone)) present at about 1% to about 10% by weight of the mixture, a flow enhancer (e.g., silicon dioxide) present at about 0.1% to about 5% by weight of the mixture, and one or more sweeteners (e.g., sucralose) present at about 0.1% to about 5% by weight of the mixture.
[0285] The mixture of the present invention can include about 25% to about 50% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof), one or more fillers (e.g., granulated mannitol and / or spray-dried mannitol) present at about 30% to 80% by weight of the mixture, one or more binders (e.g., silicified microcrystalline cellulose) present at about 5% to about 30% by weight of the mixture, one or more disintegrants (e.g., polyvinylpyrrolidone (crospovidone)) present at about 1% to about 10% by weight of the mixture, a flow enhancer (e.g., silicon dioxide) present at about 0.1% to about 5% by weight of the mixture, one or more sweeteners (e.g., sucralose) present at about 0.1% to about 5% by weight of the mixture, and one or more flavorings (e.g., lemon flavor, mixed berry flavor, grape flavor, or mint natural flavor) present at 0.01% to about 1% by weight of the mixture.
[0286] The mixture of the present invention can include about 25% to about 50% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof), one or more fillers (e.g., granulated mannitol and / or spray-dried mannitol) present at about 30% to 80% by weight of the mixture, one or more binders (e.g., silicified microcrystalline cellulose) present at about 5% to about 14% by weight of the mixture, and one or more disintegrants (e.g., polyvinyl pyrrolidone (crospovidone)) present at about 1% to about 10% by weight of the mixture.
[0287] The mixture of the present invention can include about 25% to about 50% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof), one or more fillers (e.g., granulated mannitol and / or spray-dried mannitol) present at about 30% to 80% by weight of the mixture, one or more binders (e.g., silicified microcrystalline cellulose) present at about 5% to about 14% by weight of the mixture, one or more disintegrants (e.g., polyvinyl pyrrolidone (crospovidone)) present at about 1% to about 10% by weight of the mixture, and a flow enhancer (e.g., silicon dioxide) present at about 0.1% to about 5% by weight of the mixture.
[0288] The mixture of the present invention can include about 25% to about 50% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof), one or more fillers (e.g., granulated mannitol and / or spray-dried mannitol) present at about 30% to 80% by weight of the mixture, one or more binders (e.g., silicified microcrystalline cellulose) present at about 5% to about 14% by weight of the mixture, one or more disintegrants (e.g., polyvinyl pyrrolidone (crospovidone)) present at about 1% to about 10% by weight of the mixture, a flow enhancer (e.g., silicon dioxide) present at about 0.1% to about 5% by weight of the mixture, and one or more sweeteners (e.g., sucralose) present at about 0.1% to about 5% by weight of the mixture.
[0289] The mixture of the present invention can include about 25% to about 50% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof), one or more fillers (e.g., granulated mannitol and / or spray-dried mannitol) present at about 30% to 80% by weight of the mixture, one or more binders (e.g., silicified microcrystalline cellulose) present at about 5% to about 14% by weight of the mixture, one or more disintegrants (e.g., polyvinylpyrrolidone (crospovidone)) present at about 1% to about 10% by weight of the mixture, a flow enhancer (e.g., silicon dioxide) present at about 0.1% to about 5% by weight of the mixture, one or more sweeteners (e.g., sucralose) present at about 0.1% to about 5% by weight of the mixture, and one or more flavorings (e.g., lemon flavor, mixed berry flavor, grape flavor, or mint natural flavor) present at 0.01% to about 1% by weight of the mixture.
[0290] The mixture of the present invention may include about 25% to about 50% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof), one or more fillers (e.g., granulated mannitol and / or spray-dried mannitol) present at about 30% to 80% by weight of the mixture, one or more binders (e.g., silicified microcrystalline cellulose) present at about 5% to about 30% by weight of the mixture, and one or more disintegrants (e.g., polyvinyl pyrrolidone (crospovidone)) present at about 1% to about 7% by weight of the mixture.
[0291] The mixture of the present invention can include about 25% to about 50% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof), one or more fillers (e.g., granulated mannitol and / or spray-dried mannitol) present at about 30% to 80% by weight of the mixture, one or more binders (e.g., silicified microcrystalline cellulose) present at about 5% to about 30% by weight of the mixture, one or more disintegrants (e.g., polyvinyl pyrrolidone (crospovidone)) present at about 1% to about 7% by weight of the mixture, and a flow enhancer (e.g., silicon dioxide) present at about 0.1% to about 5% by weight of the mixture.
[0292] The mixture of the present invention can include about 25% to about 50% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof), one or more fillers (e.g., granulated mannitol and / or spray-dried mannitol) present at about 30% to 80% by weight of the mixture, one or more binders (e.g., silicified microcrystalline cellulose) present at about 5% to about 30% by weight of the mixture, one or more disintegrants (e.g., polyvinyl pyrrolidone (crospovidone)) present at about 1% to about 7% by weight of the mixture, a flow enhancer (e.g., silicon dioxide) present at about 0.1% to about 5% by weight of the mixture, and one or more sweeteners (e.g., sucralose) present at about 0.1% to about 5% by weight of the mixture.
[0293] The mixture of the present invention can include about 25% to about 50% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof), one or more fillers (e.g., granulated mannitol and / or spray-dried mannitol) present at about 30% to 80% by weight of the mixture, one or more binders (e.g., silicified microcrystalline cellulose) present at about 5% to about 30% by weight of the mixture, one or more disintegrants (e.g., polyvinylpyrrolidone (crospovidone)) present at about 1% to about 7% by weight of the mixture, a flow enhancer (e.g., silicon dioxide) present at about 0.1% to about 5% by weight of the mixture, one or more sweeteners (e.g., sucralose) present at about 0.1% to about 5% by weight of the mixture, and one or more flavorings (e.g., lemon flavor, mixed berry flavor, grape flavor, or mint natural flavor) present at 0.01% to about 1% by weight of the mixture.
[0294] The mixture of the present invention may include about 25% to about 50% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof), one or more fillers (e.g., granulated mannitol and / or spray-dried mannitol) present at about 30% to 80% by weight of the mixture, one or more binders (e.g., silicified microcrystalline cellulose) present at about 5% to about 14% by weight of the mixture, and one or more disintegrants (e.g., polyvinyl pyrrolidone (crospovidone)) present at about 1% to about 7% by weight of the mixture.
[0295] The mixture of the present invention can include about 25% to about 50% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof), one or more fillers (e.g., granulated mannitol and / or spray-dried mannitol) present at about 30% to 80% by weight of the mixture, one or more binders (e.g., silicified microcrystalline cellulose) present at about 5% to about 14% by weight of the mixture, one or more disintegrants (e.g., polyvinyl pyrrolidone (crospovidone)) present at about 1% to about 7% by weight of the mixture, and a flow enhancer (e.g., silicon dioxide) present at about 0.1% to about 5% by weight of the mixture.
[0296] The mixture of the present invention can include about 25% to about 50% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof), one or more fillers (e.g., granulated mannitol and / or spray-dried mannitol) present at about 30% to 80% by weight of the mixture, one or more binders (e.g., silicified microcrystalline cellulose) present at about 5% to about 14% by weight of the mixture, one or more disintegrants (e.g., polyvinyl pyrrolidone (crospovidone)) present at about 1% to about 7% by weight of the mixture, a flow enhancer (e.g., silicon dioxide) present at about 0.1% to about 5% by weight of the mixture, and one or more sweeteners (e.g., sucralose) present at about 0.1% to about 5% by weight of the mixture.
[0297] The mixture of the present invention can include about 25% to about 50% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof), one or more fillers (e.g., granulated mannitol and / or spray-dried mannitol) present at about 30% to 80% by weight of the mixture, one or more binders (e.g., silicified microcrystalline cellulose) present at about 5% to about 14% by weight of the mixture, one or more disintegrants (e.g., polyvinylpyrrolidone (crospovidone)) present at about 1% to about 7% by weight of the mixture, a flow enhancer (e.g., silicon dioxide) present at about 0.1% to about 5% by weight of the mixture, one or more sweeteners (e.g., sucralose) present at about 0.1% to about 5% by weight of the mixture, and one or more flavorings (e.g., lemon flavor, mixed berry flavor, grape flavor, or mint natural flavor) present at 0.01% to about 1% by weight of the mixture.
[0298] The mixture of the present invention can include about 26% to about 40% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof), one or more fillers (e.g., granulated mannitol and / or spray-dried mannitol) present at about 30% to 80% by weight of the mixture, one or more binders (e.g., silicified microcrystalline cellulose) present at about 5% to about 30% by weight of the mixture, and one or more disintegrants (e.g., polyvinyl pyrrolidone (crospovidone)) present at about 1% to about 10% by weight of the mixture.
[0299] The mixture of the present invention can include about 26% to about 40% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof), one or more fillers (e.g., granulated mannitol and / or spray-dried mannitol) present at about 30% to 80% by weight of the mixture, one or more binders (e.g., silicified microcrystalline cellulose) present at about 5% to about 30% by weight of the mixture, one or more disintegrants (e.g., polyvinyl pyrrolidone (crospovidone)) present at about 1% to about 10% by weight of the mixture, and a flow enhancer (e.g., silicon dioxide) present at about 0.1% to about 5% by weight of the mixture.
[0300] The mixture of the present invention can include about 26% to about 40% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof), one or more fillers (e.g., granulated mannitol and / or spray-dried mannitol) present at about 30% to 80% by weight of the mixture, one or more binders (e.g., silicified microcrystalline cellulose) present at about 5% to about 30% by weight of the mixture, one or more disintegrants (e.g., polyvinyl pyrrolidone (crospovidone)) present at about 1% to about 10% by weight of the mixture, a flow enhancer (e.g., silicon dioxide) present at about 0.1% to about 5% by weight of the mixture, and one or more sweeteners (e.g., sucralose) present at about 0.1% to about 1% by weight of the mixture.
[0301] The mixture of the present invention can include about 26% to about 40% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof), one or more fillers (e.g., granular mannitol and / or spray-dried mannitol) present at about 30% to 80% by weight of the mixture, one or more binders (e.g., silicified microcrystalline cellulose) present at about 5% to about 30% by weight of the mixture, one or more disintegrants (e.g., polyvinyl pyrrolidone (crospovidone)) present at about 1% to about 10% by weight of the mixture, a flow enhancer (e.g., silicon dioxide) present at about 0.1% to about 5% by weight of the mixture, one or more sweeteners (e.g., sucralose) present at about 0.1% to about 5% by weight of the mixture, and one or more flavorings (e.g., lemon flavor, mixed berry flavor, grape flavor, or mint flavor) present at 0.01% to about 1% by weight of the mixture.
[0302] The mixture of the present invention can include about 26% to about 40% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof), one or more fillers (e.g., granulated mannitol and / or spray-dried mannitol) present at about 30% to 80% by weight of the mixture, one or more binders (e.g., silicified microcrystalline cellulose) present at about 5% to about 14% by weight of the mixture, and one or more disintegrants (e.g., polyvinyl pyrrolidone (crospovidone)) present at about 1% to about 10% by weight of the mixture.
[0303] The mixture of the present invention can include about 26% to about 40% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof), one or more fillers (e.g., granulated mannitol and / or spray-dried mannitol) present at about 30% to 80% by weight of the mixture, one or more binders (e.g., silicified microcrystalline cellulose) present at about 5% to about 14% by weight of the mixture, one or more disintegrants (e.g., polyvinyl pyrrolidone (crospovidone)) present at about 1% to about 10% by weight of the mixture, and a flow enhancer (e.g., silicon dioxide) present at about 0.1% to about 5% by weight of the mixture.
[0304] The mixture of the present invention can include about 26% to about 40% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof), one or more fillers (e.g., granulated mannitol and / or spray-dried mannitol) present at about 30% to 80% by weight of the mixture, one or more binders (e.g., silicified microcrystalline cellulose) present at about 5% to about 14% by weight of the mixture, one or more disintegrants (e.g., polyvinyl pyrrolidone (crospovidone)) present at about 1% to about 10% by weight of the mixture, a flow enhancer (e.g., silicon dioxide) present at about 0.1% to about 5% by weight of the mixture, and one or more sweeteners (e.g., sucralose) present at about 0.1% to about 5% by weight of the mixture.
[0305] The mixture of the present invention can include about 26% to about 40% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof), one or more fillers (e.g., granulated mannitol and / or spray-dried mannitol) present at about 30% to 80% by weight of the mixture, one or more binders (e.g., silicified microcrystalline cellulose) present at about 5% to about 14% by weight of the mixture, one or more disintegrants (e.g., polyvinylpyrrolidone (crospovidone)) present at about 1% to about 10% by weight of the mixture, a flow enhancer (e.g., silicon dioxide) present at about 0.1% to about 5% by weight of the mixture, one or more sweeteners (e.g., sucralose) present at about 0.1% to about 5% by weight of the mixture, and one or more flavorings (e.g., lemon flavor, mixed berry flavor, grape flavor, or mint natural flavor) present at 0.01% to about 1% by weight of the mixture.
[0306] The mixture of the present invention may include about 26% to about 40% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof), one or more fillers (e.g., granulated mannitol and / or spray-dried mannitol) present at about 30% to 80% by weight of the mixture, one or more binders (e.g., silicified microcrystalline cellulose) present at about 5% to about 30% by weight of the mixture, and one or more disintegrants (e.g., polyvinyl pyrrolidone (crospovidone)) present at about 1% to about 7% by weight of the mixture.
[0307] The mixture of the present invention can include about 26% to about 40% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof), one or more fillers (e.g., granulated mannitol and / or spray-dried mannitol) present at about 30% to 80% by weight of the mixture, one or more binders (e.g., silicified microcrystalline cellulose) present at about 5% to about 30% by weight of the mixture, one or more disintegrants (e.g., polyvinyl pyrrolidone (crospovidone)) present at about 1% to about 7% by weight of the mixture, and a flow enhancer (e.g., silicon dioxide) present at about 0.1% to about 5% by weight of the mixture.
[0308] The mixture of the present invention can include about 26% to about 40% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof), one or more fillers (e.g., granulated mannitol and / or spray-dried mannitol) present at about 30% to 80% by weight of the mixture, one or more binders (e.g., silicified microcrystalline cellulose) present at about 5% to about 30% by weight of the mixture, one or more disintegrants (e.g., polyvinyl pyrrolidone (crospovidone)) present at about 1% to about 7% by weight of the mixture, a flow enhancer (e.g., silicon dioxide) present at about 0.1% to about 5% by weight of the mixture, and one or more sweeteners (e.g., sucralose) present at about 0.1% to about 5% by weight of the mixture.
[0309] The mixture of the present invention can include about 26% to about 40% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof), one or more fillers (e.g., granular mannitol and / or spray-dried mannitol) present at about 30% to 80% by weight of the mixture, one or more binders (e.g., silicified microcrystalline cellulose) present at about 5% to about 30% by weight of the mixture, one or more disintegrants (e.g., polyvinyl pyrrolidone (crospovidone)) present at about 1% to about 7% by weight of the mixture, a flow enhancer (e.g., silicon dioxide) present at about 0.1% to about 5% by weight of the mixture, one or more sweeteners (e.g., sucralose) present at about 0.1% to about 5% by weight of the mixture, and one or more flavorings (e.g., lemon flavor, mixed berry flavor, grape flavor, or mint natural flavor) present at 0.01% to about 1% by weight of the mixture.
[0310] The mixture of the present invention may include about 26% to about 40% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof), one or more fillers (e.g., granulated mannitol and / or spray-dried mannitol) present at about 30% to 80% by weight of the mixture, one or more binders (e.g., silicified microcrystalline cellulose) present at about 5% to about 14% by weight of the mixture, and one or more disintegrants (e.g., polyvinyl pyrrolidone (crospovidone)) present at about 1% to about 7% by weight of the mixture.
[0311] The mixture of the present invention can include about 26% to about 40% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof), one or more fillers (e.g., granulated mannitol and / or spray-dried mannitol) present at about 30% to 80% by weight of the mixture, one or more binders (e.g., silicified microcrystalline cellulose) present at about 5% to about 14% by weight of the mixture, one or more disintegrants (e.g., polyvinyl pyrrolidone (crospovidone)) present at about 1% to about 7% by weight of the mixture, and a flow enhancer (e.g., silicon dioxide) present at about 0.1% to about 5% by weight of the mixture.
[0312] The mixture of the present invention can include about 26% to about 40% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof), one or more fillers (e.g., granulated mannitol and / or spray-dried mannitol) present at about 30% to 80% by weight of the mixture, one or more binders (e.g., silicified microcrystalline cellulose) present at about 5% to about 14% by weight of the mixture, one or more disintegrants (e.g., polyvinyl pyrrolidone (crospovidone)) present at about 1% to about 7% by weight of the mixture, a flow enhancer (e.g., silicon dioxide) present at about 0.1% to about 5% by weight of the mixture, and one or more sweeteners (e.g., sucralose) present at about 0.1% to about 5% by weight of the mixture.
[0313] The mixture of the present invention can include about 26% to about 40% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof), one or more fillers (e.g., granulated mannitol and / or spray-dried mannitol) present at about 30% to 80% by weight of the mixture, one or more binders (e.g., silicified microcrystalline cellulose) present at about 5% to about 14% by weight of the mixture, one or more disintegrants (e.g., polyvinyl pyrrolidone (crospovidone)) present at about 1% to about 7% by weight of the mixture, a flow enhancer (e.g., silicon dioxide) present at about 0.1% to about 5% by weight of the mixture, one or more sweeteners (e.g., sucralose) present at about 0.1% to about 5% by weight of the mixture, and one or more flavorings (e.g., lemon flavor, mixed berry flavor, grape flavor, or mint natural flavor) present at 0.01% to about 1% by weight of the mixture.
[0314] The mixture of the present invention may comprise about 25% to about 50% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof) and one or more disintegrants (e.g., polyvinylpyrrolidone (crospovidone)) present at about 5% to about 10% by weight of the mixture.
[0315] The mixture of the present invention may comprise about 25% to about 40% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof) and one or more disintegrants (e.g., polyvinylpyrrolidone (crospovidone)) present at about 5% to about 10% by weight of the mixture.
[0316] The mixture of the present invention may comprise about 27% by weight of granulated mannitol. The mixture of the present invention may comprise about 26.87% by weight of granulated mannitol. Preferably, the mixture of the present invention may comprise about 26.85% by weight of granulated mannitol.
[0317] The mixture of the present invention may comprise about 27% by weight of spray-dried mannitol (e.g., Mannogem The mixture of the present invention may include about 26.87% by weight of spray-dried mannitol (e.g., Mannogem Preferably, the mixture of the present invention may comprise about 26.85 wt % of spray-dried mannitol (e.g., Mannogem ).
[0318] The mixture of the present invention may comprise about 10% by weight of microcrystalline cellulose.Preferably, the mixture of the present invention may comprise about 10% by weight of silicified microcrystalline cellulose.
[0319] The mixtures according to the invention may comprise about 5% by weight of polyvinylpyrrolidone (crospovidone).
[0320] The mixture of the present invention may contain about 0.75% by weight of silica.
[0321] The mixture of the present invention may comprise about 0.5% by weight sucralose.
[0322] The mixture of the present invention may contain about 0.36% by weight of lemon flavoring.
[0323] The mixture of the present invention may contain about 0.31% by weight of mixed berry flavoring.
[0324] The mixture of the present invention may contain about 0.05% by weight of a peppermint-flavored natural flavoring.
[0325] The mixture of the present invention may comprise about 30 wt % of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof), about 26.85 wt % of granulated mannitol, about 26.85 wt % of spray-dried mannitol (e.g., Mannogem ), about 10% by weight silicified microcrystalline cellulose and about 5% by weight polyvinyl pyrrolidone (crospovidone).
[0326] The mixture of the present invention may comprise about 30 wt % of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof), about 26.87 wt % of granulated mannitol, about 26.87 wt % of spray-dried mannitol (e.g., Mannogem ), about 10% by weight silicified microcrystalline cellulose and about 5% by weight polyvinyl pyrrolidone (crospovidone).
[0327] The mixture of the present invention may comprise about 30 wt % of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof), about 26.85 wt % of granulated mannitol, about 26.85 wt % of spray-dried mannitol (e.g., Mannogem ), about 10 wt % silicified microcrystalline cellulose, about 5 wt % polyvinylpyrrolidone (crospovidone), about 0.75 wt % silicon dioxide, about 0.5 wt % sucralose and about 0.05 wt % peppermint flavoring.
[0328] The mixture of the present invention may comprise about 30 wt % of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof), about 26.87 wt % of granulated mannitol, about 26.87 wt % of spray-dried mannitol (e.g., Mannogem ), about 10 wt % silicified microcrystalline cellulose, about 5 wt % polyvinylpyrrolidone (crospovidone), about 0.75 wt % silicon dioxide and about 0.5 wt % sucralose.
[0329] The mixture of the present invention may comprise about 30 wt % of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof), about 26.85 wt % of granulated mannitol, about 26.85 wt % of spray-dried mannitol (e.g., Mannogem ), about 10 wt % silicified microcrystalline cellulose, about 5 wt % polyvinylpyrrolidone (crospovidone), about 0.75 wt % silicon dioxide, about 0.5 wt % sucralose and about 0.36 wt % lemon flavor.
[0330] The mixture of the present invention may comprise about 30 wt % of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof), about 26.85 wt % of granulated mannitol, about 26.85 wt % of spray-dried mannitol (e.g., Mannogem ), about 10 weight percent silicified microcrystalline cellulose, about 5 weight percent polyvinylpyrrolidone (crospovidone), about 0.75 weight percent silicon dioxide, about 0.5 weight percent sucralose, and about 0.31 weight percent mixed berry flavoring.
[0331] Manufacturing method of the present invention
[0332] As described above, the method of making the ODT described herein is a way to overcome the instability and degradation problems initially seen when the inventors attempted to produce an ODT of KVD900.
[0333] The present invention provides a method of making the ODT of the present invention from the mixture of the present invention, the method comprising blending the components of the mixture to form a powder mixture and compressing into an orodispersible tablet.
[0334] Specifically, the present invention provides a method for producing an orodispersible tablet according to the present invention from the mixture according to the present invention, the method comprising:
[0335] a) combining KVD900, one or more binders, and one or more disintegrants, and blending to form a powder mixture;
[0336] b) adding one or more fillers to the powder mixture from step a) and blending to form a final blend;
[0337] c) compressed into orodispersible tablets.
[0338] More specifically, the manufacturing method includes:
[0339] a) combining about 26 wt % to about 40 wt % of KVD900; about 5 wt % to about 30 wt % of one or more binders selected from microcrystalline cellulose or hydroxypropyl methylcellulose; and about 1 wt % to about 10 wt % of one or more disintegrants selected from polyvinyl pyrrolidone (crospovidone), sodium starch glycolate, and cross-linked sodium carboxymethylcellulose, and blending to form a powder mixture;
[0340] b) about 30% to about 80% by weight of a mannitol selected from the group consisting of mannitol (e.g., granulated mannitol and spray-dried mannitol (e.g., Mannogem )) is added to the powder mixture from step a) and blended to form a final blend;
[0341] c) compressed into orodispersible tablets.
[0342] More specifically, the manufacturing method includes:
[0343] a) combining about 30% by weight of KVD900; about 10% by weight of silicified microcrystalline cellulose; and about 5% by weight of polyvinyl pyrrolidone (crospovidone), and blending to form a powder mixture;
[0344] b) about 26.85 wt % of granulated mannitol and 26.85 wt % of spray-dried mannitol (e.g., Mannogem ) is added to the powder mixture from step a) and blended to form a final blend;
[0345] c) compressed into orodispersible tablets.
[0346] Alternatively, the manufacturing method comprises:
[0347] a) combining about 30% by weight of KVD900; about 10% by weight of silicified microcrystalline cellulose; and about 5% by weight of polyvinyl pyrrolidone (crospovidone), and blending to form a powder mixture;
[0348] b) about 26.87 wt % of granulated mannitol and 26.87 wt % of spray-dried mannitol (e.g., Mannogem ) is added to the powder mixture from step a) and blended to form a final blend;
[0349] c) compressed into orodispersible tablets.
[0350] In another embodiment of the present invention, the manufacturing method comprises:
[0351] a) combining KVD900, one or more binders, one or more disintegrants, a flow enhancer, one or more sweeteners, and one or more flavoring agents, and blending to form a powder mixture;
[0352] b) adding one or more fillers to the powder mixture from step a) and blending to form a final blend;
[0353] c) compressed into orodispersible tablets.
[0354] More specifically, the manufacturing method includes:
[0355] a) combining about 26 wt % to about 40 wt % of KVD900; about 5 wt % to about 30 wt % of one or more binders selected from microcrystalline cellulose or hydroxypropyl methylcellulose; about 1 wt % to about 10 wt % of one or more disintegrants selected from polyvinylpyrrolidone (crospovidone), sodium starch glycolate, cross-linked sodium carboxymethylcellulose; about 0.5 wt % to about 1 wt % of a flow enhancer; about 0.1 wt % to about 1 wt % of one or more sweeteners; and about 0.01 wt % to about 1 wt % of one or more flavoring agents, and blending to form a powder mixture;
[0356] b) about 30% to about 80% by weight of a mannitol selected from the group consisting of mannitol (e.g., granulated mannitol and spray-dried mannitol (e.g., Mannogem )) is added to the powder mixture from step a) and blended to form a final blend;
[0357] c) compressed into orodispersible tablets.
[0358] More specifically, the manufacturing method includes:
[0359] a) combining about 30 wt % KVD900, about 10 wt % silicified microcrystalline cellulose, about 5 wt % polyvinylpyrrolidone (crospovidone), about 0.75 wt % silicon dioxide, about 0.5 wt % sucralose, and about 0.05 wt % peppermint flavoring agent, and blending to form a powder mixture;
[0360] b) about 26.85 wt % of granulated mannitol and 26.85 wt % of spray-dried mannitol (e.g., Mannogem ) is added to the powder mixture from step a) and blended to form a final blend;
[0361] c) compressed into orodispersible tablets.
[0362] Alternatively, the manufacturing method comprises:
[0363] a) combining about 30% by weight of KVD900, about 10% by weight of silicified microcrystalline cellulose, about 5% by weight of polyvinylpyrrolidone (crospovidone), about 0.75% of silicon dioxide, and about 0.5% of sucralose, and blending to form a powder mixture;
[0364] b) about 26.87 wt % of granulated mannitol and 26.87 wt % of spray-dried mannitol (e.g., Mannogem ) is added to the powder mixture from step a) and blended to form a final blend;
[0365] c) compressed into orodispersible tablets.
[0366] In another embodiment, the method of manufacturing comprises:
[0367] a) combining about 30 wt % KVD900, about 10 wt % silicified microcrystalline cellulose, about 5 wt % polyvinylpyrrolidone (crospovidone), about 0.75 wt % silicon dioxide, about 0.5 wt % sucralose, and about 0.36 wt % lemon flavoring, and blending to form a powder mixture;
[0368] b) about 26.85 wt % of granulated mannitol and 26.85 wt % of spray-dried mannitol (e.g., Mannogem ) is added to the powder mixture from step a) and blended to form a final blend;
[0369] c) compressed into orodispersible tablets.
[0370] In another embodiment, the method of manufacturing comprises:
[0371] a) combining about 30 weight % KVD900, about 10 weight % silicified microcrystalline cellulose, about 5 weight % polyvinylpyrrolidone (crospovidone), about 0.75 weight % silicon dioxide, about 0.5 % sucralose, and about 0.31 weight % mixed berry flavoring, and blending to form a powder mixture;
[0372] b) about 26.85 wt % of granulated mannitol and 26.85 wt % of spray-dried mannitol (e.g., Mannogem ) is added to the powder mixture from step a) and blended to form a final blend;
[0373] c) compressed into orodispersible tablets.
[0374] In some embodiments, the manufacturing method includes the use of an external lubricant. An external lubricant is a lubricant that aids flow during the manufacturing process and may therefore be present in trace amounts in the final ODT, but is not actively added to the blend / mixture. Preferably, the external lubricant is magnesium stearate.
[0375] The manufacturing method of the present invention may further include the step of indenting the orodispersible tablet. The manufacturing method of the present invention may further include the step of indenting a logo, tablet concentration and / or one or more score lines on the orodispersible tablet. In one embodiment, the manufacturing method of the present invention further includes the step of indenting a logo on the orodispersible tablet. In another embodiment, the manufacturing method of the present invention further includes the step of indenting a tablet concentration on the orodispersible tablet. Preferably, the manufacturing method of the present invention further includes the step of indenting one or more score lines on the orodispersible tablet. The manufacturing method of the present invention further includes the step of indenting one score line on the orodispersible tablet. The manufacturing method of the present invention further includes the step of indenting two score lines on the orodispersible tablet. The manufacturing method of the present invention further includes the step of indenting two score lines on the orodispersible tablet to form a cross.
[0376] Kit of the present invention
[0377] The present invention also provides a kit for providing a dose of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof), the kit comprising more than one orodispersible tablet according to the present invention.
[0378] In some embodiments of the present invention, a kit for providing a dose of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof) comprises two orodispersible tablets according to the present invention.
[0379] The total dose of more than one orodispersible tablet in a kit of the invention may be about 500 mg, for example by providing a kit comprising two orodispersible tablets as described herein, each tablet comprising about 250 mg of KVD900.
[0380] The total dose of more than one orodispersible tablet in a kit of the invention may be about 550 mg, for example by providing a kit comprising two orodispersible tablets as described herein, each tablet comprising about 275 mg of KVD900.
[0381] The total dose of more than one orodispersible tablet in a kit of the invention may be about 600 mg, for example by providing a kit comprising two orodispersible tablets as described herein, each tablet comprising about 300 mg of KVD900.
[0382] In the kit of the present invention, more than one orodispersible tablet may be packaged in a blister pack (e.g., Alu / Alu blisters, Aclar / Alu blisters, Amcor AmSky blisters). The blister pack may be a peel-off or push-through type. More than one orodispersible tablet may also be packaged in other configurations known in the art.
[0383] When the kit comprises an orodispersible tablet debossed with a score line as described herein, the kit of the invention may further comprise instructions for dividing the orodispersible tablet into sub-tablets.
[0384] On-demand treatment of bradykinin-mediated angioedema episodes (e.g., BK AEnH episodes, preferably HAE episodes)
[0385] As mentioned above, "bradykinin-mediated angioedema" may be selected from HAE and BK-AEnH. The bradykinin-mediated angioedema may be BK-AEnH. Preferably, the bradykinin-mediated angioedema is HAE.
[0386] The present invention provides a treatment for bradykinin-mediated angioedema that is improved over any currently available bradykinin-mediated angioedema treatment. The present invention provides an oral treatment for HAE that is particularly useful as an on-demand treatment for attacks of bradykinin-mediated angioedema, and / or as an on-demand treatment to reduce the likelihood of attacks of bradykinin-mediated angioedema. Specifically, as described herein, treatments according to the present invention (i) are rapid in onset, (ii) are effective, (iii) have a good safety profile, and (iv) have a prolonged pharmacodynamic effect.
[0387] Thus, according to the present invention, there is provided a method for the on-demand treatment of bradykinin-mediated angioedema, the method comprising: administering on-demand to a patient in need thereof one or more orodispersible tablets comprising KVD900 according to the present invention.
[0388] According to one aspect of the present invention, a method for on-demand treatment of an attack of bradykinin-mediated angioedema is provided, the method comprising: administering one or more orodispersible tablets comprising KVD900 according to the present invention to a patient in need thereof, wherein the one or more orodispersible tablets are administered on-demand after the symptoms of an attack of bradykinin-mediated angioedema are identified.
[0389] When bradykinin-mediated angioedema is HAE, a "bradykinin-mediated angioedema episode" is an "HAE episode". When bradykinin-mediated angioedema is BK-AEnH, a "bradykinin-mediated angioedema episode" is a "BK-AEnH episode". As described above, bradykinin-mediated angioedema is preferably HAE.
[0390] Although the severity and affected sites of each bradykinin-mediated angioedema attack (e.g., BK-AEnH attack, preferably HAE attack) may vary, patients with bradykinin-mediated angioedema (e.g., BK-AEnH, preferably HAE), medical professionals with knowledge of bradykinin-mediated angioedema (e.g., BK-AEnH, preferably HAE), and caregivers of bradykinin-mediated angioedema (e.g., BK-AEnH, preferably HAE) patients are keen to identify symptoms of bradykinin-mediated angioedema attacks (e.g., BK-AEnH attacks, preferably HAE attacks). These symptoms include, but are not limited to: swelling of tissues (such as hands, feet, limbs, face, intestines, and / or airways); fatigue; headache; muscle aches; skin tingling; abdominal pain; nausea; vomiting; diarrhea; difficulty swallowing; hoarseness; shortness of breath; and / or mood changes. Therefore, in some embodiments, administration of KVD900 can be performed after identification of at least one of the above symptoms.
[0391] The treatment of the present invention can treat patients suffering from laryngeal attacks.
[0392] The treatment of the present invention can treat patients suffering from abdominal attacks, particularly patients suffering from abdominal attacks and experiencing vomiting episodes.
[0393] The treatment of the present invention can treat patients who also suffer from dysphagia.
[0394] The skilled artisan will also understand that "administering after the symptoms of a bradykinin-mediated angioedema attack (e.g., a BK-AEnH attack, preferably a HAE attack) are recognized" means that the administration is performed as soon as possible after the symptoms of a bradykinin-mediated angioedema attack (e.g., a BK-AEnH attack, preferably a HAE attack) are recognized. For example, patients are expected to always have easy and convenient access to KVD900 (most likely in the form of a pharmaceutically acceptable composition) to ensure that treatment can be performed after the symptoms of a bradykinin-mediated angioedema attack (e.g., a BK-AEnH attack, preferably a HAE attack) are recognized. In other words, treatment is performed on demand. For example, in some embodiments, KVD900 can be administered within 1 hour of recognizing symptoms of a bradykinin-mediated angioedema attack (e.g., a BK-AEnH attack, preferably a HAE attack), preferably within 30 minutes, within 20 minutes, within 10 minutes, or within 5 minutes of recognizing symptoms of a bradykinin-mediated angioedema attack (e.g., a BK-AEnH attack, preferably a HAE attack).
[0395] If symptoms of a bradykinin-mediated angioedema attack (e.g., a BK-AEnH attack, preferably an HAE attack) are identified in the prodromal period, then one embodiment of the present invention is that KVD900 can be administered in the prodromal period of a bradykinin-mediated angioedema attack (e.g., a BK-AEnH attack, preferably an HAE attack). In these cases, the identified symptoms can be mild swelling, particularly mild swelling affecting the face and neck. Additionally or alternatively, the symptom can be abdominal pain, particularly abdominal pain is considered to be a characteristic of a bradykinin-mediated angioedema attack (e.g., a BK-AEnH attack, preferably an HAE attack). Additionally or alternatively, the symptom can be reddening of the skin, such as erythema marginale.
[0396] Treatment according to the present invention can prevent the severity of bradykinin-mediated angioedema attacks (e.g., BK-AEnH attacks, preferably HAE attacks) from increasing. In some cases, treatment can shorten the duration of an attack, and sometimes even stop the attack completely. For example, treatment can stop the progression of peripheral bradykinin-mediated angioedema attacks (e.g., BK-AEnH attacks, preferably HAE attacks) or abdominal bradykinin-mediated angioedema attacks (e.g., BK-AEnH attacks, preferably HAE attacks). In some embodiments, treatment according to the present invention can inhibit the occurrence of subsequent swelling, sometimes completely, especially when treatment is initiated in the prodromal phase. In particular, in some embodiments, when treatment is initiated in the prodromal phase, bradykinin-mediated angioedema attacks (e.g., BK-AEnH attacks, preferably HAE attacks) can be prevented from progressing to the swelling stage.
[0397] KVD900 may be sufficient to treat bradykinin-mediated angioedema attacks (e.g., BK-AEnH attacks, preferably HAE attacks) alone, i.e., without administering any active pharmaceutical ingredient other than KVD900 to the patient. Therefore, in some embodiments of the present invention, no active pharmaceutical ingredient other than KVD900 is administered to the patient to treat bradykinin-mediated angioedema attacks (e.g., BK-AEnH attacks, preferably HAE attacks). In particular, in some embodiments, the treatment of the present invention does not require the administration of any active pharmaceutical ingredient other than KVD900 for the treatment of bradykinin-mediated angioedema attacks (e.g., BK-AEnH attacks, preferably HAE attacks) (e.g., no rescue drugs such as pdC1INH, rhC1INH or icatibant are required). More specifically, in some embodiments, no active pharmaceutical ingredient other than KVD900 is administered to the patient for treating a bradykinin-mediated angioedema attack (e.g., a BK-AEnH attack, preferably a HAE attack) (e.g., no rescue medication, such as pdC1INH, rhC1INH, or icatibant is required).
[0398] Alternatively, in some embodiments, the treatment of the present invention can be used in combination with other treatments for bradykinin-mediated angioedema (e.g., BK-AEnH, preferably HAE). For example, in some embodiments, the on-demand acute therapy described herein can be used as a "top-up" to another treatment for bradykinin-mediated angioedema (e.g., BK-AEnH, preferably HAE). In some embodiments, a patient can take preventive treatment for bradykinin-mediated angioedema (e.g., BK-AEnH, preferably HAE), and can use the on-demand treatment described herein to treat a bradykinin-mediated angioedema attack (e.g., a BK-AEnH attack, preferably a HAE attack) that is not prevented by other preventive treatments for bradykinin-mediated angioedema attacks (e.g., BK-AEnH attacks, preferably HAE attacks).
[0399] For example, in some embodiments, a method for treating a patient who has been treated with a C1 inhibitor (such as ) is a method for treating bradykinin-mediated angioedema (e.g., BK-AEnH, preferably HAE) in a patient who has been treated with lanarizumab for prevention, the method comprising: after identifying the symptoms of a bradykinin-mediated angioedema attack (e.g., a BK-AEnH attack, preferably a HAE attack), orally administering KVD900 to the patient on demand. In another embodiment, a method for treating bradykinin-mediated angioedema (e.g., BK-AEnH, preferably HAE) in a patient who has been treated with lanarizumab for prevention is provided, the method comprising: after identifying the symptoms of a bradykinin-mediated angioedema attack (e.g., a BK-AEnH attack, preferably a HAE attack), orally administering KVD900 to the patient on demand. In another embodiment, a method for treating bradykinin-mediated angioedema (e.g., BK-AEnH, preferably HAE) in a patient who has been taking berotralstat for prophylaxis is provided, the method comprising: orally administering KVD900 to the patient on demand after recognizing symptoms of an attack of bradykinin-mediated angioedema (e.g., an attack of BK-AEnH, preferably an attack of HAE).
[0400] In any of the above treatments, symptoms may be identified by the patient. In any of the above treatments, symptoms may be identified by a medical professional, such as a medical professional with knowledge of bradykinin-mediated angioedema (e.g., BK-AEnH, preferably HAE). In any of the above treatments, symptoms may be identified by the patient's caregiver.
[0401] Treatment according to the present invention can reduce the proportion of bradykinin-mediated angioedema attacks (e.g., BK-AEnH attacks, preferably HAE attacks) that progress by one or more levels on a 5-point Likert scale (5LS). Treatment according to the present invention can reduce the proportion of bradykinin-mediated angioedema attacks (e.g., BK-AEnH attacks, preferably HAE attacks) that progress by one or more levels on the 5LS within 12 hours of administration of the compound. Treatment according to the present invention can increase the resolution time of bradykinin-mediated angioedema attacks (e.g., BK-AEnH attacks, preferably HAE attacks) to "none" on the 5LS. The 5LS is a scale known in the art (see, e.g., Allergy Asthma Proc. 2018 Jan 1;39(1):74-80. doi:10.2500 / aap.2018.39.4095) that can be used to report the severity of a bradykinin-mediated angioedema attack (e.g., a BK-AEnH attack, preferably a HAE attack), e.g., can be used to report an attack as "none," "mild," "moderate," "severe," or "very severe."
[0402] Treatment according to the present invention can reduce the proportion of bradykinin-mediated angioedema attacks (e.g., BK-AEnH attacks, preferably HAE attacks) rated as "worse" or "very worse" on the 7-point transition question (7TQ). Treatment according to the present invention can increase the proportion of bradykinin-mediated angioedema attacks (e.g., BK-AEnH attacks, preferably HAE attacks) rated as "better" or "very good". 7TQ is an indicator known in the art that can be used to score the progression of bradykinin-mediated angioedema attacks (e.g., BK-AEnH attacks, preferably HAE attacks) and report the attack as "very good", "better", "slightly better", "no change", "slightly worse", "worse" or "very worse".
[0403] In some embodiments of any on-demand treatment of bradykinin-mediated angioedema attacks (e.g., BK-AEnH attacks, preferably HAE attacks) of the present invention, a single dose of KVD900 may be administered to the patient to treat bradykinin-mediated angioedema attacks (e.g., BK-AEnH attacks, preferably HAE attacks). In some other embodiments of any on-demand treatment of bradykinin-mediated angioedema attacks (e.g., BK-AEnH attacks, preferably HAE attacks) of the present invention, multiple doses of KVD900 may be administered to the patient to treat bradykinin-mediated acute angioedema attacks (e.g., BK-AEnH attacks, preferably HAE attacks). For example, on-demand treatment may include administering two doses of KVD900 within 24 hours from the time the first dose was taken. Alternatively, on-demand treatment may include administering three doses of KVD900 within 24 hours from the time the first dose was taken. Alternatively, on-demand treatment may include administering four doses of KVD900 within 24 hours from the time the first dose was taken. When multiple doses are used, the doses can be evenly spaced such that there are approximately equal periods of time between each dose, for example, with subsequent doses being taken 8 hours, 16 hours, and 24 hours after the first dose.
[0404] In some embodiments of any on-demand treatment of bradykinin-mediated angioedema attacks (e.g., BK-AEnH attacks, preferably HAE attacks) of the present invention, a daily dose can be administered to the patient in two doses per day. These two doses can be administered simultaneously, individually, or sequentially. In some embodiments, the two doses can be administered at any time within a day, and the interval between the two doses is specific to the severity of the patient and the bradykinin-mediated angioedema attack (e.g., BK-AEnH attack, preferably HAE attack). In some embodiments, the second dose can be administered within about 2 hours of the first time (more specifically, about 1 to 2 hours after the first dose). In some embodiments, the second dose can be administered within about 1 to about 4 hours of the first time (more specifically, about 1 to 3 hours, about 2 to 3 hours, or 3 hours to about 4 hours after the first dose). In some embodiments, the second dose can be administered within about 4 to about 12 hours of the first time (more specifically, about 4 to about 8 hours, or about 6 hours after the first dose). In some embodiments, the second dose can be administered within about 2 to about 6 hours of the first dose (more specifically, about 3 to about 6 hours after the first dose). In some embodiments, the second dose can be administered within about 8 hours of the first dose (more specifically, about 4 to about 8 hours after the first dose). In some embodiments, the second dose can be administered within about 12 hours of the first dose (more specifically, about 8 to about 12 hours after the first dose). In some embodiments, the second dose can be administered within about 16 hours of the first dose (more specifically, about 12 to about 16 hours after the first dose). In some embodiments, the second dose can be administered within about 20 hours of the first dose (more specifically, about 16 to about 20 hours after the first dose). In some embodiments, the second dose can be administered within about 24 hours of the first dose (more specifically, about 20 to about 24 hours after the first dose). In some embodiments, each of the two doses can be 500 mg of KVD900. Alternatively, each of the two doses can be 550 mg of KVD900. Alternatively, each of the two doses may be 600 mg of KVD900.
[0405] In any on-demand treatment of bradykinin-mediated angioedema attacks (e.g., BK-AEnH attacks, preferably HAE attacks) of the present invention, the daily dose can be administered to the patient twice a day, wherein the second dose can be administered at least about 6 hours after the first dose. The daily dose can be administered to the patient twice a day, wherein the second dose can be administered about 5 to about 7 hours after the first dose. More specifically, the daily dose can be administered to the patient twice a day, wherein the second dose can be administered about 6 hours after the first dose. In these embodiments, each of the two doses can be 500 mg of KVD900. Each of these 500 mg doses can be two orodispersible tablets containing 250 mg of KVD900. In these embodiments, each of the two doses can be 550 mg of KVD900. Each of these 550 mg doses can be two orodispersible tablets containing 275 mg of KVD900. In these embodiments, each of the two doses can be 600 mg of KVD900. Each of these 600 mg doses can be two orodispersible tablets containing 300 mg of KVD900.
[0406] In some embodiments of any on-demand treatment of bradykinin-mediated angioedema attacks (e.g., BK-AEnH attacks, preferably HAE attacks) of the present invention, a daily dose can be administered to the patient in three doses per day. These three doses can be administered simultaneously, individually or sequentially. In some embodiments, the three doses can be administered at any time within a day, and the intervals between the three doses are specific to the severity of the patient and the bradykinin-mediated angioedema attack (e.g., BK-AEnH attacks, preferably HAE attacks). In some embodiments, both the second dose and the third dose can be administered within about 4 hours of the first dose. More specifically, the second dose can be administered about 1 to 3 hours after the first dose, and the third dose can be administered about 3 to about 4 hours after the first dose. The second dose can be administered within about 4 to about 12 hours of the first dose (more specifically, about 4 to about 8 hours, or about 6 hours after the first dose), and the third dose can be administered within about 4 to about 12 hours of the second dose (more specifically, about 4 to about 8 hours, or about 6 hours after the second dose). Even more specifically, the second dose can be administered about 2 hours after the first dose, and the third dose can be administered about 4 hours after the first dose. In some embodiments, both the second dose and the third dose can be administered within about 8 hours of the first dose. More specifically, the second dose can be administered within about 3 to 5 hours of the first dose, and the third dose can be administered about 7 to about 8 hours after the first dose. Even more specifically, the second dose can be administered about 4 hours after the first dose, and the third dose can be administered about 8 hours after the first dose. In some embodiments, both the second dose and the third dose can be administered within about 16 hours of the first dose. More specifically, the second dose can be administered within about 7 to 9 hours of the first dose, and the third dose can be administered about 15 to about 16 hours after the first dose. Even more specifically, the second dose can be administered about 8 hours after the first dose, and the third dose can be administered about 16 hours after the first dose. In some embodiments, each of the three doses can be 500 mg of KVD900. Alternatively, each of the three doses can be 550 mg of KVD900. Alternatively, each of the three doses may be 600 mg of KVD900.
[0407] In any on-demand treatment of bradykinin-mediated angioedema attacks (e.g., BK-AEnH attacks, preferably HAE attacks) of the present invention, the daily dose can be administered to the patient in three doses per day, wherein the second dose and the third dose can be administered at least about 6 hours after the previous dose. The daily dose can be administered to the patient in three doses per day, wherein the second dose can be administered about 5 to about 7 hours after the first dose, and the third dose can be administered about 11 to about 13 hours after the first dose. More specifically, the daily dose can be administered to the patient in three doses per day, wherein the second dose can be administered about 6 hours after the first dose, and the third dose can be administered about 12 hours after the first dose. In these embodiments, each of the three doses can be 500 mg of KVD900. Each of these 500 mg doses can be two orodispersible tablets containing 250 mg of KVD900. In these embodiments, each of the three doses can be 550 mg of KVD900. Each of these 550 mg doses can be two orodispersible tablets containing 275 mg of KVD900. In these embodiments, each of the three doses can be 600 mg of KVD900. Each of these 600 mg doses can be two orodispersible tablets containing 300 mg of KVD900.
[0408] If, for example, a bradykinin-mediated angioedema attack (e.g., a BK-AEnH attack, preferably a HAE attack) persists after administration of a first dose, multiple doses may be administered. When used in this context, "persistent" may mean, for example, that the first dose does not prevent an increase in the severity of a bradykinin-mediated angioedema attack (e.g., a BK-AEnH attack, preferably a HAE attack), or that the first dose does not completely stop a bradykinin-mediated angioedema attack (e.g., a BK-AEnH attack, preferably a HAE attack), or that the first dose does not reduce the severity of a bradykinin-mediated angioedema attack (e.g., a BK-AEnH attack, preferably a HAE attack). Therefore, the on-demand treatment of a bradykinin-mediated angioedema attack (e.g., a BK-AEnH attack, preferably a HAE attack) of the present invention may include administering a first dose, and then administering a second dose if a bradykinin-mediated angioedema attack (e.g., a BK-AEnH attack, preferably a HAE attack) persists after administration of the first dose. The on-demand treatment of bradykinin-mediated angioedema attacks (e.g., BK-AEnH attacks, preferably HAE attacks) of the present invention may also include administering a first dose, then administering a second dose if the bradykinin-mediated angioedema attack (e.g., BK-AEnH attack, preferably HAE attack) persists after the first dose is administered, and then administering a third dose if the bradykinin-mediated angioedema attack (e.g., BK-AEnH attack, preferably HAE attack) persists after the second dose is administered. In each case, each subsequent dose may be administered simultaneously, individually or sequentially. In each case, each subsequent dose may be administered at least about 6 hours (e.g., about 6 hours) after the previous dose. In each case, each dose may contain 500 mg of KVD900, for example, administered as two orodispersible tablets containing 250 mg of KVD900. Alternatively, each dose may contain 550 mg of KVD900, for example, administered as two orodispersible tablets containing 275 mg of KVD900. Alternatively, each dose may contain 600 mg of KVD900, for example administered as two orodispersible tablets containing 300 mg of KVD900.
[0409] Specifically, the on-demand treatment of bradykinin-mediated angioedema attacks (e.g., BK-AEnH attacks, preferably HAE attacks) of the present invention may include administering a first dose containing 500 mg of the compound (e.g., as two orodispersible tablets containing 250 mg of the compound), and then if the bradykinin-mediated angioedema attack (e.g., BK-AEnH attack, preferably HAE attack) persists after administration of the first dose, administering a second dose containing 500 mg of the compound (e.g., as two orodispersible tablets containing 250 mg of the compound). The second dose may be administered at least about 6 hours (e.g., about 6 hours) after the first dose. If the bradykinin-mediated angioedema attack (e.g., BK-AEnH attack, preferably HAE attack) persists after the second dose, the on-demand treatment of bradykinin-mediated angioedema attacks (e.g., BK-AEnH attacks, preferably HAE attacks) of the present invention may include administering a third dose containing 500 mg of the compound (e.g., as two orodispersible tablets containing 250 mg of the compound). The third dose can be administered at least about 6 hours (eg, about 6 hours) after the second dose.
[0410] Alternatively, the on-demand treatment of a bradykinin-mediated angioedema attack (e.g., a BK-AEnH attack, preferably a HAE attack) of the present invention may include administering a first dose containing 550 mg of the compound (e.g., as two orodispersible tablets containing 275 mg of the compound), and then if the bradykinin-mediated angioedema attack (e.g., a BK-AEnH attack, preferably a HAE attack) persists after administration of the first dose, administering a second dose containing 550 mg of the compound (e.g., as two orodispersible tablets containing 275 mg of the compound). The second dose may be administered at least about 6 hours (e.g., about 6 hours) after the first dose. If the bradykinin-mediated angioedema attack (e.g., a BK-AEnH attack, preferably a HAE attack) persists after the second dose, the on-demand treatment of a bradykinin-mediated angioedema attack (e.g., a BK-AEnH attack, preferably a HAE attack) of the present invention may include administering a third dose containing 550 mg of the compound (e.g., as two orodispersible tablets containing 275 mg of the compound). The third dose can be administered at least about 6 hours (eg, about 6 hours) after the second dose.
[0411] Alternatively, the on-demand treatment of a bradykinin-mediated angioedema attack (e.g., a BK-AEnH attack, preferably a HAE attack) of the present invention may include administering a first dose containing 600 mg of the compound (e.g., as two orodispersible tablets containing 300 mg of the compound), and then if the bradykinin-mediated angioedema attack (e.g., a BK-AEnH attack, preferably a HAE attack) persists after administration of the first dose, administering a second dose containing 600 mg of the compound (e.g., as two orodispersible tablets containing 300 mg of the compound). The second dose may be administered at least about 6 hours (e.g., about 6 hours) after the first dose. If the bradykinin-mediated angioedema attack (e.g., a BK-AEnH attack, preferably a HAE attack) persists after the second dose, the on-demand treatment of a bradykinin-mediated angioedema attack (e.g., a BK-AEnH attack, preferably a HAE attack) of the present invention may include administering a third dose containing 600 mg of the compound (e.g., as two orodispersible tablets containing 300 mg of the compound). The third dose can be administered at least about 6 hours (eg, about 6 hours) after the second dose.
[0412] Even if the severity of a bradykinin-mediated angioedema attack (e.g., a BK-AEnH attack, preferably a HAE attack) appears to have decreased (or even completely stopped) after administration of the first dose, multiple doses may be administered to prevent the severity of a bradykinin-mediated angioedema attack (e.g., a BK-AEnH attack, preferably a HAE attack) from increasing again. For example, multiple doses may be used to calm the patient, for example to relieve the patient's anxiety. Therefore, the on-demand treatment of a bradykinin-mediated angioedema attack (e.g., a BK-AEnH attack, preferably a HAE attack) of the present invention may include administering a first dose, and then administering a second dose to prevent the severity of a bradykinin-mediated angioedema attack (e.g., a BK-AEnH attack, preferably a HAE attack) from increasing again, even if the severity of a bradykinin-mediated angioedema attack (e.g., a BK-AEnH attack, preferably a HAE attack) appears to have decreased (or even completely stopped) after administration of the first dose. Even if the severity of a bradykinin-mediated angioedema attack (e.g., a BK-AEnH attack, preferably a HAE attack) appears to have decreased (or even completely stopped) after administration of the first dose and / or the second dose, the on-demand treatment of a bradykinin-mediated angioedema attack (e.g., a BK-AEnH attack, preferably a HAE attack) of the present invention may also include administering a third dose to prevent the severity of a bradykinin-mediated angioedema attack (e.g., a BK-AEnH attack, preferably a HAE attack) from increasing again. In each case, each subsequent dose may be administered simultaneously, separately, or sequentially. In each case, each subsequent dose may be administered at least about 6 hours (e.g., about 6 hours) after the previous dose. In each case, each dose may contain 500 mg of the compound, for example, administered as two tablets containing 250 mg of the compound. Alternatively, each dose may contain 550 mg of the compound, for example, administered as two tablets containing 275 mg of the compound. Alternatively, each dose may contain 600 mg of the compound, for example administered as two tablets containing 300 mg of the compound.
[0413] Specifically, the on-demand treatment of bradykinin-mediated angioedema attacks (e.g., BK-AEnH attacks, preferably HAE attacks) of the present invention may include administering a first dose of 500 mg of the compound (e.g., as two tablets containing 250 mg of the compound), and then administering a second dose of 500 mg of the compound (e.g., as two tablets containing 250 mg of the compound) to prevent the severity of bradykinin-mediated angioedema attacks (e.g., BK-AEnH attacks, preferably HAE attacks) from increasing again, even if the severity of the bradykinin-mediated angioedema attacks (e.g., BK-AEnH attacks, preferably HAE attacks) appears to have decreased (or even stopped completely) after the administration of the first dose. The second dose may be administered at least about 6 hours (e.g., about 6 hours) after the first dose. Even if the severity of bradykinin-mediated angioedema episodes (e.g., BK-AEnH episodes, preferably HAE episodes) appears to have decreased (or even completely stopped) after administration of the first and / or second doses, the on-demand treatment of bradykinin-mediated angioedema episodes (e.g., BK-AEnH episodes, preferably HAE episodes) of the present invention may also include administering a third dose containing 500 mg of the compound (e.g., as two tablets containing 250 mg of the compound) to prevent the severity of bradykinin-mediated angioedema episodes (e.g., BK-AEnH episodes, preferably HAE episodes) from increasing again. The third dose may be administered at least about 6 hours (e.g., about 6 hours) after the second dose.
[0414] Alternatively, the on-demand treatment of bradykinin-mediated angioedema attacks (e.g., BK-AEnH attacks, preferably HAE attacks) of the present invention may include administering a first dose containing 550 mg of the compound (e.g., as two tablets containing 275 mg of the compound), and then administering a second dose containing 550 mg of the compound (e.g., as two tablets containing 275 mg of the compound) to prevent the severity of the bradykinin-mediated angioedema attacks (e.g., BK-AEnH attacks, preferably HAE attacks) from increasing again, even if the severity of the bradykinin-mediated angioedema attacks (e.g., BK-AEnH attacks, preferably HAE attacks) appears to have decreased (or even stopped completely) after the administration of the first dose. The second dose may be administered at least about 6 hours (e.g., about 6 hours) after the first dose. Even if the severity of a bradykinin-mediated angioedema attack (e.g., a BK-AEnH attack, preferably a HAE attack) appears to have decreased (or even completely stopped) after administration of the first and / or second doses, the on-demand treatment of a bradykinin-mediated angioedema attack (e.g., a BK-AEnH attack, preferably a HAE attack) of the present invention may also include administering a third dose (e.g., as two tablets containing 275 mg of the compound) containing 550 mg to prevent the severity of a bradykinin-mediated angioedema attack (e.g., a BK-AEnH attack, preferably a HAE attack) from increasing again. The third dose may be administered at least about 6 hours (e.g., about 6 hours) after the second dose.
[0415] Alternatively, the on-demand treatment of bradykinin-mediated angioedema attacks (e.g., BK-AEnH attacks, preferably HAE attacks) of the present invention may include administering a first dose containing 600 mg of the compound (e.g., as two tablets containing 300 mg of the compound), and then administering a second dose containing 600 mg of the compound (e.g., as two tablets containing 300 mg of the compound) to prevent the severity of the bradykinin-mediated angioedema attacks (e.g., BK-AEnH attacks, preferably HAE attacks) from increasing again, even if the severity of the bradykinin-mediated angioedema attacks (e.g., BK-AEnH attacks, preferably HAE attacks) appears to have decreased (or even stopped completely) after the administration of the first dose. The second dose may be administered at least about 6 hours (e.g., about 6 hours) after the first dose. Even if the severity of bradykinin-mediated angioedema episodes (e.g., BK-AEnH episodes, preferably HAE episodes) appears to have decreased (or even completely stopped) after administration of the first and / or second doses, the on-demand treatment of bradykinin-mediated angioedema episodes (e.g., BK-AEnH episodes, preferably HAE episodes) of the present invention may also include administering a third dose containing 600 mg of the compound (e.g., as two tablets containing 300 mg of the compound) to prevent the severity of bradykinin-mediated angioedema episodes (e.g., BK-AEnH episodes, preferably HAE episodes) from increasing again. The third dose may be administered at least about 6 hours (e.g., about 6 hours) after the second dose.
[0416] On-demand treatment of bradykinin-mediated angioedema attacks (e.g., BK-AEnH attacks, preferably HAE attacks) of the present invention may include administering no more than three doses in 24 hours (e.g., three doses containing 500 mg of the compound, optionally as 6 tablets, each tablet containing 250 mg of the compound). Alternatively, on-demand treatment of bradykinin-mediated angioedema attacks (e.g., BK-AEnH attacks, preferably HAE attacks) of the present invention may include administering no more than three doses in 24 hours (e.g., three doses containing 550 mg of the compound, optionally as 6 tablets, each tablet containing 275 mg of the compound). Alternatively, on-demand treatment of bradykinin-mediated angioedema attacks (e.g., BK-AEnH attacks, preferably HAE attacks) of the present invention may include administering no more than three doses in 24 hours (e.g., three doses containing 600 mg of the compound, optionally as 6 tablets, each tablet containing 300 mg of the compound).
[0417] On-demand prophylactic treatment of bradykinin-mediated angioedema episodes (e.g., BK AEnH episodes, preferably HAE episodes)
[0418] According to one aspect of the present invention, a method for on-demand treatment of bradykinin-mediated angioedema (e.g., BK-AEnH, preferably HAE) is provided, the method comprising: administering one or more orodispersible tablets comprising KVD900 according to the present invention to a patient in need thereof, wherein the one or more orodispersible tablets are administered on-demand to prophylactically reduce the likelihood of an attack of bradykinin-mediated angioedema (e.g., an attack of BK-AEnH, preferably an attack of HAE).
[0419] In some embodiments, KVD900 can be administered to prevent a bradykinin-mediated angioedema episode (eg, a BK-AEnH episode, preferably a HAE episode). As described above, preferably, the bradykinin-mediated angioedema is HAE.
[0420] As discussed above, treatment according to the present invention does not require administration of KVD900 at regular intervals to provide preventive treatment. In fact, in some embodiments, KVD900 can be administered on demand. For example, KVD900 can be administered on demand to reduce the likelihood of bradykinin-mediated angioedema attacks (e.g., BK-AEnH attacks, preferably HAE attacks), for example, when bradykinin-mediated angioedema attacks (e.g., BK-AEnH attacks, preferably HAE attacks) are expected to be induced (or triggered), i.e., the patient is expected to suffer from bradykinin-mediated angioedema attacks (e.g., BK-AEnH attacks, preferably HAE attacks), to prevent bradykinin-mediated angioedema attacks (such as BK-AEnH attacks, preferably HAE attacks). In some embodiments, the patient can be expected to induce (or trigger) bradykinin-mediated angioedema attacks (e.g., BK-AEnH attacks, preferably HAE attacks). In some embodiments, a medical professional (such as a medical professional with knowledge of bradykinin-mediated angioedema (e.g., BK-AEnH, preferably HAE)) can anticipate the induction (or triggering) of a bradykinin-mediated angioedema attack (e.g., a BK-AEnH attack, preferably a HAE attack). In some embodiments, a caregiver of a patient can anticipate the induction (or triggering) of a bradykinin-mediated angioedema attack (e.g., a BK-AEnH attack, preferably a HAE attack). For example, a bradykinin-mediated angioedema attack (e.g., a BK-AEnH attack, preferably a HAE attack) can be induced (or triggered) by various stimuli, such as physical trauma (e.g., medical, dental, or surgical procedures) and / or stress (e.g., high-pressure situations, such as mental stress, which in some cases may be associated with undergoing an examination, or mental stress associated with a medical, dental, or surgical procedure). For example, when a patient may be expected to suffer from a bradykinin-mediated angioedema attack (e.g., a BK-AEnH attack, preferably an HAE attack), an increased stress / anxiety level in the patient may induce (or trigger) a bradykinin-mediated angioedema attack (e.g., a BK-AEnH attack, preferably an HAE attack). In addition, the frequency of bradykinin-mediated angioedema attacks (e.g., BK-AEnH attacks, preferably HAE attacks) in the same patient may vary over time. Patients may often experience bradykinin-mediated angioedema attacks (e.g., BK-AEnH attacks, preferably HAE attacks) at a higher frequency than normal periods. Therefore, bradykinin-mediated angioedema attacks (e.g., BK-AEnH attacks, preferably HAE attacks) can be expected during a period when the patient experiences bradykinin-mediated angioedema attacks (e.g., BK-AEnH attacks, preferably HAE attacks) more frequently than normal.Those familiar with bradykinin-mediated angioedema (e.g., BK-AEnH, preferably HAE) will be aware that bradykinin-mediated angioedema episodes (e.g., BK-AEnH episodes, preferably HAE episodes) can be induced (or triggered) in this manner. Patients, medical professionals with bradykinin-mediated angioedema (e.g., BK-AEnH, preferably HAE), and caregivers of patients can also be sensitive to anticipating such triggers. Therefore, according to the present invention, treatment can be administered as needed when it is expected that a patient will experience one or more of these stimuli or situations.
[0421] As discussed above, KVD900 can be administered to a patient as part of an on-demand preventive treatment of a bradykinin-mediated angioedema attack (e.g., a BK-AEnH attack, preferably a HAE attack). As discussed above, such treatment reduces the likelihood of a bradykinin-mediated angioedema attack (e.g., a BK-AEnH attack, preferably a HAE attack). However, in some cases, a patient may still suffer from a bradykinin-mediated angioedema attack (e.g., a BK-AEnH attack, preferably a HAE attack). Thus, one embodiment of the invention is that KVD900 can be administered to a patient as part of an on-demand preventive treatment of a bradykinin-mediated angioedema attack (e.g., a BK-AEnH attack, preferably a HAE attack), as discussed above, and also includes taking an on-demand dose of KVD900 to treat a bradykinin-mediated angioedema attack (e.g., a BK-AEnH attack, preferably a HAE attack) after the symptoms of the bradykinin-mediated angioedema attack (e.g., a BK-AEnH attack, preferably a HAE attack) are recognized, if they occur. These on-demand treatments of bradykinin-mediated angioedema attacks (e.g., a BK-AEnH attack, preferably a HAE attack) are discussed above.
[0422] Thus, in some embodiments, a method for treating bradykinin-mediated angioedema (e.g., BK-AEnH, preferably HAE) on demand is provided, the method comprising: administering one or more orodispersible tablets comprising KVD900 according to the present invention to a patient in need thereof, wherein the one or more orodispersible tablets are administered on demand to prophylactically reduce the likelihood of an attack of bradykinin-mediated angioedema (e.g., a BK-AEnH attack, preferably a HAE attack), and further comprising administering one or more orodispersible tablets on demand after symptoms of an acute HAE attack are recognized.
[0423] In some embodiments of any on-demand treatment of bradykinin-mediated angioedema attacks (e.g., BK-AEnH attacks, preferably HAE attacks) of the present invention, a single dose of KVD900 may be administered to the patient to treat bradykinin-mediated angioedema attacks (e.g., BK-AEnH attacks, preferably HAE attacks). In some other embodiments of any on-demand treatment of bradykinin-mediated angioedema attacks (e.g., BK-AEnH attacks, preferably HAE attacks) of the present invention, multiple doses of KVD900 may be administered to the patient to treat bradykinin-mediated angioedema attacks (e.g., BK-AEnH attacks, preferably HAE attacks). For example, on-demand treatment may include administering two doses of KVD900 within 24 hours from the time the first dose was taken. Alternatively, on-demand treatment may include administering three doses of KVD900 within 24 hours from the time the first dose was taken. Alternatively, on-demand treatment may include administering four doses of KVD900 within 24 hours from the time the first dose was taken. When multiple doses are used, the doses can be evenly spaced such that there are approximately equal periods of time between each dose, for example, subsequent doses are taken 8 hours, 16 hours, and 24 hours after the initial dose.
[0424] In some embodiments of any on-demand preventive treatment of bradykinin-mediated angioedema attacks (e.g., BK-AEnH attacks, preferably HAE attacks) described herein, it can be administered to the patient in two doses per day. These two doses can be administered simultaneously, individually or sequentially. In some embodiments, two doses can be administered at any time within a day, and the interval between the two doses is specific to the patient. In some embodiments, the second dose can be administered within about 2 hours of the first time (more specifically, about 1 to 2 hours after the first dose). In some embodiments, the second dose can be administered within about 1 to about 4 hours of the first time (more specifically, about 1 to 3 hours, about 2 to 3 hours, or 3 hours to about 4 hours after the first dose). In some embodiments, the second dose can be administered within about 4 to about 12 hours of the first time (more specifically, about 4 to about 8 hours, or about 6 hours after the first dose). In some embodiments, the second dose can be administered within about 2 to about 6 hours of the first time (more specifically, about 3 to about 6 hours after the first dose). In some embodiments, the second dose can be administered within about 8 hours of the first dose (more specifically, about 4 to about 8 hours after the first dose). In some embodiments, the second dose can be administered within about 12 hours of the first dose (more specifically, about 8 to about 12 hours after the first dose). In some embodiments, the second dose can be administered within about 16 hours of the first dose (more specifically, about 12 to about 16 hours after the first dose). In some embodiments, the second dose can be administered within about 20 hours of the first dose (more specifically, about 16 to about 20 hours after the first dose). In some embodiments, the second dose can be administered within about 24 hours of the first dose (more specifically, about 20 to about 24 hours after the first dose). In some embodiments, each of the two doses can be 500 mg of KVD900. Alternatively, each of the two doses can be 550 mg of KVD900. Alternatively, each of the two doses can be 600 mg of KVD900.
[0425] In any on-demand preventive treatment of bradykinin-mediated angioedema attacks (e.g., BK-AEnH attacks, preferably HAE attacks) described herein, the daily dose can be administered to the patient twice a day, wherein the second dose can be administered at least about 6 hours after the first dose. The daily dose can be administered to the patient twice a day, wherein the second dose can be administered about 5 to about 7 hours after the first dose. More specifically, the daily dose can be administered to the patient twice a day, wherein the second dose can be administered about 6 hours after the first dose. In these embodiments, each of the two doses can be 500 mg of KVD900. Each of these 500 mg doses can be two orodispersible tablets containing 250 mg of KVD900. Alternatively, in these embodiments, each of the two doses can be 550 mg of KVD900. Each of these 550 mg doses can be two orodispersible tablets containing 275 mg of KVD900. Alternatively, in these embodiments, each of the two doses can be 600 mg of KVD900. Each of these 600 mg doses can be two orodispersible tablets containing 300 mg of KVD900.
[0426] In some embodiments of any on-demand preventive treatment of bradykinin-mediated angioedema attacks (e.g., BK-AEnH attacks, preferably HAE attacks) described herein, a daily dose can be administered to a patient in three doses per day. These three doses can be administered simultaneously, individually or sequentially. In some embodiments, three doses can be administered at any time within a day, and the interval between the three doses is specific to the patient. In some embodiments, both the second dose and the third dose can be administered within about 4 hours of the first dose. More specifically, the second dose can be administered about 1 to 3 hours after the first dose, and the third dose can be administered about 3 to about 4 hours after the first dose. The second dose can be administered within about 4 to about 12 hours of the first dose (more specifically, about 4 to about 8 hours or about 6 hours after the first dose), and the third dose can be administered within about 4 to about 12 hours of the second dose (more specifically, about 4 to about 8 hours or about 6 hours after the second dose). Even more specifically, the second dose can be administered about 2 hours after the first dose, and the third dose can be administered about 4 hours after the first dose. In some embodiments, both the second dose and the third dose can be administered within about 8 hours of the first dose. More specifically, the second dose can be administered within about 3 to 5 hours of the first dose, and the third dose can be administered about 7 to about 8 hours after the first dose. Even more specifically, the second dose can be administered about 4 hours after the first dose, and the third dose can be administered about 8 hours after the first dose. In some embodiments, both the second dose and the third dose can be administered within about 16 hours of the first dose. More specifically, the second dose can be administered within about 7 to 9 hours of the first dose, and the third dose can be administered about 15 to about 16 hours after the first dose. Even more specifically, the second dose can be administered about 8 hours after the first dose, and the third dose can be administered about 16 hours after the first dose. In some embodiments, each of the three doses can be 500 mg of KVD900. Alternatively, each of the three doses can be 550 mg of KVD900. Alternatively, each of the three doses can be 600 mg of KVD900.
[0427] In any on-demand preventive treatment of bradykinin-mediated angioedema attacks described herein (e.g., BK-AEnH attacks, preferably HAE attacks), the daily dose can be administered to the patient in three doses per day, wherein the second dose and the third dose can be administered at least about 6 hours after the previous dose. The daily dose can be administered to the patient in three doses per day, wherein the second dose can be administered about 5 to about 7 hours after the first dose, and the third dose can be administered about 11 to about 13 hours after the first dose. More specifically, the daily dose can be administered to the patient in three doses per day, wherein the second dose can be administered about 6 hours after the first dose, and the third dose can be administered about 12 hours after the first dose. In these embodiments, each of the three doses can be 500 mg of KVD900. Each of these 500 mg doses can be two orodispersible tablets containing 250 mg of KVD900. Alternatively, in these embodiments, each of the three doses can be 550 mg of KVD900. Each of these 550 mg doses can be two orodispersible tablets containing 275 mg of KVD900. Alternatively, in these embodiments, each of the three doses can be 600 mg of KVD900. Each of these 600 mg doses can be two orodispersible tablets containing 300 mg of KVD900.
[0428] As discussed above, multiple doses may be administered if, for example, there continues to be a need to prophylactically reduce the likelihood of a bradykinin-mediated angioedema attack (e.g., a BK-AEnH attack, preferably a HAE attack), for example, if the patient continues to be expected to likely induce a bradykinin-mediated angioedema attack (e.g., a BK-AEnH attack, preferably a HAE attack). Thus, the on-demand treatment of a bradykinin-mediated angioedema attack (e.g., a BK-AEnH attack, preferably a HAE attack) of the present invention may include administering a first dose, and then administering a second dose if there continues to be a need to prophylactically reduce the likelihood of a bradykinin-mediated angioedema attack (e.g., a BK-AEnH attack, preferably a HAE attack) after administration of the first dose. The on-demand treatment of bradykinin-mediated angioedema attacks (e.g., BK-AEnH attacks, preferably HAE attacks) of the present invention may also include administering a first dose, and then administering a second dose if there is a continued need to preventively reduce the likelihood of bradykinin-mediated angioedema attacks (e.g., BK-AEnH attacks, preferably HAE attacks) after administering the first dose, and then administering a third dose if there is a continued need to preventively reduce the likelihood of bradykinin-mediated angioedema attacks (e.g., BK-AEnH attacks, preferably HAE attacks) after administering the second dose. In each case, each subsequent dose may be administered simultaneously, separately, or sequentially. In each case, each dose may contain 500 mg of KVD900, for example, administered as two orodispersible tablets containing 250 mg of KVD900. Alternatively, each dose may contain 550 mg of KVD900, for example, administered as two orodispersible tablets containing 275 mg of KVD900. Alternatively, each dose may contain 600 mg of KVD900, for example administered as two orodispersible tablets containing 300 mg of KVD900.
[0429] Specifically, the on-demand preventive treatment of bradykinin-mediated angioedema attacks (e.g., BK-AEnH attacks, preferably HAE attacks) described herein may include administering a first dose containing 500 mg of the compound (e.g., as two tablets, each tablet containing 250 mg of the compound), and then if there is a continued need to preventively reduce the likelihood of an acute HAE attack after administration of the first dose, administering a second dose containing 500 mg of the compound (e.g., as two tablets, each tablet containing 250 mg of the compound). The second dose may be administered at least about 6 hours (e.g., about 6 hours) after the first dose. If there is a continued need to preventively reduce the likelihood of a bradykinin-mediated angioedema attack (e.g., BK-AEnH attack, preferably HAE attack) after the second dose, the on-demand treatment of bradykinin-mediated angioedema attacks (e.g., BK-AEnH attacks, preferably HAE attacks) of the present invention may include administering a third dose containing 500 mg of the compound (e.g., as two tablets, each tablet containing 250 mg of the compound). The third dose can be administered at least about 6 hours (eg, about 6 hours) after the second dose.
[0430] Alternatively, the on-demand preventive treatment of bradykinin-mediated angioedema attacks (e.g., BK-AEnH attacks, preferably HAE attacks) described herein may include administering a first dose containing 550 mg of the compound (e.g., as two tablets, each containing 275 mg of the compound), and then administering a second dose containing 550 mg of the compound (e.g., as two tablets, each containing 275 mg of the compound) if there is a continued need to preventively reduce the likelihood of an acute HAE attack after administration of the first dose. The second dose may be administered at least about 6 hours (e.g., about 6 hours) after the first dose. If there is a continued need to preventively reduce the likelihood of a bradykinin-mediated angioedema attack (e.g., BK-AEnH attack, preferably HAE attack) after the second dose, the on-demand treatment of bradykinin-mediated angioedema attacks (e.g., BK-AEnH attacks, preferably HAE attacks) of the present invention may include administering a third dose containing 550 mg of the compound (e.g., as two tablets, each containing 275 mg of the compound). The third dose can be administered at least about 6 hours (eg, about 6 hours) after the second dose.
[0431] Alternatively, the on-demand preventive treatment of bradykinin-mediated angioedema attacks (e.g., BK-AEnH attacks, preferably HAE attacks) described herein may include administering a first dose containing 600 mg of the compound (e.g., as two tablets, each tablet containing 300 mg of the compound), and then if there is a continued need to preventively reduce the likelihood of an acute HAE attack after administration of the first dose, administering a second dose containing 600 mg of the compound (e.g., as two tablets, each tablet containing 300 mg of the compound). The second dose may be administered at least about 6 hours (e.g., about 6 hours) after the first dose. If there is a continued need to preventively reduce the likelihood of a bradykinin-mediated angioedema attack (e.g., BK-AEnH attack, preferably HAE attack) after the second dose, the on-demand treatment of bradykinin-mediated angioedema attacks (e.g., BK-AEnH attacks, preferably HAE attacks) of the present invention may include administering a third dose containing 600 mg of the compound (e.g., as two tablets, each containing 300 mg of the compound). The third dose can be administered at least about 6 hours (eg, about 6 hours) after the second dose.
[0432] The on-demand preventive treatment of bradykinin-mediated angioedema attacks (e.g., BK-AEnH attacks, preferably HAE attacks) described herein may include administering no more than three doses in 24 hours (e.g., three doses containing 500 mg of the compound, optionally as 6 tablets, each tablet containing 250 mg of the compound). Alternatively, the on-demand preventive treatment of bradykinin-mediated angioedema attacks (e.g., BK-AEnH attacks, preferably HAE attacks) described herein may include administering no more than three doses in 24 hours (e.g., three doses containing 550 mg of the compound, optionally as 6 tablets, each tablet containing 275 mg of the compound). Alternatively, the on-demand preventive treatment of bradykinin-mediated angioedema attacks (e.g., BK-AEnH attacks, preferably HAE attacks) described herein may include administering no more than three doses in 24 hours (e.g., three doses containing 600 mg of the compound, optionally as 6 tablets, each tablet containing 300 mg of the compound).
[0433] Continuous and regular preventive treatment of bradykinin-mediated angioedema (e.g. BK AEnH, preferably HAE)
[0434] According to one aspect of the present invention, there is provided a method for treating bradykinin-mediated angioedema (e.g., BK-AEnH, preferably HAE), the method comprising: administering one or more orodispersible tablets comprising KVD900 according to the present invention to a patient in need thereof, wherein the one or more orodispersible tablets are administered to prophylactically reduce the likelihood of an attack of bradykinin-mediated angioedema (e.g., an attack of BK-AEnH, preferably an attack of HAE), wherein the one or more orodispersible tablets of the present invention are administered to the patient regularly.
[0435] The term "regular administration" is intended to mean continuous administration of KVD900 at regular intervals (e.g., once a week, twice a week, etc.) to provide effective treatment. KVD900 is administered with one or more ODTs described herein. Healthcare professionals readily understand what is meant by regular (or continuous) administration.
[0436] In some embodiments, KVD900 can be administered to prevent a bradykinin-mediated angioedema episode (eg, a BK-AEnH episode, preferably a HAE episode).
[0437] In some embodiments, one or more orodispersible tablets may be administered once a day. In another embodiment, one or more orodispersible tablets may be administered twice a day. In another embodiment, one or more orodispersible tablets may be administered three times a day. In another embodiment, one or more orodispersible tablets may be administered every other day.
[0438] As discussed above, KVD900 can be administered to a patient as part of a continuous and regular preventive treatment of bradykinin-mediated angioedema (e.g., BK-AEnH, preferably HAE). As discussed above, such treatment reduces the likelihood of an attack of bradykinin-mediated angioedema (e.g., an attack of BK-AEnH, preferably an attack of HAE). However, in some cases, a patient may still suffer from an attack of bradykinin-mediated angioedema (e.g., an attack of BK-AEnH, preferably an attack of HAE). Thus, one embodiment of the present invention is that KVD900 can be administered to a patient as part of a continuous and regular preventive treatment of bradykinin-mediated angioedema (e.g., BK-AEnH, preferably HAE), as discussed above, and also includes taking an on-demand dose of KVD900 to treat a bradykinin-mediated angioedema attack (e.g., a BK-AEnH attack, preferably a HAE attack) after the symptoms of a bradykinin-mediated angioedema attack (e.g., a BK-AEnH attack, preferably a HAE attack) are recognized, if it occurs. These on-demand treatments of bradykinin-mediated angioedema attacks (e.g., a BK-AEnH attack, preferably a HAE attack) are discussed above.
[0439] Thus, in some embodiments, a method for treating bradykinin-mediated angioedema (e.g., BK-AEnH, preferably HAE) is provided, the method comprising: administering one or more orodispersible tablets comprising KVD900 according to the present invention to a patient in need thereof, wherein the one or more orodispersible tablets are administered to prophylactically reduce the likelihood of an attack of bradykinin-mediated angioedema (e.g., an attack of BK-AEnH, preferably an attack of HAE), wherein the one or more orodispersible tablets of the present invention are administered to the patient regularly, and further comprising administering the one or more orodispersible tablets as needed after the symptoms of an attack of bradykinin-mediated angioedema (e.g., an attack of BK-AEnH, preferably an attack of HAE) are recognized.
[0440] BK-AEnH
[0441] As described above, bradykinin-mediated angioedema may be BK-AEnH.
[0442] In the case where BK-AEnH is angioedema induced by a dipeptidyl peptidase 4 inhibitor, BK-AEnH may be induced by using a dipeptidyl peptidase 4 inhibitor as an antidiabetic drug. BK-AEnH may be induced by a dipeptidyl peptidase 4 inhibitor such as sitagliptin, metformin, saxagliptin, linagliptin, empagliflozin, alogliptin, or pioglitazone.
[0443] In cases where the BK-AEnH is ACE inhibitor-induced angioedema, the BK-AEnH may be ACE inhibitor-induced by benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, or trandolapril.
[0444] In cases where the BK-AEnH is tPA-induced angioedema, the BK-AEnH may be induced by thrombolytic therapy using tissue plasminogen activator. The patient may be receiving thrombolytic therapy using tissue plasminogen activator, for example, to treat an acute stroke, such as an ischemic stroke.
[0445] In the case where BK-AEnH is non-hereditary angioedema with normal C1 inhibitor (AE-nC1 Inh) and is drug-induced (i.e., drug-induced AE-nC1 Inh), BK-AEnH may be drug-induced by at least one of a nonsteroidal anti-inflammatory agent, a β-lactam antibiotic, and a non-β-lactam antibiotic. The nonsteroidal anti-inflammatory agent may be at least one of aspirin, celecoxib, diclofenac, diflunisal, etodolac, ibuprofen, indomethacin, ketoprofen, ketorolac, nabumetone, naproxen, oxaprozin, piroxicam, salicylic acid, sulindac, and tolmetin.
[0446] In the case where BK-AEnH is non-hereditary angioedema with normal C1 inhibitor (AE-nC1 Inh) and is drug-induced (i.e., drug-induced AE-nC1 Inh), BK-AEnH may be induced by angiotensin II receptor blocker (ARB). For example, BK-AEnH may be induced by azilsartan, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, or valsartan.
[0447] In the case where the BK-AEnH is drug-induced AE-nC1 Inh, the BK-AEnH may be drug-induced by a beta blocker.
[0448] In the case where BK-AEnH is non-hereditary angioedema with normal C1 inhibitor (AE-nC1 Inh) and is hormonally induced, AE-nC1 Inh can be hormonally induced by hormonal contraceptives. In some embodiments, AE-nC1 Inh can be hormonally induced by estrogen. For example, the patient can be female and is taking estrogen, for example, as a contraceptive.
[0449] Drug administration
[0450] In any of the treatments of the invention described herein, KVD900 is administered orally in a therapeutically effective amount in the form of an orodispersible tablet.
[0451] KVD900 can be used with a daily dose of about 5mg to about 2000mg every day." daily dose " means the total amount used in one day. More specifically, the compound of formula A can be used with a daily dose of about 100mg to about 1500mg, about 300mg to about 1800mg, about 100mg to about 1400mg, about 200mg to about 1200mg, about 300mg to about 1200mg, about 600mg to about 1200mg, about 550mg to about 1200mg, about 500mg to about 1000mg, about 450mg to about 900mg, about 450mg to about 600mg, about 500mg to about 700mg (more specifically 600mg), about 800mg to about 1000mg, about 900mg to about 1400mg (more specifically 1200mg) or about 900mg to about 1200mg every day. In a specific embodiment, the daily dose is 300mg. In another specific embodiment, the daily dose is 500 mg. In another specific embodiment, the daily dose is 550 mg. In another specific embodiment, the daily dose is 600 mg. In another specific embodiment, the daily dose is 900 mg. In another specific embodiment, the daily dose is 1000 mg. In another specific embodiment, the daily dose is 1100 mg. In another specific embodiment, the daily dose is 1200 mg. In another specific embodiment, the daily dose is 1500 mg. In another specific embodiment, the daily dose is 1650 mg. In another specific embodiment, the daily dose is 1800 mg.
[0452] The daily dose can be administered as a single dose, or divided into multiple doses for administration at different times throughout the day. Accordingly, each dose can be administered as a single dosage form, or divided into multiple dosage forms. When multiple doses and multiple dosage forms are used, these can be administered simultaneously, individually or sequentially.
[0453] In some embodiments, each single unit dosage form comprising KVD900 comprises about 250 mg of KVD900. Alternatively, each single unit dosage form comprising KVD900 comprises about 275 mg of KVD900. Alternatively, each single unit dosage form comprising KVD900 comprises about 300 mg of KVD900.
[0454] Each dose administered to a patient may contain 500 mg of KVD900, which may be subdivided into two tablets containing 250 mg of KVD900. Alternatively, each dose administered to a patient may contain 550 mg of KVD900, which may be subdivided into two tablets containing 275 mg of KVD900. Alternatively, each dose administered to a patient may contain 600 mg of KVD900, which may be subdivided into two tablets containing 300 mg of KVD900.
[0455] Alternatively, each dose may contain 250 mg of the compound, which may be a tablet containing 250 mg of the compound. Alternatively, each dose may contain 275 mg of the compound, which may be a tablet containing 275 mg of the compound. Alternatively, each dose may contain 300 mg of the compound, which may be a tablet containing 300 mg of the compound.
[0456] In one specific embodiment, a daily dose of 500 mg is administered to a patient as a single dose. In one specific embodiment, a daily dose of 550 mg is administered to a patient as a single dose. In another specific embodiment, a daily dose of 600 mg is administered to a patient as a single dose.
[0457] In another specific embodiment, a daily dose of 1000 mg is administered to a patient as two doses. In particular, the second dose is administered within 2 to 6 hours of the first dose, preferably within about 3 to 6 hours of the first dose. Alternatively, a daily dose of 1100 mg is administered to a patient as two doses. In particular, the second dose is administered within 2 to 6 hours of the first dose, preferably within about 3 to 6 hours of the first dose. Alternatively, a daily dose of 1200 mg is administered to a patient as two doses. In particular, the second dose is administered within 2 to 6 hours of the first dose, preferably within about 3 to 6 hours of the first dose.
[0458] In another specific embodiment, the daily dose of 1500mg is applied to the patient, and it is applied as three doses. In particular, when the second dose is applied in 2 to 8 hours (for example, about 2 hours, about 4 hours, about 6 hours or about 8 hours) for the first time, the third dose is applied in about 4 to 16 hours (for example, about 4 hours, about 6 hours, about 8 hours, about 12 hours or about 16 hours) of the first dose. Alternatively, the daily dose of 1650mg is applied to the patient, and it is applied as three doses. In particular, when the second dose is applied in 2 to 8 hours (for example, about 2 hours, about 4 hours, about 6 hours or about 8 hours) for the first time, the third dose is applied in about 4 to 16 hours (for example, about 4 hours, about 6 hours, about 8 hours, about 12 hours or about 16 hours) of the first dose. Alternatively, the daily dose of 1800mg is applied to the patient, and it is applied as three doses. In particular, when the second dose is administered within 2 to 8 hours (e.g., about 2 hours, about 4 hours, about 6 hours, or about 8 hours) of the first dose, the third dose is administered within about 4 to 16 hours (e.g., about 4 hours, about 6 hours, about 8 hours, about 12 hours, or about 16 hours) of the first dose.
[0459] Further details of the treatment of the invention
[0460] Thus, in the treatment of the present invention, one or more orodispersible tablets according to the present invention may be administered to a patient in need thereof, wherein the patient is aged from 2 to less than 18 years, more particularly aged from 2 to less than 12 years. Alternatively or additionally, one or more orodispersible tablets according to the present invention may be administered to a patient in need thereof, wherein the patient suffers from a laryngeal attack.
[0461] Alternatively, one or more orodispersible tablets according to the present invention may be administered to a patient in need thereof, wherein the patient is an elderly patient (e.g., a patient older than 70 years old) who has difficulty swallowing tablets. Alternatively or additionally, one or more orodispersible tablets according to the present invention may be administered to a patient in need thereof, wherein the patient suffers from a laryngeal attack.
[0462] As shown herein, KVD900 has a fast onset. Specifically, KVD900 is an effective inhibitor of plasma kallikrein activity, which effectively interrupts the positive feedback loop of the contact activation system between plasma kallikrein, prekallikrein, factor XII (FXII) and factor XIIa (FXIIa). The pharmacokinetic and pharmacodynamic data provided herein (as well as WO2020 / 249977 and WO2020 / 249979) prove that after oral administration of an orodispersible tablet comprising KVD900, these effects are rapidly displayed. Therefore, the treatment of the present invention is fast-acting, and is therefore particularly suitable for treating bradykinin-mediated angioedema (e.g., BK-AEnH, preferably HAE) on demand.
[0463] The treatment of the present invention is particularly advantageous when the concentration of KVD900 in plasma is at least 500 ng / mL. A plasma concentration of at least 500 ng / mL can be observed after administration of a dose of at least about 60 mg (more specifically, at least about 70 mg or about 80 mg) of KVD900.
[0464] Treatment according to the present invention provides rapid protection against HK (high molecular weight kininogen) cleavage, which is particularly suitable for prophylactically reducing the likelihood of bradykinin-mediated angioedema attacks (e.g., BK-AEnH attacks, preferably HAE attacks) and / or shortening (or even stopping) the severity of ongoing bradykinin-mediated angioedema attacks (e.g., BK-AEnH attacks, preferably HAE attacks). As described herein, treatment according to the present invention also has a prolonged pharmacodynamic effect. The pharmacodynamic effects of KVD900 associated with the treatment of bradykinin-mediated angioedema (e.g., BK-AEnH, preferably HAE) include providing protection against HK cleavage, which, as discussed above, may lead to bradykinin-mediated angioedema attacks (e.g., BK-AEnH attacks, preferably HAE attacks). For example, KVD900 can provide protection against HK cleavage by at least (i) inhibiting plasma kallikrein, (ii) reducing the cleavage of plasma prekallikrein, and / or (iii) reducing the generation of factor XIIa from factor XII.
[0465] Attached photos
[0466] In the drawings, the term "compound" means KVD900.
[0467] Figure 1 : X-ray powder diffraction pattern of KVD900 produced in Example 1.
[0468] Figure 2 : PK profiles showing comparable PK profiles of 500 mg and 600 mg ODT and 600 mg FCT used in the Phase 2 study.
[0469] Figure 3 : Figure 2 LogPK curve of the PK curve.
[0470] Figure 4 : Geometric mean plasma concentrations following a single dose of 500 mg and 600 mg ODT or 600 mg FCT.
[0471] The embodiments provided herein may be more fully understood by reference to the following examples. These examples are intended to illustrate the treatment provided herein, but are not intended to be limiting in any way. In fact, the scope of the present invention is defined by the claims.
[0472] Although examples of certain specific embodiments are provided herein, various changes and modifications may be made that will be apparent to those skilled in the art. Such modifications are also intended to fall within the scope of the appended claims.
[0473] General experimental details
[0474] In the following examples, the following abbreviations and definitions are used:
[0475]
[0476] Example 1 - Preparation of KVD900
[0477] A. 1-(4-Hydroxymethyl-benzyl)-1H-pyridin-2-one
[0478] 4-(Chloromethyl)benzyl alcohol (5.0 g, 31.93 mmol) was dissolved in acetone (150 mL). 2-Hydroxypyridine (3.64 g, 38.3 mmol) and potassium carbonate (13.24 g, 95.78 mmol) were added and the reaction mixture was stirred at 50 ° C for 3 hours, after which the solvent was removed in vacuo and the residue was dissolved in chloroform (100 mL). The solution was washed with water (30 mL), brine (30 mL), dried (Na2SO4) and evaporated in vacuo. The residue was purified by flash chromatography (silica) with 3% MeOH / 97% CHCl3 as eluent to give a white solid identified as 1-(4-hydroxymethyl-benzyl)-1H-pyridine-2-one (5.30 g, 24.62 mmol, 77% yield).
[0479] [M+Na] + =238
[0480] B. 1-(4-Chloromethyl-benzyl)-1H-pyridin-2-one
[0481] 1- (4- hydroxymethyl-benzyl) -1H- pyridine -2- one (8.45g, 39.3mmol), anhydrous DCM (80mL) and triethylamine (7.66ml, 55.0mmol) are cooled in an ice bath. Methanesulfonyl chloride (3.95ml, 51.0mmol) is added and stirred in an ice bath for 15min. The ice bath is removed and stirring is continued at room temperature overnight. The reaction mixture is distributed between DCM (100mL) and saturated NH4Cl aqueous solution (100mL). The aqueous layer is extracted with other DCM (2x 50mL), and the organic matter combined is washed with brine (50mL), through Na2SO4, dried, filtered and concentrated to obtain 1- (4- chloromethyl-benzyl) -1H- pyridine -2- one (8.65g, 36.6mmol, 93% yield) as a light yellow solid.
[0482] [MH] + =234.1
[0483] C. 3-(Methoxymethyl)-1-(4-((2-oxopyridin-1(2H)-yl)methyl)benzyl)-1H-pyrazole-4-carboxylic acid methyl ester
[0484] Potassium carbonate (519 mg, 3.76 mmol) was added to a solution of methyl 3-(methoxymethyl)-1H-pyrazole-4-carboxylate (320 mg, 1.88 mmol; CAS No. 318496-66-1 (synthesized according to the method described in WO 2012 / 009009)) and 1-(4-(chloromethyl)benzyl)pyridin-2(1H)-one (527 mg, 2.26 mmol) in DMF (5 mL) and heated at 60°C overnight. The reaction mixture was diluted with EtOAc (50 mL) and washed with brine (2 x 100 mL), dried over magnesium sulfate, filtered and concentrated in vacuo. The crude product was purified by flash chromatography (40 g column, 0%-100% EtOAc in isohexane) to obtain two regioisomers. The second isomer that exited the column was collected to give methyl 3-(methoxymethyl)-l-(4-((2-oxopyridin-l(2H)-yl)methyl)benzyl)-lH-pyrazole-4-carboxylate (378 mg, 1.01 mmol, 53.7% yield) as a colorless gum.
[0485] [MH] + =368.2
[0486] D. 3-(Methoxymethyl)-1-(4-((2-oxopyridin-1(2H)-yl)methyl)benzyl)-1H-pyrazole-4-carboxylic acid
[0487] To methyl 3-(methoxymethyl)-1-(4-((2-oxopyridin-1(2H)-yl)methyl)benzyl)-1H-pyrazole-4-carboxylate (3.77 g, 10.26 mmol) in THF (5 mL) and MeOH (5 mL) was added 2M NaOH solution (15.39 ml, 30.8 mmol) and stirred at room temperature overnight. 1M HCl (50 mL) was added and extracted with EtOAc (50 mL). The organic layer was washed with brine (50 mL), dried over magnesium sulfate, filtered and concentrated in vacuo to give 3-(methoxymethyl)-1-(4-((2-oxopyridin-1(2H)-yl)methyl)benzyl)-1H-pyrazole-4-carboxylic acid (1.22 g, 3.45 mmol, 33.6% yield) as a white powder.
[0488] [MH] + =354.2
[0489] E. 3-Fluoro-4-methoxy-pyridine-2-carbonitrile
[0490] In large microwave bottle, copper cyanide (I) (1.304g, 14.56mmol) is added to the solution of 2-bromo-3-fluoro-4-methoxypyridine (1g, 4.85mmol) in DMF (5mL).The reaction bottle is sealed and heated to 100 DEG C for 16 hours.The reaction mixture is diluted with water (20mL) and EtOAc (20mL).The thick suspension is ultrasonically treated, and other water (40mL) and EtOAc (2x 50mL) are needed to crush the solid of precipitation in ultrasonic treatment.The combined layer is filtered through diatomite plug, and the organic layer is separated, washed with salt water (50mL), dried over magnesium sulfate, filtered and decompressed to remove solvent, obtain light green solid, accredited as required compound 3-fluoro-4-methoxy-pyridine-2-carbonitrile (100mg, 0.578mmol, 12% yield).
[0491] F. (3-Fluoro-4-methoxy-pyridin-2-ylmethyl)-carbamic acid tert-butyl ester
[0492] 3-Fluoro-4-methoxy-pyridine-2-carbonitrile (100mg, 0.578mmol) is dissolved in anhydrous methanol (10mL, 247mmol), and nickel chloride hexahydrate (14mg, 0.058mmol) is added, followed by di-tert-butyl dicarbonate (255mg, 1.157mmol). The resulting light green solution is cooled to -5°C in an ice-salt bath, and then sodium borohydride (153mg, 4.05mmol) is added in batches, keeping the reaction temperature at about 0°C. The dark brown solution is stirred at 0°C and slowly warmed to room temperature, and then stirred at room temperature for 3 hours. The reaction mixture is evaporated to dryness at 40°C to obtain a black residue, which is diluted with DCM (10mL) and washed with sodium bicarbonate (10mL). An emulsion is formed, so the organic matter is separated and concentrated via a phase separation cartridge. The crude liquid was purified by chromatography eluting with EtOAc / isohexane to afford the title compound (3-fluoro-4-methoxy-pyridin-2-ylmethyl)-carbamic acid tert-butyl ester (108 mg, 62% yield) as a clear yellow oil.
[0493] [MH] + =257
[0494] GC-(3-Fluoro-4-methoxy-pyridin-2-yl)-methylamine hydrochloride
[0495] (3-Fluoro-4-methoxy-pyridin-2-ylmethyl)-carbamic acid tert-butyl ester (108 mg, 0.358 mmol) was dissolved in isopropanol (1 mL) and then HCl (6N in isopropanol) (1 mL, 0.578 mmol) was added at room temperature and stirred at 40° C. for 2 hours. The reaction mixture was concentrated under reduced pressure and then triturated with diethyl ether, sonicated, and then decanted to give a cream-colored solid (75 mg, 55% yield) identified as C-(3-fluoro-4-methoxy-pyridin-2-yl)-methylamine hydrochloride.
[0496] [MH] + =157
[0497] Example 1a-N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxy [(1-( ...
[0498] 3-(Methoxymethyl)-1-(4-((2-oxopyridin-1(2H)-yl)methyl)benzyl)-1H-pyrazole-4-carboxylic acid (825 mg, 2.34 mmol) and C-(3-fluoro-4-methoxy-pyridin-2-yl)-methylamine hydrochloride (450 mg, 2.34 mmol) were dissolved in DCM while cooling to 0°C. 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (627.0 mg, 3.27 mmol), HOBt (378.8 mg, 2.80 mmol) and triethylamine (1.63 mL, 1182 mmol) were added while stirring, the mixture was warmed to room temperature and stirring was continued for 20 hours. Chloroform (50 mL) was added, the mixture was washed with saturated NaHCO3(aq) and concentrated in vacuo. The crude material was purified by chromatography eluting with methanol / DCM. The solvent was removed in vacuo and the resulting solid was triturated with diethyl ether. The resulting solid was collected by filtration to obtain a compound of Formula A.
[0499] [MH] + =492.0
[0500] NMR(CD3OD)δ:3.41(3H,s),4.03(3H,s),4.65(2H,s),4.72(2H,d,J=2.3Hz),5.24(2H,s),5.37(2H,s),6.44(1H,td,J=1.4,6.8Hz),6.62(1H ,d,J=9.0Hz),7.18-7.22(1H,m),7.31-7.38(4H,m),7.56-7.60(1H,m),7.75(1H,dd,J=1.9,7.1Hz),8.18(1H,s),8.27(1H,d,J=5.6Hz)ppm.
[0501] The XRPD diffraction pattern of KVD900 obtained by the above procedure is Figure 1 Shown in.
[0502] Peak position table:
[0503]
[0504]
[0505] Example 2 - Preparation of an orodispersible tablet comprising KVD900 of the present invention
[0506] ODT of KVD900 was prepared according to the following method.
[0507] method
[0508] 1. Add KVD900, silicified microcrystalline cellulose, crospovidone, sucralose NF, silicon dioxide, and peppermint natural flavoring into a blender and blend to form a powder mixture.
[0509] 2. Granular mannitol, spray-dried mannitol (e.g., Mannogem ) is added to the powder mixture from step 1 in a blender and blended.
[0510] 3. The final blend was compressed into tablets using external magnesium stearate as lubricant.
[0511] Table 1: Composition of KVD900 250 mg and 300 mg orodispersible tablets (ODT)
[0512]
[0513]
[0514] *Trace amounts of magnesium stearate (USP / NF, Ph Eur, JP) are only used for external lubrication
[0515] Orodispersible tablets of the invention according to Table 1 were prepared on a 5 kg scale.
[0516] The results presented in Examples 3-8 are for orodispersible tablets of the present invention according to Table 1.
[0517] Example 3 - Disintegration and dissolution of orodispersible tablets of the present invention
[0518] method
[0519] Disintegration test
[0520] Disintegration testing can be performed according to the following protocol USP <701> and Ph Eur 2.9.1.
[0521] Place 1 tablet in each of the six tubes of the basket and operate the equipment using USP water maintained at 37 ± 2 ° C. At the end of the specified time (see table below), lift the basket from the liquid and observe the tablet. If there is still a visible tablet core in the basket, start the test procedure again with a new tablet.
[0522] When the tablet was completely disintegrated, the value listed in the Result column was reported.
[0523]
[0524]
[0525] Dissolution testing
[0526] Dissolution testing can be performed according to the following protocol USP <711> (Category II) and Ph Eur 2.9.3.
[0527] The specific conditions are as follows:
[0528] Paddle speed: 50rpm to 45 minutes Dissolution medium: pH 4.5 Sodium acetate buffer with 0.5% w / v sodium lauryl sulfate Medium volume: 1,000mL Dissolution temperature: 37℃±0.5℃ Sample volume: 1.5mL Cannula filter: 10 micron cannula filter Sampling points: 5, 10, 20, 30 and 45 minutes Dissolution time: 45 minutes Sample Analysis: UPLC-UV
[0529] The chromatographic conditions were as follows:
[0530]
[0531] Table 2: Gradient elution details
[0532] Time (min) A% B% 0.00 90 10 0.50 50 50 1.31 50 50 1.32 90 10 2.50 90 10
[0533] Total running time = 2.5 minutes
[0534] result
[0535] Disintegration time (seconds) Dissolution (%) KVD900 300mg ODT 15-20 97 KVD900 250mg ODT <20 99
[0536] The orodispersible tablets of the present invention have a disintegration specification of >80% in less than about 15-20 seconds. This meets the USP <701> and the acceptance criteria of not more than (NMT) 45 seconds for the standard procedure of Ph Eur 2.9.1. This also meets the FDA guidance for an orodispersible tablet disintegration time of about 30 seconds or less when based on the United States Pharmacopoeia (USP) disintegration test method or an alternative method, and this meets the European Pharmacopoeia definition of an orodispersible tablet disintegration time of not more than 3 minutes.
[0537] The orodispersible tablet of the present invention achieves a dissolution specification of >95% in 45 minutes. This meets the acceptance criteria of Q=80% at 45 minutes in the QC dissolution test, which complies with USP <711> and the standard procedure of Ph Eur 2.9.3.
[0538] Example 4 - Uniformity and Water Content of Orodispersible Tablets of the Invention
[0539] The uniformity of the dosage unit can be determined according to the following protocol USP <905> and Ph Eur 2.9.40 were obtained using mass variation.
[0540] Water content can be used in accordance with USP <921> The apparatus for determining the water content as required is described in Method 1c / Ph Eur 2.5.12 and is determined by Karl Fischer volumetric titration.
[0541] Uniformity of dosage units Water content (%w / w) KVD900 300mg ODT conform to 2.1% KVD900 250mg ODT conform to 1.4%
[0542] The uniformity of the dosage unit of the orodispersible tablet of the present invention meets the requirements of USP <905> and the acceptance criteria of Ph Eur 2.9.40.
[0543] The water content of the orodispersible tablets of the present invention meets the requirements of USP <921> and acceptance criteria for Method 1c / Ph Eur 2.5.12.
[0544] Example 5 - Stability Test
[0545] Stability of KVD900 300 mg ODT of the present invention
[0546] Samples of KVD900 300 mg ODT were packaged in Aclar / Alu blister packs and stored at 25°C / 60% RH. KVD900 300 mg ODT samples were tested as described in Table 3.
[0547] Table 3: Stability data of KVD900 300mg ODT, storage conditions 25℃ / 60%RH, in Aclar / Alu blisters
[0548]
[0549] A second sample of KVD900 300 mg ODT was packaged in an Aclar / Alu blister pack and stored at 40°C / 75% RH. The KVD900 300 mg ODT samples were tested as described in Table 4.
[0550] Table 4: Stability data of KVD900 300mg ODT, storage conditions 40℃ / 75%RH, in Aclar / Alu blisters
[0551]
[0552] Stability of KVD900250mgODT of the present invention
[0553] Samples of KVD900 250 mg ODT were packaged in Aclar / Alu blister packs and stored at 25°C / 60% RH. KVD900 250 mg ODT samples were tested as described in Table 5.
[0554] Table 5: Stability data of KVD900 250mg ODT, stored at 25°C / 60%RH, in Aclar / Alu blisters
[0555]
[0556] A second sample of KVD900 250 mg ODT was packaged in an Aclar / Alu blister pack and stored at 40°C / 75% RH. The KVD900 250 mg ODT samples were tested as described in Table 6.
[0557] Table 6: Stability data of KVD900 250mg ODT, stored at 40°C / 75%RH, in Aclar / Alu blisters
[0558]
[0559] Example 6 - Hardness Test of Orodispersible Tablets of the Present Invention
[0560] The hardness of the dosage unit can be determined according to USP <1217> Obtain. Place a single tablet into the tablet hardness machine and record the hardness value. Repeat the analysis 10 times and report the average value.
[0561] result
[0562] Hardness data for orodispersible tablets of the present invention are provided in Tables 7-10.
[0563] Table 7: Hardness of KVD900 300mg ODT, storage conditions 25°C / 60%RH, in Aclar / Alu blisters
[0564]
[0565] Table 8: Hardness of KVD900 300mg ODT, storage condition 40℃ / 75%RH, in Aclar / Alu blisters
[0566]
[0567] Table 9: Hardness of KVD900 250mg ODT, storage conditions 25°C / 60%RH, in Aclar / Alu blisters
[0568]
[0569] Table 10: Hardness of KVD900 250mg ODT, storage conditions 40°C / 75%RH, in Aclar / Alu blisters
[0570]
[0571] Example 7 - Determination of the orodispersible tablets of the present invention and related substance testing
[0572] Typical chromatographic conditions:
[0573] HPLC Column: Waters CSH C18, 2.1 x 75 mm, 1.7 micron (or equivalent) Flow Rate: 0.21mL / min Detector wavelength: 225nm PDA: 190nm to 400nm PDA for identification Injection Volume: 1.0 μL (Assay, Content Uniformity, Identification) 2.0 μl (related substance) Column temperature: 25℃ Mobile phase A: HPLC water + 0.05% formic acid Mobile phase B: HPLC MeCN + 0.05% formic acid Washing / Purge Solvents 90:10MeCN:Water gradient: See Table 11 Sample concentration: About 0.12 mg / mL (determination); about 0.24 mg / mL (related substances)
[0574] Table 11: Gradient elution details
[0575]
[0576]
[0577] Total running time = 18.0 minutes
[0578] result
[0579] Assay and related material data for the orodispersible tablets of the present invention are provided in Tables 12 to 15. These data support the excellent stability of the orodispersible tablets of the present invention.
[0580] Table 12: Assay and related substance data for KVD900 300 mg ODT, storage conditions 25°C / 60%RH, in Aclar / Alu blisters
[0581]
[0582] Table 13: Assay and related substance data for KVD900 300 mg ODT, storage conditions 40°C / 75%RH, in Aclar / Alu blisters
[0583]
[0584] Table 14: Assay and related substance data for KVD900 250 mg ODT, storage conditions 25°C / 60% RH, in Aclar / Alu blisters
[0585]
[0586] Table 15: Assay and related substance data for KVD900 250 mg ODT, storage conditions 40°C / 75%RH, in Aclar / Alu blisters
[0587]
[0588] The orodispersible tablets of the present invention were assayed to meet the acceptance criteria of 90%-110% of the labeled amount. "Labeled amount" refers to the dosage on the label. Thus, for the 300 mg ODT of Tables 12 and 13, the acceptance limits of 90%-110% are equivalent to 270 mg-330 mg. For the 250 mg ODT of Tables 14 and 15, the acceptance limits of 90%-110% are equivalent to 225 mg-275 mg.
[0589] The related substances analysis of the orodispersible tablets of the present invention met the acceptance criteria of NMT 0.5% for any individual impurity and NMT 2.0% for total impurities.
[0590] Example 8 - Microbiological Limits
[0591] Total viable aerobic count (total viable aerobic count) according to USP <61> / Ph Eur 2.6.12 by the Pour-Plate Method. Tests for specific microorganisms Escherichia coli (E. coli) according to USP <62> / Ph Eur 2.6.13.
[0592] result
[0593] Microbiological limit data for the orodispersible tablets of the present invention are provided in Tables 16-19.
[0594] Table 16: Microbiological limit data for KVD900 300mg ODT, stored at 25°C / 60%RH, in Aclar / Alu blisters
[0595]
[0596] NT = Not Tested
[0597] Table 17: Microbiological limit data for KVD900 300mg ODT, stored at 40°C / 75%RH, in Aclar / Alu blisters
[0598]
[0599] NT = Not Tested
[0600] Table 18: Microbiological limit data for KVD900 250mg ODT, stored at 25°C / 60%RH, in Aclar / Alu blisters
[0601]
[0602] NT = Not Tested
[0603] Table 19: Microbiological limit data for KVD900 250mg ODT, stored at 40°C / 75%RH, in Aclar / Alu blisters
[0604]
[0605] NT = Not Tested
[0606] The microbial limit data in Tables 16-19 demonstrate that the orodispersible tablets of the present invention meet the requirement of TAMC≤10 in 1 g. 3 CFU / g, TYMC≤10 2 Acceptance criteria for CFU / g and absence of E. coli.
[0607] Example 9-Phase 1 Trial: Pharmacokinetic (PK) Study
[0608] Target
[0609] To compare the single-dose PK of KVD900 in healthy adult subjects after administration of orodispersible tablets (ODT) or film-coated tablets. The secondary objective was to determine the safety and tolerability of a single dose of KVD900 in healthy adult subjects after administration of ODT or film-coated tablets under fasting conditions.
[0610] method
[0611] This study was an open-label, randomized, single-dose, 3-way crossover pharmacokinetic study.
[0612] Thirty-six (36) healthy adult male and female subjects were recruited.
[0613] On day 1 of each cycle, a single dose of KVD900 was administered at two different concentrations as ODT under fasting conditions (Treatment A or B) or as a film-coated tablet under fasting conditions (Treatment C) in a 3-cycle crossover.
[0614] Treatment groups AC were as follows:
[0615] • Treatment A: 600 mg KVD900 ODT (2 x 300 mg ODT) at 0 hours on day 1.
[0616] • Treatment B: 500 mg KVD900 ODT (2 x 250 mg ODT) at 0 hours on day 1.
[0617] Treatment C: 600 mg KVD900 film-coated tablets (2 x 300 mg tablets, FCT) at 0 hours on day 1.
[0618] Film-coated tablets are those used in the Phase 2 study described herein (NCT04208412).
[0619] There was a washout period of at least 4 days between doses in Cycle 1 and Cycle 2 and between doses in Cycle 2 and Cycle 3.
[0620] Pharmacokinetic sampling of KVD900 was performed prior to dosing and up to 48 hours after dosing.
[0621] The following PK parameters of KVD900 in plasma were calculated: AUC 0-t , AUC 0-inf , AUC %外推 , C max 、T lag 、T max ,Kel,t 1 / 2, CL / F and Vz / F.
[0622] The natural logarithm (ln) transformed AUC was analyzed using appropriate statistical procedures. 0-t , AUC 0-inf , AUC %外推 and C max Analysis of variance (ANOVA) was performed. The ln-transformed AUC of KVD900 for the following comparison targets was estimated: 0-t , AUC 0-inf , AUC %外推 and C max 90% confidence interval (Ci) for the ratio of the least squares means (LSM):
[0623] Treatment A versus Treatment C
[0624] Treatment B versus Treatment C
[0625] Comparison of the pharmacokinetic properties of KVD900 after administration of an orodispersible tablet (ODT) or a film-coated tablet (FCT) according to the present invention is shown in Table 20.
[0626] Preliminary PK data from a Phase 1 study Figure 2 and Figure 3 Specifically, the PK curve is shown in Figure 2 As shown in the figure, the LogPK curve is Figure 3 These figures show that the ODT of the present invention has a PK profile comparable to that of FCT, which has been shown to be safe and effective in a Phase 2 study of KVD900.
[0627] Table 20: Preliminary PK data from the Phase 1 study described herein.
[0628]
[0629] Further PK data from the Phase 1 study are described below.
[0630] A comparison of the pharmacokinetic profile of plasma KVD900 after administration of a single oral dose of an orodispersible tablet (ODT) or film-coated tablet (FCT) according to the present invention is shown in Table 21.
[0631] Further PK data from the Phase 1 study were Figure 4 shown in . Specifically, Figure 4 Geometric mean plasma concentrations after a single dose of KVD900 ODT or FCT are shown.
[0632] Table 21: Further PK data from the Phase 1 study described herein: Plasma KVD900 PK parameters following administration of a single oral dose.
[0633]
[0634]
[0635] AUC0-inf, area under the concentration-time curve extrapolated from time 0 to infinity; AUC0-t, area under the concentration-time curve from time 0 to the last observed non-zero concentration; Cmax, maximum observed plasma concentration; CV%, coefficient of variation; Tmax, time to reach maximum observed plasma concentration.
[0636] A summary of the statistical comparison of plasma KVD900 pharmacokinetic parameters following administration of a single dose of 600 mg ODT versus 600 mg FCT is shown in Table 22.
[0637] Table 22: Summary of Statistical Comparison of Plasma KVD900 PK Parameters Following Administration of a Single Dose of 600 mg ODT vs. 600 mg FCT (Treatment A vs. Treatment C)
[0638]
[0639] ANOVA, analysis of variance; AUC0-inf, area under the concentration-time curve extrapolated from time 0 to infinity; AUC0-t, area under the concentration-time curve from time 0 to the last observed nonzero concentration; Cmax, maximum observed concentration; CV%, coefficient of variation; GMR, geometric mean ratio; LSM, least squares mean.
[0640] The geometric LSM was calculated by exponentiating the LSM obtained from ANOVA.
[0641] GMR was calculated as 100×(test / reference).
[0642] The within-participant CV% was calculated as 100×square root(exp[MSE]-1), where the mean square error (MSE) represents the residual variance from the ANOVA.
[0643] A summary of the statistical comparison of plasma KVD900 pharmacokinetic parameters following administration of a single dose of 500 mg ODT versus 600 mg FCT is shown in Table 23.
[0644] Table 23: Summary of Statistical Comparison of Plasma KVD900 PK Parameters Following Administration of a Single Dose of 500 mg ODT vs. 600 mg FCT (Treatment B vs. Treatment C)
[0645]
[0646] ANOVA, analysis of variance; AUC0-inf, area under the concentration-time curve extrapolated from time 0 to infinity; AUC0-t, area under the concentration-time curve from time 0 to the last observed nonzero concentration; Cmax, maximum observed concentration; CV%, coefficient of variation; GMR, geometric mean ratio; LSM, least squares mean.
[0647] A single dose of 500 mg or 600 mg KVD900 in ODT or FCT administered was well tolerated in healthy adult participants recruited to the trial.
[0648] These data further demonstrate that the ODT of the present invention has a PK profile comparable to that of FCT, which has been shown to be safe and effective in a Phase 2 study of KVD900.
[0649] Example 10 - Preparation of an alternative orodispersible tablet of the present invention
[0650] Alternative ODTs for KVD900 according to Tables 24-26 were prepared according to the method described in Example 2.
[0651] Table 24: Alternative compositions of ODTs of the present invention (without added flavoring)
[0652]
[0653] Table 25: Alternative compositions of ODTs of the present invention (lemon flavor)
[0654]
[0655]
[0656] Table 26: Alternative compositions of ODTs of the present invention (mixed berry flavoring)
[0657]
[0658] Orodispersible tablets of the invention (75 mg, 50 mg, 25 mg) were prepared at 4 kg scale using a single blend according to Table 26. This 4 kg blend was then split to provide approximately the same number of tablets for each concentration:
[0659] 75 mg: 1800 g (7,200 tablets)
[0660] 50 mg: 1400 g (8,400 tablets)
[0661] 25 mg: 800 g (9,600 tablets)
[0662] Orodispersible tablets of the invention according to Tables 24-26 were prepared, demonstrating the versatility of the mixtures / blends used to make orodispersible tablets of the invention. In particular, rapid disintegration times were obtained regardless of the size and / or concentration of the orodispersible tablets of the invention.
[0663] Example 11 - Further uniformity and disintegration testing of orodispersible tablets of the invention
[0664] KVD900 300mg ODT with debossed logo and score line
[0665] KVD900 300 mg ODT was prepared according to Table 24. The KVD900 300 mg ODT was debossed with logos and score lines.
[0666] The disintegration test of these KVD900 300 mg ODTs with indented logos and score lines was performed according to the method in Example 3. Specifically, the disintegration test was performed according to the following protocol USP <701> and Ph Eur 2.9.1.
[0667] The disintegration data for KVD900 300 mg ODT with debossed logo and score line is provided in Table 27.
[0668] Table 27: Disintegration data of KVD900 300mg ODT with debossed logo and score line
[0669]
[0670] The disintegration specification of KVD900 300mg ODT with debossed logo and score line meets the FDA guideline standard of <30 seconds.
[0671] The uniformity of KVD900 300 mg ODT with indented logo and score line (before and after splitting) was measured according to the method in Example 4. Specifically, the uniformity of the dosage unit was measured accord...
Claims
1. An orodispersible tablet comprising KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof), Among them, KVD900 is 2. The orodispersible tablet according to claim 1, comprising: About 100 mg to about 1000 mg of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof); or About 200 mg to about 350 mg of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof); or About 250 mg of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof); or About 275 mg of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof); or About 300 mg of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof).
3. The orodispersible tablet according to any one of claims 1 to 2, wherein the orodispersible tablet comprises about 26 wt % to about 40 wt % of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof), Preferably wherein the orodispersible tablet comprises about 30% by weight of KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof).
4. The orodispersible tablet of any one of claims 1 to 3, wherein the orodispersible tablet comprises one or more disintegrants present in about 1% to about 10% by weight of the orodispersible tablet; or wherein the one or more disintegrants are present in about 4% to about 5% by weight of the orodispersible tablet; or wherein the one or more disintegrants are present in about 5% by weight of the orodispersible tablet.
5. The orodispersible tablet according to claim 4, wherein the one or more disintegrants are selected from the group consisting of: polyvinylpyrrolidone (crospovidone), sodium starch glycolate and sodium starch glycolate, cross-linked sodium carboxymethylcellulose, Preferably wherein the orodispersible tablet comprises polyvinylpyrrolidone (crospovidone).
6. The orodispersible tablet of any one of claims 1 to 5, wherein the orodispersible tablet comprises one or more fillers present in about 30% to about 80% by weight of the orodispersible tablet; or wherein the orodispersible tablet comprises one or more fillers present in about 50% to about 60% by weight of the orodispersible tablet; or wherein the orodispersible tablet comprises one or more fillers present in about 53% to about 54% by weight of the orodispersible tablet.
7. The orodispersible tablet of claim 6, wherein the one or more fillers are selected from the group consisting of isomalt, lactose and its derivatives (e.g., lactose monohydrate, spray-dried lactose, anhydrous lactose), sorbitol, mannitol (e.g., granulated mannitol, powdered mannitol, spray-dried mannitol (e.g., Mannogem )), sorbitol, sucrose, starch, pregelatinized starch and mixtures thereof, Preferably, wherein the orodispersible tablet comprises a mixture selected from granular mannitol and spray-dried mannitol (e.g., Mannogem ) of one or more fillers.
8. The orodispersible tablet of any one of claims 1 to 7, wherein the orodispersible tablet comprises one or more binders present in about 5% to about 40% by weight of the orodispersible tablet; or wherein the orodispersible tablet comprises one or more binders present in about 5% to about 30% by weight of the orodispersible tablet; or wherein the orodispersible tablet comprises one or more binders present in about 5% to about 10% by weight of the orodispersible tablet; or wherein the orodispersible tablet comprises one or more binders present in about 10% by weight of the orodispersible tablet.
9. The orodispersible tablet of claim 8, wherein the one or more binders are selected from microcrystalline cellulose (e.g., silicified microcrystalline cellulose) and hydroxypropyl methylcellulose, Preferably wherein the orodispersible tablet comprises silicified microcrystalline cellulose.
10. The orodispersible tablet according to any one of claims 1 to 9, wherein the orodispersible tablet further comprises a flow enhancer; preferably wherein the flow enhancer is present in about 0.5% to about 3% by weight of the orodispersible tablet; or wherein the flow enhancer is present in about 0.75% by weight of the orodispersible tablet.
11. The orodispersible tablet of claim 10, wherein the flow enhancer is silicon dioxide.
12. The orodispersible tablet according to any one of claims 1 to 11, wherein the orodispersible tablet further comprises one or more sweeteners, Preferably wherein the one or more sweeteners are present in about 0.1 % to about 1 % by weight of the orodispersible tablet.
13. The orodispersible tablet of claim 12, wherein the one or more sweeteners are selected from the group consisting of sucralose, aspartame, sugar derivatives, glucose, polydextrose, xylitol, fructose, sucrose, lactitol, maltitol and saccharin sodium and mixtures thereof, Preferably wherein the orodispersible tablet comprises sucralose as sweetener.
14. The orodispersible tablet according to any one of claims 1 to 13, wherein the orodispersible tablet further comprises one or more flavoring agents, Preferably wherein the one or more flavoring agents are present in about 0.03% to about 0.4% by weight of the orodispersible tablet.
15. The orodispersible tablet of claim 14, wherein the one or more flavoring agents are selected from the group consisting of lemon flavor, mixed berry flavor, grape flavor, peppermint flavor, mint flavor, banana flavor, chocolate flavor, maple flavor, strawberry flavor, raspberry flavor, cherry flavor, orange flavor, and vanilla flavor, and mixtures thereof, Optionally, wherein the orodispersible tablet comprises a mint-flavored natural flavoring.
16. An orodispersible tablet according to any one of claims 1 to 15 comprising granulated mannitol, spray-dried mannitol (e.g., Mannogem ), one or more of silicified microcrystalline cellulose, polyvinyl pyrrolidone (e.g., crospovidone), sucralose, silicon dioxide, and mint-flavored natural flavoring.
17. The orodispersible tablet of any one of claims 1 to 16, wherein the orodispersible tablet is debossed, optionally wherein the orodispersible tablet is debossed with one or more score lines.
18. A mixture comprising: a) about 26 wt % to about 40 wt % KVD900; b) from about 30% to about 80% by weight of one or more fillers; c) from about 5% to about 40% by weight of one or more binders; d) from about 1% to about 10% by weight of one or more disintegrants.
19. The mixture according to claim 18, comprising: a) about 30% by weight of KVD900; b) about 26.85 wt % granulated mannitol and about 26.85 wt % spray dried mannitol (e.g., Mannogem ); c) about 10% by weight of silicified microcrystalline cellulose; d) about 5% by weight of polyvinylpyrrolidone (eg, crospovidone).
20. A method of manufacturing an orodispersible tablet according to any one of claims 1 to 17 from a mixture according to claim 18 or 19, comprising blending the components of the mixture to form a powder mixture and compressing into the orodispersible tablet.
21. A kit for providing a dose of KVD900 comprising more than one orodispersible tablet according to any one of claims 1 to 17.
22. The kit of claim 21 comprising two orodispersible tablets.
23. A method for on-demand treatment of bradykinin-mediated angioedema comprising: One or more orodispersible tablets according to any one of claims 1 to 17 are administered as needed to a patient in need thereof.
24. The method of claim 23, wherein the bradykinin-mediated angioedema is hereditary angioedema (HAE); or wherein the bradykinin-mediated angioedema is bradykinin-mediated non-hereditary angioedema (BK AEnH).
25. The method of claim 23 or 24, wherein the patient suffers from a laryngeal attack.
26. The method according to any one of claims 23 to 25, wherein KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof) is administered at a dose of about 500 mg, Optionally, wherein each dose is subdivided into two orodispersible tablets containing 250 mg of KVD900.
27. The method according to any one of claims 23 to 25, wherein KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof) is administered at a dose of about 550 mg, Optionally, wherein each dose is subdivided into two orodispersible tablets containing 275 mg of KVD900.
28. The method according to any one of claims 23 to 25, wherein KVD900 (or a pharmaceutically acceptable salt and / or solvate thereof) is administered at a dose of about 600 mg, Optionally, wherein each dose is subdivided into two orodispersible tablets containing 300 mg of KVD900.
Citation Information
Patent Citations
Peptide boronic acid inhibitors of trypsin-like proteases
US5187157A
Kininogenase inhibitors
WO1992004371A1
New peptides derivatives
WO1994029335A1
Chemical compounds, their preparation and use
WO1995007921A1
Diode-pumped laser with funnel-coupled pump source
WO2000044073A1
